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ABSTRACT 
Primary varicose vein wall weakness and dilatation are thought to be caused by various 
biochemical and structural changes. Hypoxia and mechanical stress have been postulated to 
contribute to primary varicose vein wall changes. Hypoxia-inducible factors (HIF) are nuclear 
transcriptional factors that regulate the transcription of genes of oxygen homoeostasis. The HIF 
pathway is regulated by factors including oxygen tension and mechanical stress. The study aimed 
to assess the expression of HIF and its target genes in varicose and non-varicose veins, and 
examine their regulation by hypoxia, mechanical stress and pharmacological agents. 
Structural variations between varicose and non-varicose veins were demonstrated using 
histological analysis with special stains. Increased mRNA and protein expression of HIF-1α, HIF-
2α and their target genes was found in varicose compared to non-varicose veins. 
Immunohistochemistry demonstrated that HIF-1α was only expressed in some endothelial cells, 
whereas HIF-2α was more widely expressed in endothelial and smooth muscle cells of varicose 
and non-varicose veins. Furthermore, a vein organ culture model was prepared and validated. 
Exposure of varicose and non-varicose vein organ cultures to 16 hours of 1% oxygen or the 
hypoxia mimetic dimethyloxallyl glycine up-regulated the expression of HIF-1α, HIF-2α proteins, 
and their target genes. Micronised purified flavonoid fraction at a concentration corresponding to 
therapeutic dose appeared to reduce the increases in expression of HIF-1α, HIF-2α, and their 
target genes in varicose vein organ cultures exposed to hypoxia, although the reduction was not 
statistically significant. Meanwhile, doxycycline at a concentration corresponding to therapeutic 
dose did not alter the expression of HIF-1α, HIF-2α, and their target genes in varicose and non-
varicose vein organ cultures exposed to hypoxia. In rat inferior vena cava model, prolonged 
increases in vein wall tension were associated with over expression of HIF-1α and HIF-2α. The 
up-regulation of HIF-1α and HIF-2α secondary to prolonged increases in vein wall tension was 
associated with elevated MMP-2 and MMP-9 expression and changes in venous tone. 
In conclusion, HIF-α and target genes expression is increased in varicose compared to 
non-varicose veins. The expression of HIF-α and target genes in venous tissues appeared to be 
regulated by hypoxia and mechanical stress. The data suggest that the HIF pathway may be an 
important regulator of various biochemical and structural changes in varicose vein wall. 
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OVERVIEW 
Varicose veins affect about one-third of the adult Western population. Patients with 
varicose veins may suffer from symptoms and signs including leg pain, ache, itch, heaviness, 
cramp, oedema, venous eczema, lipodermatosclerosis and ulcers. Treatment of the complications 
of varicose veins has been estimated to consume about 2% of the National Health Service (NHS) 
budget. 
Despite the burden, the mechanism of varicose veins formation remains unclear. Valvular 
dysfunction and reflux are often observed in varicose veins and have long been thought to cause 
vein wall changes, weakness and dilatation. Although valvular incompetence may precede vein 
dilatation in many cases, there is a significant body of evidence supporting the view that vein 
dilatation can also precede venous reﬂux, and that valvular dysfunction may be an 
epiphenomenon of vein wall dilatation. 
Many cellular and extracellular matrix (ECM) changes have been shown in varicose 
veins, including intimal hyperplasia, smooth muscle cell (SMC) proliferation, altered collagen and 
elastin content, and imbalances of matrix metalloproteinases (MMPs) and tissue inhibitors of 
MMPs (TIMPs). The overall effect is weakening of vein wall and reduction of venous tone, 
leading to venous dilatation and reflux. The causes of the changes in the vein wall leading to 
varicose veins formation remain unclear. Genetic susceptibility is likely to contribute but other 
acquired factors are also involved. Stresses from abnormal venous flow including hypoxia, 
mechanical strain and low shear stress have been postulated to contribute to varicose vein wall 
remodelling. Hypoxia and mechanical stretch are thought to be caused by blood stasis and venous 
hypertension. 
Eukaryotic cells have evolved with mechanisms to adapt and protect themselves from 
various stresses. One of these mechanisms is the hypoxia-inducible factor (HIF) pathway which 
helps cells to adapt to changes in the surrounding oxygen tension, and possibly several other 
stresses including mechanical strain and radiation. HIFs are nuclear transcriptional factors 
consisting of α and β subunit, and regulate the transcription of various genes of oxygen 
homoeostasis. Genes regulated by HIF are involved in many functions that help cells to adapt to 
hypoxia such as angiogenesis, glucose metabolism, pH regulation, matrix metabolism, cell cycle 
and apoptosis, erythropoiesis, and regulation of vascular tone. 
Interestingly, many of these processes have been shown to be altered in varicose 
compared to non-varicose veins. Furthermore, hypoxia and mechanical stretch which have been 
postulated to contribute to varicose vein wall changes are known to regulate the expression of 
HIF-. Therefore, we postulated the hypothesis that varicose veins are associated with increased 
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expression of HIF- and target genes, which are regulated by oxygen-dependent and oxygen-
independent factors including mechanical stress. The aims of this study are 
1. To demonstrate that varicose and non-varicose veins are structurally different using 
special histological stains. 
2. To investigate the expression of HIF-1α and HIF-2α, their target genes, and HIF 
regulatory enzymes in varicose compared to non-varicose veins 
3. To develop and use a varicose and non-varicose vein organ culture to assess the 
regulation of HIF-1α and HIF-2α, and their target genes by oxygen tension, and the 
effects of doxycycline and micronised purified flavonoid fraction (MPFF) at a 
concentration corresponding to their physiological therapeutic dose on the HIF pathway 
4. To study the effects of prolonged increases in vein wall tension on the expression of HIF-
1, HIF-2 and MMPs, and venous tone 
Varicose and non-varicose veins that were retrieved from patients undergoing surgery 
were collected, stored and processed appropriately. Some of these varicose and non-varicose 
veins were stained with haematoxylin and eosin (H&E), elastic van Gieson (EVG) and Masson 
trichrome (MT), and were assessed under the light microscopy for structural changes. Increased 
SMC and reduced elastic tissue content in tunica media were observed in varicose compared to 
non-varicose veins. Intimal hyperplasia was present in some but not all of the varicose and non-
varicose veins, and with different severity. Overall, there was no difference observed in terms of 
the presence and severity of intimal hyperplasia between the two types of veins.  
The HIF pathway in varicose and non-varicose vein wall was assessed by analysing the 
mRNA and protein expression of HIF-1α, HIF-2α and several HIF target genes including glucose 
transporter-1 (GLUT-1), carbonic anhydrase 9 (CA9), enolase-1 (ENO-1), vascular endothelial 
growth factor (VEGF) and BCL2/adenovirus E1B 19 kd-interacting protein 3 (BNIP-3). The 
expression of several HIF regulatory enzymes was also assessed. The mRNA and protein 
expression of HIF-1α, HIF-2α, and HIF target genes were found to be up-regulated in varicose 
compared to non-varicose veins, suggesting that the HIF pathway is activated in varicosities. 
Furthermore, HIF-1α was found to be expressed in some endothelial cells, whereas HIF-2α was 
expressed by endothelial cells and SMC of all the layers in varicose and non-varicose veins. The 
data suggest that increased HIF activation in varicose compared to non-varicose veins, and HIF-
2α rather than HIF-1α may be the key regulator of the HIF pathway. 
A vein organ culture model was then used to assess the in vitro regulation of HIF-1α, 
HIF-2α, and their target gene expression by hypoxia and two drugs i.e. doxycycline and MPFF, 
both known to modify vascular wall remodelling. The viability of the vein organ culture model 
was first validated with a cell death assay. Exposure of varicose and non-varicose vein organ 
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cultures to 16 hours of hypoxia (oxygen tension of 1%) was associated with increased expression 
of HIF-1α and HIF-2α protein, and their target genes. Treatment with hypoxia mimetic 
dimethyloxallyl glycine (DMOG) 1mM was also associated with elevated expression of HIF-1α 
and HIF-2α protein, and their target genes in varicose and non-varicose vein organ cultures in 
normoxia. Doxycycline at a concentration corresponding to the therapeutic physiological 
concentration did not appear to alter the expression of HIF-1α, HIF-2α, and their target genes. 
Meanwhile, MPFF at a concentration corresponding to the therapeutic physiological 
concentration significantly reduced the expression of HIF-1α mRNA in varicose vein organ 
cultures exposed to hypoxia compared to those untreated. MPFF also appeared to reverse the 
increased expression of HIF target genes caused by hypoxia in varicose vein organ cultures 
compared to those untreated, although the findings did not achieve statistical significance. 
Furthermore, such effects of MPFF were less obvious in non-varicose vein organ cultures.  
Finally, the effects of prolonged increases in vein wall tension secondary to mechanical 
stress on the HIF pathway in venous tissues was investigated using an in vitro model that 
stretched segments of rat inferior vena cava (IVC) to pre-determined tensions and measured their 
isometric contraction induced by maximum potassium chloride (KCl) and phenylephrine (PHE), 
an α1-agonist. The regulation of MMP-2 and MMP-9 expression and venous contraction to KCl 
and PHE stimulation was also studied. Prolonged increases in vein wall tension were found to be 
associated with over expression of HIF-1 and HIF-2 in rat IVC. The up-regulation of HIF-1 
and HIF-2 secondary to prolonged increases in rat IVC wall tension was also associated with 
increased MMP-2 and MMP-9 expression and alteration to venous tone. 
In conclusion, the study demonstrated that the expression and activity of HIF was 
increased in varicose compared to non-varicose veins. HIF-2α was more widely expressed and 
was found in SMC and endothelium as compared to HIF-1α which was only seen in some 
endothelial cells. Hypoxia and prolonged increases in vein wall tension secondary to mechanical 
stretch are associated with increased expression of HIF-1α, HIF-2α and their target genes in 
venous tissues. MPFF at a concentration corresponding to therapeutic dose appears to reverse the 
increases of HIF and target genes expression in in vitro varicose vein tissues exposed to hypoxia, 
although the findings are not statistically significant. Meanwhile, doxycycline at a concentration 
corresponding to therapeutic dose does not have any effect on the HIF pathway. The data suggest 
that the HIF pathway may be an important regulator of various biochemical and structural 
changes in varicose vein wall. Furthermore, HIF-2α instead of HIF-1α may be the key regulator 
of the HIF pathway in varicose and non-varicose veins. Therefore, the HIF pathway is potentially 
an important therapeutic target in the pharmacological treatment development for varicose veins. 
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1. INTRODUCTION 
Varicose veins (Figure 1-1) are a common manifestation of chronic venous disease, 
affecting about one-third of the adult population in the Western world. They were first described 
in the Ebers papyrus over 3500 years ago. Since then many hypotheses including primary valvular 
dysfunction, vein wall hypoxia and venous hypertension have been postulated to cause or 
contribute to varicose vein formation, although to date, the pathogenesis of the disease remains 
not fully understood. Meanwhile, HIF was first discovered in 1992. The discovery of HIF has led 
to major advances in our understanding of cellular responses to hypoxia including in the 
pathogenesis of many common diseases such as cancers, rheumatoid arthritis, atherosclerosis and 
pulmonary hypertension. HIF has also become an attractive therapeutic target for these diseases 
with many HIF modulating agents being developed. However, little is known about the role of 
HIF in the pathogenesis of varicose veins. Therefore, this PhD thesis investigated the role of the 
HIF pathway in varicose vein formation with the aim to identify new potential therapeutic target 
for the disease. 
 
Figure 1-1 Varicose veins 
Typical appearance of varicose veins in a leg 
1.1. CHRONIC VENOUS DISEASE 
The manifestation of symptoms and signs of venous disease in the lower limb is generally 
known as chronic venous disease (CVD) (Eberhardt and Raffetto 2005; Bergan et al. 2006). The 
most common manifestations of CVD are dilated cutaneous veins, such as telangiectases and 
reticular veins, and varicose veins (Eberhardt and Raffetto 2005). Besides the appearance of the 
veins, patients with CVD may also present with a wide range of symptoms and signs including 
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pain, heaviness, itch, oedema, eczema, lipodermatosclerosis, thrombophlebitis, bleeding, and 
ulceration (Figure 1-2). Meanwhile, chronic venous insufficiency (CVI) often refers to more 
severe manifestations of CVD i.e. those that involve dermal changes (Bergan et al. 2006). In 
general, symptoms and signs of CVD and CVI are attributed to venous hypertension secondary to 
either venous reflux or obstruction or both (Eberhardt and Raffetto 2005; Bergan et al. 2006). 
 
Figure 1-2 Venous ulcer 
Typical appearance of a venous ulcer in the gaiter area 
CVD is a common disorder in industrialised nations with significant socioeconomic 
impact (Meissner et al. 2007a; Nicolaides et al. 2008). Patients with CVD have been shown to 
demonstrate impaired quality of life due to pain, physical limitation, poor mobility and social 
seclusion (Nicolaides et al. 2008). The estimated prevalence of CVI has been reported to be from 
<1% to 17% in men and <1% to 40% in women (Robertson et al. 2008). Up to 1.5% of people 
living in industrialised nations will suffer from venous ulceration and this percentage increases to 
4% for patients aged 65 years and older (1988; Criqui et al. 2003; Meissner et al. 2007a). In the 
United States of America (USA), CVI has been ranked the seventh leading cause of chronic 
debilitating disease (Meissner et al. 2007a). The cost of treating CVD has been estimated at 1-3% 
of the total annual healthcare budget of many Western countries (Nicolaides 2000; Nicolaides et 
al. 2008). 
1.1.1. CEAP Classification System 
CVD is often classified using the „Clinical, aEtiologic, Anatomic, and Pathophysiologic‟ 
or (CEAP) classification system (Bergan et al. 2006). CEAP classification system was created by 
an international ad hoc committee of the American Venous Forum (AVF) in 1994 to standardise 
the reporting and treatment of the diverse manifestations of CVD. CEAP classification system has 
evolved over time and will continue to do so (Meissner et al. 2007b). Table 1-1 summarises the 
currently used CEAP classification system (Meissner et al. 2007a). Although a comprehensive 
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CEAP classification provides a much more detailed description of the disease in a patient, 
simplified versions of CEAP are often used. The most simplified version involves stating only the 
highest „Clinical‟ or „C‟ class. CVD encompasses the full spectrum of symptoms and signs of 
venous disease associated with C0,S to C6. Meanwhile, CVI which is often restricted to CVD with 
dermal changes is classified as C4 to C6. 
Table 1-1 CEAP classification of chronic venous disease 
Clinical classification 
C0 No visible or palpable signs of venous disease 
C1 Telangiectases or reticular veins 
C2 Varicose veins 
C3 Oedema 
C4a Pigmentation or eczema 
C4b Lipodermatosclerosis or atrophic blanche 
C5 Healed venous ulcer 
C6 Active venous ulcer 
S Symptomatic (e.g. pain, ache, tightness, skin irritation, muscle cramp) 
A Asymptomatic 
aEtiologic classification 
Ec Congenital 
Ep Primary 
Es Secondary (post-thrombotic) 
En No venous cause identified 
Anatomic classification 
As Superficial veins 
Ap Perforator veins 
Ad Deep veins 
An No venous location identified 
Pathophysiologic classification 
Pr Reflux 
Po Obstruction 
Pr,o Reflux and obstruction 
Pn No pathophysiology identified 
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1.2. VARICOSE VEINS 
1.2.1. Definition 
Varicose veins are excessively elongated, dilated, and tortuous veins in the lower limbs. 
The word “varicose” is derived from the Latin word “varix” which means twisted (Lim and 
Davies 2009). Patients with varicose veins may present with symptoms and signs associated with 
CVD. Varicose veins may be classified into primary or secondary depending on the cause. 
Primary varicose veins account for majority of the cases and have no known cause. Meanwhile, 
secondary varices have a known cause with deep vein thrombosis being the most common factor. 
Varices are also sometimes classified into trunk, reticular and hyphenweb varices based on their 
size and anatomical distribution (Evans et al. 1999). In CEAP classification, asymptomatic 
varicose vein is graded as C2. 
1.2.2. Epidemiology and Aetiology 
Varicose vein is often described as a “Western disease” as it seems to occur more 
frequently in industrialised than underdeveloped countries (Lim and Davies 2009). In the Western 
countries, varicose veins affect up to one third of the adult population (Evans et al. 1999; Lee et 
al. 2003; Robertson et al. 2008). Epidemiological studies conducted in different regions of the 
world reported huge variations in the prevalence of varicose veins (Robertson et al. 2008). Some 
studies have also shown that the prevalence of varicose veins vary with ethnicity in the same 
community (Robertson et al. 2008). 
Several predisposing factors are thought to contribute to the formation of varicose veins. 
Family history, age, gender and pregnancy are likely the most important factors (Laurikka et al. 
2002; Carpentier et al. 2004). For example, a multivariate analysis of a questionnaire survey of 
3284 men and 3590 women in Finland found that the odd ratios of developing varicose veins for 
female gender, increasing age, positive family history, and increasing number of childbirths were 
2.2, 2.2-2.8, 4.9 and 1.2-2.8, respectively (Laurikka et al. 2002). It is important to realise that the 
differences shown in epidemiological studies might also be due to variations in the study design 
such as the inclusion criteria, diagnostic definition and imaging modality. 
1.2.2.1. Family history 
A study in France reported that the presence of a family history of varicose veins in the 
first-degree relatives was the most important risk factor in both males and females (Carpentier et 
al. 2004). Patients with varicose veins were 21.5 times more likely to report a positive family 
history (Scott et al. 1995). Another study in Japan found that 42% of patients with varicose veins 
had a positive family history compared to only 14% in those without varicosities (Hirai et al. 
1990). 
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1.2.2.2. Age 
The prevalence of varicose veins increases with age (Brand et al. 1988; Bradbury et al. 
1999; Robertson et al. 2008). The Framingham study demonstrated a prevalence of 1% in men 
and 10% in women of less than 30 years of age, compared to 57% in men and 77% in women 
over 70 years (Brand et al. 1988). The Edinburgh Vein Study also reported an increase of 
prevalence with age; 11.5% and 55.7% in those aged 18-24 and 55-64 years, respectively (Evans 
et al. 1999). The increased risk of developing varicose veins with age may be related to a 
combination of factors including weakening of calf muscles, decreased mobility and overall 
reduction of the matrix components of the veins (Naoum et al. 2007). 
1.2.2.3. Sex 
So far, the prevalence of varicose veins reported in several studies varied widely from 2% 
to 56% in men and <1% to 73% in women (Robertson et al. 2008). Most studies showed that 
varicose veins were more common in women than men while some reported the opposite (Brand 
et al. 1988; Bradbury et al. 1999; Evans et al. 1999; Laurikka et al. 2002; Raffetto and Khalil 
2008b; Robertson et al. 2008). It has also been postulated that women were more likely to be 
aware of and report varices than men (Campbell 2006; Robertson et al. 2008) . 
1.2.2.4. Pregnancy 
During pregnancy, weight gain from increased total body fluid and raised intra-abdominal 
pressure may predispose a woman to varicose vein formation. Furthermore, up-regulation of 
certain hormones such as relaxin, oestrogen and progesterone during pregnancy causes venous 
relaxation and increases the vein capacitance (Naoum et al. 2007). The risk of developing 
varicose veins also increases with parity with one study reported the prevalence of 32%, 38%, 
43%, 48% and 59% in women with 0, 1, 2, 3, and 4 or more pregnancies, respectively (Laurikka 
et al. 2002). 
1.2.2.5. Others 
Obesity and decrease mobility are controversial risk factors of varicose veins with several 
studies supported them but not the others (Stvrtinova et al. 1991; Scott et al. 1995; Evans et al. 
1999; Danielsson et al. 2002; Robertson et al. 2008). Other risk factors such as cigarette smoking, 
oestrogen therapy, hypertension and diabetes mellitus have also been postulated to contribute to 
or exacerbate the formation of varicose veins although their roles remain to be validated (Brand et 
al. 1988; Evans et al. 1999; Naoum et al. 2007; Raffetto and Khalil 2008b; Robertson et al. 2008). 
1.2.2.6. Genetic associations 
Although there has not been a gene identified specifically for the development of varicose 
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veins, several congenital and genetic disorders are associated with varicosities. Patients with 
Klippel-Trenaunay Syndrome (KTS) present with varicose veins, limb hypertrophy and dermal 
capillary haemangioma. These patients have various venous abnormalities including atresia, 
agenesis, valvular incompetence, and venous aneurysms (Lee et al. 2005a; Kihiczak et al. 2006). 
It has been reported that 72% of patients with KTS developed varicose veins (Jacob et al. 1998). 
Another example of a genetic disorder associated with varicose veins is Chuvash polycythaemia 
with 74.4% of the patients had varices compared to 39.0% of those without the polycythaemia 
(Gordeuk et al. 2004). Chuvash polycythaemia is an autosomal recessive disorder caused by 
Arg200Trp mutation (C598T) of the von Hippel-Lindau gene (VHL), leading to dysfunction in 
oxygen tension sensing and inappropriate increased expression of HIF-α (Gordeuk et al. 2004; 
Gordeuk and Prchal 2006). Other gene mutations associated with varicose vein formation include 
the FOXC2 which is commonly found in patients with lymphoedema-distichiasis, and NOTCH3 
in patients suffering from cerebral autosomal dominant arteriopathy with subcortical infarcts and 
leukoencephalopathy (CASADIL) (Saiki et al. 2006; Mellor et al. 2007; Raffetto and Khalil 
2008b). FOXC2, a gene situated on chromosome 16q24.3 and encodes a regulatory transcription 
factor, is implicated in both lymphatic and vascular development (Mellor et al. 2007). In one 
study, all 18 patients with FOXC2 mutation had great saphenous vein (GSV) reflux on duplex 
ultrasonography compared to only 1 in 12 controls without the mutation (including 10 family 
members of subjects with FOXC2 mutation) (Mellor et al. 2007). 
It is important to stress that these genetic and congenital disorders are very rare compared 
to the overall prevalence of varicose veins, indicating the multi-factorial aetiology of varices. For 
example, the rarity of KTS was reflected by the existence of only 94 subjects in the Dutch 
Klippel-Trenaunay Syndrome register (Aelvoet et al. 1992). Chuvash polycythaemia is also very 
rare worldwide (allele frequency of 0.001377) despite being endemic in Chuvashia in Russia and 
Ischia in Italy (0.070 and 0.057, respectively) (Perrotta et al. 2006). 
1.3. TREATMENT OF VARICOSE VEINS 
Treatment of varicose veins has evolved rapidly in the last decade, after a century of 
consistency with open surgery as the mainstay procedure (Gohel and Davies 2008). Many 
therapeutic options are now available for the treatment of varicose veins including open surgery, 
minimally invasive interventions (e.g. endovenous thermal ablation and injection sclerotherapy), 
and non-invasive management (e.g. compression and drugs). These treatment options can be used 
on its own or in combinations. The choice of treatment varies widely depending on several factors 
including the anatomical distribution of venous reflux, pathophysiology of the disease, general 
health and well-being of the patient, individual patient‟s and surgeon‟s preference, availability of 
treatment options, and funding or affordability (Gohel and Davies 2008; Qureshi et al. 2010a; 
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Shepherd et al. 2010a; Shepherd et al. 2010b). 
1.3.1. Open Surgery 
Physical obliteration of the refluxing vein remains the underlying principle governing the 
surgical treatment of varicose veins. Friedrich Trendelenberg described the ligation of the GSV in 
1890 and modifications of the procedure have been the mainstay of treatment of varicose veins 
for more than a century. Surgical treatments remain the mainstay management of varicose veins 
in the UK, and have been shown to provide better outcomes than no surgical treatment. For 
example, ESCHAR trial demonstrated that combining surgery and compression therapy reduced 
recurrence of venous ulcers compared to compression therapy alone (Gohel et al. 2007). 
GSV incompetence is treated with ligation of saphenofemoral junction (SFJ), an 
operation commonly known as „high tie‟, and stripping of the GSV (Figure 1-3). In general, 
incision is made along the groin crease over the SFJ (2 cm inferior and 2 cm lateral to the pubic 
tubercle or marked using ultrasonography). The GSV is dissected to the SFJ. All the tributaries 
close to the SFJ are ligated. The GSV is then ligated and divided close to the SFJ (flush ligation). 
The GSV is then stripped with a „stripper‟. Stripping has been demonstrated to reduce the risk of 
reoperation by two-thirds after 5 years (Dwerryhouse et al. 1999). 
Short saphenous vein (SSV) incompetence is treated with ligation of the saphenopopliteal 
junction (SPJ) with or without stripping of the SSV. Incision is made in the popliteal fossa and the 
SSV is located (some surgeons prefer to localise the SSV with ultrasonography prior to the 
surgery) and dissected to the SPJ. The SSV is then flush ligated and divided closed to the SPJ. 
The SSV can then be stripped with a „stripper‟. However, not all surgeons perform stripping of 
SSV due to potential risk of sural nerve injury which runs close to the SSV. 
Varicosities of the tributary veins are usually treated with multiple phlebectomies or 
avulsions (Figure 1-3). Stab incisions are made over the varicosities which are then avulsed with 
artery forceps. The stab incisions are usually closed with sterile strips or a simple interrupted 
suture. 
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Figure 1-3 Open surgery involving ligation of saphenofemoral junction, stripping of 
great saphenous vein and multiple phlebectomies 
(a) Exposure of the saphenofemoral junction (white arrow). (b) Ligation of saphenofemoral junction or 
high-tie (within the dotted circle). (c) Stripping of great saphenous vein with a stripper (d) Multiple 
phlebectomies. 
1.3.2. Endovenous Thermal Ablation 
Endovenous thermal ablation involves inserting and passing a catheter or fibre along the 
lumen of varicose veins under ultrasound guidance. Ablation which causes occlusion of the 
varicose veins is then performed either with laser or radiofrequency (Figure 1-4) while slowly 
withdrawing the catheter from the vessels. This can be done under general or local anaesthetics. 
Tumescent, a diluted local anaesthetic (for example diluting 30ml of 2% lidocaine and 1:200,000 
adrenaline in 500ml of normal saline) is usually infiltrated into the surrounding tissues of the 
varicose veins to be treated. Besides acting as local anaesthetics, tumescent infiltration also 
protects the surrounding tissues from injury, and compresses the vein during the treatment. 
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Figure 1-4 Endovenous thermal ablation of varicose veins 
(a) Cannulation of the great saphenous vein. (b) VNUS Closure Fast™ radiofrequency ablation. 
1.3.3. Injection Sclerotherapy 
Injection sclerotherapy involves injecting a sclerosant into the varicosities. Injection 
sclerotherapy can be performed on its own or in combination with open surgery or endovenous 
thermal ablation (Geroulakos and Davies 2009). Commonly used sclerosant include sodium 
tetradecyl and polidocanol (Coleridge Smith 2009). Sclerosant may also be mixed with air or 
other gas such as carbon dioxide (CO2) to produce foam, known as foam sclerotherapy (Figure 
1-5). The optimum ratio of gas to liquid is 4:1, although a range of ratios has been reported 
(Coleridge Smith 2009). Foam injected into the varicosities will spread widely through the vessels 
allowing long segments of veins to be treated. Blood in the varicosities is displaced by the foam 
which then causes vasospasms and venous occlusion. Injection sclerotherapy has the advantages 
of being less invasive, cheaper and can be done in out-patients settings. However, injection 
sclerotherapy is associated with increase in repeat treatments and risks including local tissue 
necrosis and scarring, venous thromboembolism, visual disturbances, migraine and headache. 
1.3.4. Compression Therapy 
Compression therapy with bandages or hosiery works by physically occluding the 
superficial veins, and hence preventing blood stasis (Morris and Woodcock 2004). Compression 
has remained an important therapy of venous disease, with and without the use of other treatment 
modality such as surgery, endovenous thermal ablation and injection sclerotherapy. It has been 
shown to be safe and effective, although occasionally patients may not be able to tolerate it 
(Morris and Woodcock 2004; Blattler and Zimmet 2008; Partsch et al. 2008). Therefore, it should 
be considered for all patients suffering with varicose veins especially those with skin changes and 
ulceration (Morris and Woodcock 2004; Partsch et al. 2008). Besides, patients who are waiting 
for surgical or endovenous treatment of varicose veins should also be prescribed with 
compression therapy unless contraindicated, for example by significant peripheral arterial disease. 
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Figure 1-5 Foam sclerotherapy 
(a) Preparation of foam sclerotherapy, in this case mixing sodium tetradecyl with air. (b) Injection of foam 
sclerotherapy into varicose vein. 
1.3.5. Pharmacological Therapy 
Although open surgery, endovenous thermal ablation and injection sclerotherapy are 
overall effective and safe, recurrent varicose veins after these treatments remains high, and has 
been quoted to be between 20% and 40% (Tsang et al. 2005). It is also impossible to predict 
which patients with varicose veins are likely to develop severe symptoms, complications or 
recurrence following treatment. These difficulties and limitations are likely in parts due to our 
lack of understanding of the disease. For e.g., recurrent varicose veins were previously thought 
to be caused by poor surgical technique, especially when performed by surgical trainees (Negus 
1993), anatomical variability and complexity of the SFJ (Royle 1986) and disease progression 
(Turton et al. 1999). However, it is now believed that neovascularisation reconnecting the 
venous channels is likely the most important cause of recurrent disease after open surgery 
(Jones et al. 1996; Nyamekye et al. 1998). 
There are pharmacological agents available for the treatment of CVD and CVI. 
Venoactive drugs such as flavonoids and horse-chestnut extracts have been shown to improve 
symptoms and signs of CVI in randomised controlled trials (Guilhou et al. 1997; Struckmann 
1999; Martinez et al. 2005). The mechanisms of action of venoactive drugs include increasing 
venous tones, reducing vein wall inflammation and decreasing capillary permeability (Martinez et 
al. 2005). Flavonoids such as micronised purified flavonoid fraction (MPFF), containing 90% 
diosmin and 10% hesperidin, may protect vein wall from hypoxia and inhibit the expression of 
adhesion molecules on the endothelium and leukocytes (MacKay 2001; Nicolaides 2003). MPFF 
has been shown to improve symptoms of CVI such as oedema and discomfort in randomised 
controlled trials (Guilhou et al. 1997; Struckmann 1999). Horse-chestnut extracts which contain 
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the active component triterpenic saponin, aescin exhibit venotonic, anti-inflammatory and free 
radical scavenging properties (MacKay 2001). Pycnogenol, containing phenolic compounds 
extracted from the bark of the French maritime plant, may improve symptoms of CVD and CVI 
through its anti-inflammatory properties including inhibition of 5-lipoxygenase and 
cyclooxygenase-2 gene expression and phospholipase A2 activity (Canali et al. 2009). 
Mesoglycan, another anti-inflammatory drug which inhibits neutrophil adhesion, is a sulphated 
polysaccharide compound consisting of heparan sulphate, dermatan sulphate, heparin and 
chondroitin sulphate that has also been shown to relieve symptomatic CVD and CVI (Arosio et al. 
2001; Andreozzi 2007). 
The overall use of pharmacological agents in the treatment of varicose veins and CVI is 
limited and often not available in the UK. However, pharmacological treatment of varicose veins 
remains an attractive therapeutic option for future research due to its non-invasive nature and low 
cost. Current treatment of varicose veins and their complications is very expensive and not 
affordable to all including in the National Health Service (NHS) in the UK. Therefore, finding a 
cost-effective treatment including pharmacological treatment will benefit many patients with 
varicose veins. Further research on the understanding of the pathogenesis of varicose veins will 
help identify potential pharmacological targets. 
1.4. VENOUS BLOOD FLOW IN THE LOWER LIMBS 
1.4.1. Anatomy and Physiology 
Two venous systems are present in the lower limbs, i.e. superficial (Figure 1-6) and deep. 
The superficial venous system drains the skin and subcutaneous tissue while the deep system, 
which lies within the muscles, carries blood from the rest of the lower limbs. Several 
communications (perforators) exist between the two systems, allowing the passage of blood from 
the superficial into the deep system. There are two major truncal veins in the superficial system, 
i.e. the GSV and SSV. The most important driving force of venous blood flow is the contraction 
of the skeletal muscles surrounding the vessels, primarily the calf but also the foot and thigh 
muscles, which act as pumps compressing and emptying the veins through the increase in 
pressure within the fascial compartment (Eberhardt and Raffetto 2005). Of the skeletal muscles, 
the calf muscle pump is the most efficient and generates the highest pressure with contraction, 
ejecting over 40-60% of venous volume with a single contraction (Bergan et al. 2006). The 
muscle pump works in conjunction with competent valves, which serve to prevent retrograde flow 
and together reduce the volume of blood in leg veins. Walking and tiptoeing while stationary 
reduce lower limb venous pressures from 100mmHg to an average value of 22mmHg within 12 
steps or ten movements (Meissner et al. 2007b). Bicuspid valves are present in both deep and 
superficial venous systems to ensure that the blood flow is in a single direction, i.e. from the 
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superficial to the deep system, towards the heart or cephalad direction, and against the gravity 
(Lim and Davies 2009; Qureshi et al. 2010a). 
1.4.2. Venous Hypertension 
The haemodynamic blood flow in varicose veins is disrupted resulting in blood stasis, 
venous reflux, dilatation and hypertension. In a normal venous system, the resting standing 
venous pressure is about 80 to 90mmHg. During calf exercise, the venous pressure drops by more 
than 50% to about 20 to 30mmHg. The return pressure is gradual with a refilling time of over 20 
seconds. However, patients with venous reflux demonstrate a much less venous pressure drop 
(less than 50%) during calf exercise, and a much shorter refilling time after exercise (Eberhardt 
and Raffetto 2005). As a result, patients with abnormal venous system are being exposed to an 
overall higher venous pressure for a longer duration. The cause and sequence of events leading to 
such inefficient blood flow remain unclear although valvular incompetence, vein wall weakness 
and venous dilatation are features associated with varicose veins. These features are thought to 
cause and/or be caused by blood stasis which generates venous hypertension in the leg (Lim and 
Davies 2009). Chronically occurring venous hypertension is then thought to cause ischaemia, 
injury and inflammation to the vein wall, surrounding subcutaneous tissues and skin leading to 
symptoms and signs of CVD. 
 
Figure 1-6 Superficial venous system in the lower limb 
Great and small saphenous venous drainage systems in the lower limb 
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1.5. PATHOGENESIS OF VARICOSE VEINS 
Figure 1-7 summarises the current understanding of varicose vein formation although 
many aspects of the disease pathogenesis remain unclear. Valvular incompetence causing venous 
reflux is frequently observed in varicose veins, and has long been postulated as the primary cause 
of vein wall weakness and dilatation. However, this hypothesis has recently been challenged with 
evidence suggesting that primary vein wall changes may precede valvular incompetence. 
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Figure 1-7 Pathogenesis of varicose vein formation 
Schematic diagram summarises potential mechanisms that may contribute to varicose vein formation. ECM, 
extracellular matrix; MMP, matrix metalloproteinase; TIMP, tissue inhibitor of metalloproteinase; SMC, 
smooth muscle cell 
1.5.1. Primary Valvular Dysfunction 
Absence and deformities including tearing, thinning, thickening, splitting and scarring 
of the saphenous vein valves were found more frequently in varicose than non-varicose veins 
retrieved from surgery and during angioscopy (Blanchemaison 1992; Van Cleef et al. 1992; 
Corcos et al. 2000). Varicose veins also demonstrate hypotrophy of the valves and widening of 
the valvular annulus compared to non-varicose veins (Corcos et al. 1996; Ono et al. 1998; 
Corcos et al. 2000). The valves of the varicose veins have been shown to contain less collagen 
and have lost the normal viscoelastic features compared to those of non-varices (Psaila and 
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Melhuish 1989) Monocytes and macrophages infiltration into the valvular sinuses were also 
found to be greater compared to the distal vein wall of varicose veins, indicating increased 
inflammatory activities in the valves (Ono et al. 1998). 
One hypothesis proposed that valvular dysfunction causing reflux is the initial 
pathological change that occurs in varicose veins. Venous reflux causes blood stasis and venous 
hypertension which damage the vein wall leading to weakness and dilatation. Venous dilatation 
separates the valve cusps further and worsens the valvular incompetence triggering a vicious 
cycle. Furthermore, distal valves may also become incompetent secondary to the proximal 
reflux and dilatation leading to a retrograde progression of the disease (Somers and Knaapen 
2006; Meissner et al. 2007a; Raffetto and Khalil 2008b). 
This previously seemed plausible hypothesis has recently been challenged by several 
ultrasonographic and histological findings of varicose veins. Varicosities are often observed 
below competent valves, and not uncommonly found to precede valvular incompetence. Venous 
dilatation is also frequently seen distal to a valve rather than proximal which one would expect 
if valvular dysfunction is the initial event (Rose and Ahmed 1986; Labropoulos et al. 1997; 
Naoum et al. 2007). In a study involving 109 consecutive patients, reflux in 33 of the 139 limbs 
(24%) examined were detected in the main saphenous trunk or tributaries alone with no 
junctional incompetence (Labropoulos et al. 2000). In another study, 90 patients (116 limbs) 
who were waiting for varicose vein surgery were investigated with duplex ultrasonography 
twice over a median period of 19 months (Labropoulos et al. 2005). During the second imaging, 
new sites of reflux were found in 14 limbs while the remaining 17 legs demonstrated reflux 
progression from the existing incompetent sites, with 7 antegrade, 7 retrograde and 3 in both 
directions. Retrospective review of 10 years duplex ultrasonography reports at the Charing 
Cross Hospital vascular laboratory demonstrated that venous reflux could occur in any parts of 
the superficial and deep venous system without the necessity of a more proximal incompetence 
in patients with primary CVD (Qureshi et al. 2010a). These data support a multifocal initiation 
of the disease rather than following the ascending or descending theory of reflux progression. 
Therefore, varicose veins do not always initiate at SFJ or SPJ, and progress in a descending or 
retrograde manner. Anterograde or ascending disease progression is more likely to be caused by 
primary vein wall changes leading to subsequent valvular incompetent than vice versa. 
Alternatively, the primary valvular incompetence may represent a multi-centric process that 
develops simultaneously in discontinuous venous segments (Labropoulos et al. 1997; Naoum et 
al. 2007). 
1.5.2. Primary Varicose Vein Wall Changes 
Recent studies of varicose vein pathogenesis focused more on the structural and 
biochemical changes in the vein wall (Somers and Knaapen 2006; Meissner et al. 2007a; Raffetto 
Chapter 1 
41 
and Khalil 2008b). These studies hypothesised that the formation of varicose veins was secondary 
to the underlying defects of the cellular and ECM components causing weakness and altered 
venous tone (Leu et al. 1979; Clarke et al. 1992; Vanhoutte et al. 1997; Somers and Knaapen 
2006; Raffetto and Khalil 2008b). The triggers for these changes remain unclear although several 
factors associated with haemodynamic abnormality are likely to be involved including hypoxia, 
mechanical stretch and low shear stress (Michiels et al. 2002a; Naoum et al. 2007). 
Numerous changes in the cellular and ECM components of all the layers of the vein wall 
have been demonstrated in varicosities. These changes occur randomly rather than continuous or 
following a particular pattern (Naoum et al. 2007). Areas of irregular intimal hyperplasia with 
associated collagen deposits, SMC infiltration and plaques underneath the endothelial lining are 
common in varicose veins (Milroy et al. 1989; London and Nash 2000; Wali and Eid 2002; Wali 
et al. 2003; Somers and Knaapen 2006; Elsharawy et al. 2007). Changes in the media including 
SMC proliferation and ECM degradation are also often seen in varicose compared to non-varicose 
veins (Gandhi et al. 1993; Wali et al. 2003; Aunapuu and Arend 2005; Elsharawy et al. 2007). 
Similarly, the adventitia of varicose veins demonstrates areas of increased SMC, fibroblasts and 
connective tissues with regions of atrophy and devoid of vasa vasorum (Aunapuu and Arend 
2005; Naoum et al. 2007). 
1.5.2.1. Genes regulating vein wall structure 
Several gene expressions associated with the regulation of vein wall homoeostasis have 
been found to be altered in varicose compared to non-varicose veins. Complementary 
deoxyribonucleic acid (cDNA) microarrays comparing the differential gene expression of 
varicose and non-varicose veins demonstrated an up-regulation of 82 genes of the 3063 cDNA 
clones in varices. The up-regulated genes included those of ECM molecules, cytoskeletal 
proteins and myofibroblasts such as transforming growth factor β-induced gene (BIGH3), 
tubulin, lumican, actinin, type I collagen, versican, actin and tropomyosin (Lee et al. 2005b). 
Another study found three cDNAs similar to the L1M4 repeat sequence of clone RP11-57L9, 
clone RP11-299H13, and Alu repetitive sequence of human tropomyosin 4 messenger 
ribonucleic acid (mRNA) to be expressed differently in varicose compared to non-varicose 
veins (Kim et al. 2005). Tropomyosins are actin-binding proteins found in both muscular and 
non muscular cells. They have structural roles including in the assembly and regulation of 
specific contractile systems (Kim et al. 2005). 
1.5.2.2. Extracellular matrix degradation 
The ECM provides a structural framework of collagen, proteoglycans, elastin, 
glycoproteins and fibronectin in which various cellular components are embedded (Hobeika et 
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al. 2007). The ECM is a dynamic structure that maintains the integrity and homoeostasis of the 
vein through interactions with the cellular components such as the endothelium and SMC 
(Hobeika et al. 2007). Degradation of this component is likely to contribute to the weakening 
and dilatation of the veins. Disruption to the elastic fibres including fragmentation of the elastic 
laminae, and thickening of individual collagen fibres has often been observed in varicose veins 
(Bouissou et al. 1988; Goldman and Fronek 1989; Lowell et al. 1992; Jones et al. 1999; Porto et 
al. 2002; Wali and Eid 2002; Wali et al. 2003). The total elastin content in varicose compared to 
non-varicose veins is decreased (Andreotti and Cammelli 1979; Gandhi et al. 1993; Venturi et 
al. 1996; Elsharawy et al. 2007). Meanwhile, the overall collagen content in varicose compared 
to non-varicose veins remains unclear, with some studies reported an increase (Gandhi et al. 
1993; Travers et al. 1996; Sansilvestri-Morel et al. 2001; Wali and Eid 2002; Wali et al. 2003), 
some unchanged (Venturi et al. 1996) and the others a reduction (Andreotti and Cammelli 
1979). The subtypes of collagen in varicose veins are also altered compared to non-varicose 
veins. Type III collagen which contributes to elasticity is down-regulated while type I collagen 
that provides tensile strength is up-regulated in varicose compared to non-varicose veins 
(Sansilvestri-Morel et al. 2001). Loss of elastin and type III collagen have been shown to 
correlate negatively to the vein diameter measured with ultrasonography at rest and during 
valsalva manoeuvre, respectively (Jeanneret et al. 2007). Therefore, alteration to the balance of 
the elastin and collagen content is likely to contribute to varicose vein wall weakening (Wali 
and Eid 2002; Wali et al. 2003; Elsharawy et al. 2007). 
1.5.2.3. Matrix metalloproteinases 
The homoeostasis of the ECM is regulated by a group of enzymes called the MMP and 
TIMP (Somers and Knaapen 2006; Hobeika et al. 2007; Raffetto and Khalil 2008a; Lim et al. 
2010). MMPs are zinc-dependent endopeptidases from a family of proteases known as 
metzincins. These enzymes are able to degrade most constituents of the ECM. To date, 23 MMPs 
have been identified in human with at least 14 of them expressed in vascular tissues (Raffetto and 
Khalil 2008a; Lim et al. 2010). Even though their structures are highly homologous, their 
activities and roles in the ECM may vary significantly (Vartak and Gemeinhart 2007; Raffetto and 
Khalil 2008a). Furthermore, the regulation of the MMPs is complex and occurs at different levels 
including at gene transcription, protein translation, pro-MMP activation and endogenous 
inhibition by plasma proteins such as 2-macroglobulin and TIMPs (Hobeika et al. 2007; Vartak 
and Gemeinhart 2007; Raffetto and Khalil 2008a). Figure 1-8 demonstrates the structure and 
examples of the five major groups of MMPs. 
MMP/TIMP imbalances have been observed in varicose veins (Aravind et al. 2010; Lim 
et al. 2010). The expression and/or activity of MMP-1, -2, -3, -9, -12, and -13, and TIMP-1 and -3 
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have been shown to be up-regulated in varicose compared to non-varicose veins (Raffetto and 
Khalil 2008b; Lim and Davies). Significant increase of the concentration of pro-MMP-9 and 
leukocytes (L-selectin) were observed in blood sampled from varicose compared to non-varicose 
veins after 30 minutes of postural blood stasis (standing or sitting with the legs hanging down) 
(Jacob et al. 2002). Recently, Raffetto and colleagues showed that increases in the magnitude and 
duration of venous wall tension were associated with over expression of MMP-2 and MMP-9 
(Raffetto et al. 2008). The authors also demonstrated that MMP-2 induced by increases in vein 
wall tension also caused significant venous relaxation (Raffetto et al. 2007). These observations 
suggest that venous hypertension secondary to blood stasis may elevate the production of MMPs, 
which not only increase ECM degradation, but also cause venous relaxation. 
1.5.2.4. Activation of endothelium 
Endothelial cells play active roles in the regulation of vascular inflammation, remodelling 
and tone (Lim et al. 2010). Endothelial cells of varicose veins appeared desquamated and 
degenerated under electron microscopy (Aunapuu and Arend 2005). Such injured endothelial cells 
are activated and known to release various types of inflammatory mediators and growth factors 
(Michiels et al. 2002a; Naoum et al. 2007). Increased expression of inflammatory markers such as 
vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1) and 
von Willebrand factor (vWf) by the endothelium of varicose compared to non-varicose veins have 
been measured (Aunapuu and Arend 2005; Somers and Knaapen 2006). Furthermore, 
significantly more mast cells, macrophages and monocytes infiltration have also been observed in 
varicose compared to non-varicose veins (Yamada et al. 1996; Kakkos et al. 2003; Sayer and 
Smith 2004). Activated leukocytes may also release high amount of superoxide anions and 
proteases which are able to degrade the ECM (Michiels et al. 2002a; Naoum et al. 2007). 
Meanwhile, the release of growth factors including basic fibroblast growth factor (bFGF) and 
platelet-derived growth factors (PDGF) may induce SMC proliferation, migration, and 
dedifferentiation (Badier-Commander et al. 2001; Michiels et al. 2002a; Somers and Knaapen 
2006; Naoum et al. 2007). 
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Figure 1-8 The major groups of matrix metalloproteinases (MMPs) 
The structure of the major groups of MMPs. T, A, and G represent tyrosine, aspartic acid and glycine amino 
acids that are present in the catalytic domain of collagenases 
Besides vascular inflammation and remodelling, endothelium also regulates venous tone 
through the release of various vasoactive substances, some constricting and the others relaxing the 
veins. The imbalance of these vasoactive substances may contribute to the overall relaxation of 
varicose veins (Somers and Knaapen 2006). For e.g. the reduction in factors contributing to 
vasoconstriction such as the noradrenaline, endothelin-1 binding and endothelin-B receptor 
density, probably due to endothelial injury, have been shown in varicose compared to non-
varicose veins (Thulesius et al. 1991; Agu et al. 2002). Meanwhile, factors that contribute to 
vasodilatation including nitric oxide, prostacyclin, and hyperpolarisation of the underlying SMC 
by endothelial-derived hyperpolarising factor have been shown to be up-regulated in varicose 
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compared to non-varicose veins (Somers and Knaapen 2006; Raffetto and Khalil 2008b). 
1.5.2.5. Smooth muscle cell proliferation and migration 
Areas of SMC hypertrophy and proliferation have been observed in the media of varicose 
veins, although regions of atrophy are also present (Milroy et al. 1989; Travers et al. 1996; 
London and Nash 2000; Wali et al. 2003; Somers and Knaapen 2006; Naoum et al. 2007). 
Furthermore, rearrangement and migration of SMC into the intima have also been seen (Wali and 
Eid 2001; Wali and Eid 2002; Somers and Knaapen 2006; Elsharawy et al. 2007). The SMC in 
varicose veins appear disorganised and dedifferentiated from contractile to synthetic and 
proliferative phenotype. They demonstrate features such as vacuolisation and phagocytosis 
(Sansilvestri-Morel et al. 2001; Wali and Eid 2001; Somers and Knaapen 2006). Mediators 
released by endothelium such as PDGF and bFGF may contribute to some of the alterations of 
SMC in varicose veins (Badier-Commander et al. 2001; Michiels et al. 2002a; Somers and 
Knaapen 2006; Naoum et al. 2007) although hormonal changes such as oestrogen and 
progesterone have also been implicated (Kockx et al. 1998; Wali and Eid 2001). For example, the 
estimated medial SMC volume was found to correlate with the expression of oestrogen-receptor- 
(Knaapen et al. 2005). 
The contractile function of the SMC of varicose veins has been shown to be impaired. For 
example, phenylephrine induced contraction was absent in severe varicose veins (Brunner et al. 
2001). Meanwhile, mild varicose veins demonstrated reduced endothelial-independent relaxation 
to nitroprusside (Brunner et al. 2001). The reduction of contractility of SMC cultured from 
varicose veins has also been demonstrated (Cario-Toumaniantz et al. 2002). SMC cultured from 
varicose veins exhibited decreased actin cytoskeleton organisation and fibronectin matrix 
deposition compared to those from non-varicose veins (Cario-Toumaniantz et al. 2002). . 
1.5.2.6. Dysregulation of smooth muscle cell apoptosis 
Apoptosis, a type of programmed cell death, is characterised by membrane blebbing 
(zeiosis), cytoplasmic condensation and activation of endogenous endonucleases as well as 
specific proteases. Apoptosis is an important physiological process in normal development, 
morphogenesis and tissue regulation (Ducasse et al. 2005). Improperly regulated apoptosis may 
contribute to pathological conditions in which faulty DNA repair mechanisms and cell cycle 
disruption are involved such as cancer, Alzheimer‟s disease, ischaemic heart disease, and spinal 
muscular atrophy (Ducasse et al. 2005). 
Dysregulated apoptosis and dysfunction of the cell cycle have been demonstrated in 
varicose veins (Ascher et al. 2000; Ascher et al. 2001; Urbanek et al. 2004; Ducasse et al. 2005; 
Ducasse et al. 2008). The overall number of apoptotic cells and activity were shown to be reduced 
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in varicose compared to non-varicose veins (Ascher et al. 2000; Bujan et al. 2000; Ascher et al. 
2001). The dedifferentiation of the SMC has been suggested to be due to dysregulated apoptosis 
(Jurokova and Milenkov 1982). Differential expression of cyclin D1, a proto-oncogene essential 
for the progression of cell cycle through G1 phase, between varicose and non-varicose veins 
further suggests alteration of cell cycle in varicose veins (Ascher et al. 2000). In varicose veins, 
the expression of cyclin D1 was significantly increased in nuclei but decreased in cytoplasm. The 
expression of bax and poly (ADP-ribose) polymerase (PARP) were shown to be reduced in 
varicose compared to non-varicose veins. Neither bax nor PARP was detectable in the adventitia 
of varicosities, although both were present in non-varicose veins. Bax is a member of the bcl-2 
family and an inducer of apoptosis. PARP is an enzyme involved in genome surveillance and 
DNA repair, and is a macromolecular downstream substrate of apoptosis (Ascher et al. 2001). 
Using immunohistochemistry, significant reduction in the expression of bax and caspase-9 in 
SMC of varicose compared to non-varicose veins has been demonstrated. Meanwhile, the 
expression of caspase 8 and Fas in SMC did not differ significantly between varicose and non-
varicose veins (Ducasse et al. 2005; Ducasse et al. 2008). Therefore, the intrinsic rather than the 
extrinsic pathway seems dysregulated in varicose veins since bax and caspase-9 are involved in 
the former, while caspase 8 and Fas in the latter (Ducasse et al. 2005; Ducasse et al. 2008) (Figure 
1-9). 
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Figure 1-9 Apoptosis pathway 
Schematic diagram summarises the intrinsic, extrinsic and common pathway of apoptosis 
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1.6. HYPOXIA AS A POTENTIAL CONTRIBUTING FACTOR TO VARICOSE VEIN 
FORMATION 
Vein wall hypoxia has been suggested as a contributing factor for varicose vein formation 
(Taccoen et al. 1996; Michiels et al. 2002a; Somers and Knaapen 2006; Lim and Davies 2009). 
For several decades, many in vivo and in vitro studies have assessed the relationship between 
hypoxia and varicose vein formation. However, opinions remain divided on the evidence 
evaluating hypoxia as a possible factor contributing to varicose vein formation. 
1.6.1. Blood Supply to the Vein Wall 
Vein wall oxygenation is achieved by diffusion of oxygen from blood in the lumen and 
vasa vasorum (Figure 1-10). The lumen of the superficial venous system of the lower limbs 
contains deoxygenated blood from skin and subcutaneous tissue of the legs. Meanwhile, vasa 
vasorum of the saphenous veins and tributaries originate from feeding arteries in the surrounding 
adipose tissue and penetrate the fascia of the veins before opening into the media and adventitia 
(Kachlik et al. 2003). It has been reported that the main sources of blood in the vasa vasorum for 
the GSV were the external pudendal artery and descending artery of the knee, while for the SSV 
were the small saphenous artery which was a branch of the popliteal artery (Lefebvre and Lescalie 
1996). 
 
 
Figure 1-10 Oxygen supply of vein wall 
Vein wall receives oxygen from luminal blood and vasa vasorum 
In a study to assess the oxygenation of the vein wall, Taccoen and colleagues used a 
microdriven stepwise progression needle probe attached to a computerised polarographic system 
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to measure the in vivo oxygen tension across the saphenous vein wall of patients undergoing 
surgery. The authors found that the oxygen tension of the saphenous vein wall decreased from the 
adventitia to the union of the middle and inner third of the media followed by a marked increased 
in oxygen tension in the intima and lumen (Taccoen et al. 1996). This suggested that the 
oxygenation of the inner one-third of the vein wall was provided by luminal blood and the outer 
two-third by vasa vasorum. This was supported by several detailed histological and anatomical 
studies of vasa vasorum including those in saphenous veins. These studies found that in normal 
veins, vasa vasorum only opened into the adventitia and outer two-third of the media but never 
into the inner one-third and intima (Kachlik et al. 2003; Kachlik et al. 2007). The relative 
oxygenation and nourishment of the vascular wall contributed by the luminal blood and vasa 
vasorum may vary depending on several factors including the type and size of the vessel and 
luminal oxygen tension (PO2) (Heistad et al. 1986; Kachlik et al. 2003). Despite having a thicker 
wall, the overall relative contribution of oxygenation from blood in the vasa vasorum is less in 
arteries than in veins (Heistad et al. 1986). It has been postulated that low oxygen content of the 
luminal blood in the veins is compensated by increased formation of vasa vasorum (Heistad et al. 
1986). Conversely, veins with relatively thinner walls were found to have lower blood flow in the 
vasa vasorum in comparison to veins with thicker media (Heistad et al. 1986; Kachlik et al. 2007). 
It has also been found that vasa vasorum dilate leading to increase in blood flow when veins were 
subjected to acute hypoxia (Heistad et al. 1986). 
Pathological changes in the vein wall including intimal hyperplasia and degenerative 
changes in the innermost layer such as in varicosities and phlebosclerosis have also been found to 
be associated with alterations to the distribution and density of vasa vasorum. In areas of intimal 
hyperplasia, vasa vasorum were found to penetrate the whole media as compared to only the outer 
two-third of the media in normal segments of veins (Kachlik et al. 2007). Similar observations 
were reported by Bigel and Taccoen in varicose veins where the vasa vasorum were increased 
close to the intimal layer but not in non-varicose veins (Bigel and Taccoen 1996). In a study of 22 
patients, Kachlik and colleagues found increased numbers of vasa vasorum in varicose veins 
especially those of recurrent disease and those with thrombophlebitis compared to non-varicose 
veins. Interestingly, tortuosities and irregular dilatations of adventitial veins were also observed in 
varicose veins (Kachlik et al. 2008). It has been suggested that degenerative changes and intimal 
hyperplasia in the innermost layer of the vein wall cause intraluminal and/or intramural hypoxia 
lead to an increase in vasa vasorum via neovascularisation ensuring adequate oxygenation of the 
entire media (Kachlik et al. 2007). 
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1.6.2. Mechanisms of Vein Wall Hypoxia in Varicose Veins 
Inadequate oxygen supply from luminal blood or vasa vasorum or both could potentially 
cause vein wall hypoxia. Two mechanisms, both related to blood stasis and venous hypertension 
(Figure 1-11), have been postulated to cause hypoxia to varicose vein wall hypoxia: 
1. „Endoluminal hypoxia‟: stagnation of venous blood flow results in reduced oxygen 
replenishment in comparison to normal venous flow. Endothelial and inner layers of the 
vein wall are first affected in endoluminal hypoxia (Michiels et al. 2000; Nicolaides 2003; 
Colm Malone and Agutter 2009) 
2. „Medial hypoxia‟: distension of the vein by hydrostatic pressure secondary to blood stasis 
causes compression of vasa vasorum. Therefore, the media and outer layers of the vein 
wall are first affected (Nicolaides 2003; Colm Malone and Agutter 2009) 
1.6.3. Luminal Blood Oxygenation in Varicose and Non-Varicose Veins 
For many decades, researchers have attempted to assess the oxygen content of venous 
blood carried in varicose and non-varicose veins. However, findings from these studies have been 
inconsistent as some studies demonstrated lower oxygen content in blood from varicose compared 
to non-varicose veins (deTakats et al. 1929; McEwan and McArdle 1971; Reikeras and Sorlie 
1983), whereas others showed no significant differences (Holling et al. 1938; Schraibman 1966; 
Scott et al. 1990; Wali 2002; Murphy and Hands 2008). Paradoxically, some studies even 
reported higher oxygen content in blood of varicose than non-varicose veins (Blalock 1929; 
Holling et al. 1938; Blumoff and Johnson 1977; Baron and Cassaro 1986; Scott et al. 1990). 
Numerous factors may have contributed to these variations. Clearly, huge inconsistencies in study 
design and sampling variations existed between studies as contralateral superficial veins, deep 
veins, femoral veins and antecubital veins had all been used as controls and the posture of patients 
during sampling was not consistent (Blalock 1929; deTakats et al. 1929; Wali 2002). Moreover, 
in some studies, non-varicose and varicose veins of the same patients were compared while in 
others, patients without varicosities were recruited as controls (deTakats et al. 1929; Jacob et al. 
2002). 
Studies comparing the oxygen content of blood from varicosities with blood from 
superficial leg veins of patients without varicose vein disease as controls are summarised in Table 
1-2 and Table 1-3. On the basis of current evidence, it is not possible to conclude that the blood in 
the lumen of varicose veins contains less oxygen content than blood in non-varicose veins. 
Interestingly, in non dependent (lying) positions, the oxygen content of blood from varicose veins 
appeared to be similar or even higher than non-varicose veins. In the dependent positions, the 
oxygen content of blood from both varicose and non-varicose veins decreased, but the reduction 
may be greater in blood from varicose veins (Holling et al. 1938; Scott et al. 1990). 
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Table 1-2 Oxygen tension in varicose veins 
Summary of the designs and findings of studies that measure and compare oxygenation of blood in 
varicosities of patients and leg veins of controls with no varicose vein disease. PvO2: oxygen tension of 
venous blood 
Study Patients Controls Other 
Veins 
Studied 
Positions Results 
(Holling et 
al. 1938) 
Varicose 
veins of 13 
patients (7 
without 
and 6 with 
ulcers) 
Similarly 
located veins of 
4 patients with 
no varicose 
veins. 
Nil “from bed 
and seated 
for 2 hours 
with his 
foot in a 
dependent 
position” 
No significant difference 
between oxygenation of 
blood of varicose and non-
varicose veins 
(Schraibman 
1966) 
Varicose 
veins of 62 
patients 
Leg veins of 14 
patients with no 
varicose veins 
Femoral 
arteries 
and 
femoral 
veins 
2 and 10 
minutes of 
standing 
from a 
recumbent 
position 
No significant difference 
between the oxygen 
saturation of blood from 
varicose and non-varicose 
veins. 
(McEwan 
and 
McArdle 
1971)  
Varicose 
veins of 14 
patients 
with 
impaired 
distal skin 
nutrition 
Leg veins of 6 
patients without 
varicose veins  
Nil Sitting 
with 
studied 
legs in 
dependent 
position 
for 10-15 
minutes 
PvO2, oxygen saturation and 
calculated venous oxygen 
content were significantly 
lower in blood from varicose 
than non-varicose veins. 
Oxygen extraction in tissues 
was significantly higher in 
varicose than non-varicose 
veins.  
(Blumoff 
and Johnson 
1977) 
Varicose 
veins of 20 
patients 
Saphenous veins 
harvested for 
either aortico-
renal or femoro-
popliteal bypass 
graft of 18 
patients with no 
varicose veins 
Femoral 
arteries, 
femoral 
veins and 
proximal 
saphenou
s veins 
Supine  PvO2 was significantly 
higher in varicose than non-
varicose saphenous veins. 
PvO2 of superficial leg veins 
was significantly higher than 
those of femoral veins in 
patients with and without 
varicose veins.  
(Reikeras 
and Sorlie 
1983) 
Varicose 
veins of 22 
patients (6 
were 
recurrence) 
Leg veins of 9 
patients with no 
varicose veins 
Popliteal 
veins  
Standing PvO2 was significantly lower 
in varicose than non-varicose 
saphenous veins. PvO2 was 
significantly lower in 
varicose than contralateral 
non-varicose veins of 
patients with varicose veins. 
(Baron and 
Cassaro 
1986) 
Varicose 
veins of 49 
patients 
Leg veins of 43 
patients with no 
varicose veins 
Antecubi
tal veins  
Recumbent 
position 
PvO2, oxygen saturation and 
calculated venous oxygen 
content were significantly 
higher in blood from varicose 
than non-varicose veins.  
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Continued... 
(Scott et al. 
1990) 
Varicose 
veins of 13 
patients 
Leg veins of 13 
patients without 
varicose veins 
Antecubi
tal veins  
Laid 
supine for 
20 minutes 
and stood 
for 30 
minutes 
with arms 
at the 
sides. 
PvO2 was significantly 
higher in varicose than non-
varicose veins during supine. 
No significant difference in 
PvO2 between varicose and 
non-varicose veins during 
standing. PvO2 was 
significantly higher in leg 
veins than in arm veins in 
both varicose and non-
varicose vein groups during 
supine. PvO2 in leg veins 
dropped significantly from 
supine to standing in both 
varicose and non-varicose 
vein groups.  
(Wali 2002) Varicose 
veins of 21 
patients  
Leg veins of 21 
controls 
(doctors and 
nurses) with no 
varicose veins 
Antecubi
tal veins 
At least 5 
minutes of 
standing 
before 
venepunct
ure of leg 
veins and 
sitting for 
antecubital 
veins 
No significant difference in 
PvO2 and oxygen saturation 
between blood of varicose 
and non-varicose veins 
during standing. PvO2 and 
oxygen saturation were 
significantly higher in veins 
of lower than upper limbs of 
patients with varicose veins. 
In controls, oxygen saturation 
and PvO2 were also seemed 
to be higher in veins of lower 
than upper limbs (only 
significant in the former). 
(Murphy 
and Hands 
2008) 
Varicose 
veins of 39 
patients 
(C2-C6) 
Median cubital 
veins of 10 
patients 
underwent 
hernia repair 
and 
cholecystectomy 
Nil 2 minutes 
of lying 
and 2 
minutes of 
standing. 
No significant difference of 
PvO2 between varicose and 
control veins. Reduction of 
PvO2 in both varicose and 
control veins during standing 
compared to supine 
(significance not reported)  
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Table 1-3 Oxygen tension in blood sampled from varicosities 
Mean values of the oxygen tension and saturation of blood sampled from varicosities of patients and leg 
veins of controls with no varicose veins in gravity dependent and non dependent positions. 
(NGDP: Non-gravity dependent positions; GDP: Gravity dependent positions, Sats: saturation) 
* Only 12 readings out of the 13 patients studied were available in the article 
† Only 12 readings out of the 14 patients studied were available in the article 
ﬃ Only 61 readings out of the 62 patients studied were available in the article 
 
STUDY CONTROLS (NO VARICOSE VEINS) PATIENTS (WITH VARICOSE VEINS) 
N Mean 
PO2 in 
NGDP 
(mmHg) 
Mean 
O2 sats 
in 
NGDP 
(%) 
Mean 
PO2 in 
GDP 
(mmHg) 
Mean 
O2 
sats 
in 
GDP 
(%) 
N Mean 
PO2 in 
NGDP 
(mmHg) 
Mean 
O2 sats 
in 
NGDP 
(%) 
Mean 
PO2 in 
GDP 
(mmHg) 
Mean 
O2 
sats 
in 
GDP 
(%) 
(Holling et 
al. 1938) 
4 42.1 71.4 35.8 63.4 13 39.3 70.2* 31.1* 54.0 
(Schraibman 
1966) 
14 Not 
tested 
Not 
tested 
Not 
tested 
57.4
†
 62 Not 
tested 
Not 
tested 
Not 
tested 
55.9
ﬃ
 
(McEwan 
and 
McArdle 
1971) 
6 Not 
tested 
Not 
tested 
35.2 78.3 14 Not 
tested 
Not 
tested 
22.7 54.4 
(Blumoff 
and Johnson 
1977) 
18 54.0 Not 
tested 
Not 
tested 
Not 
tested 
20 69.0 Not 
tested 
Not 
tested 
Not 
tested 
(Reikeras 
and Sorlie 
1983)  
9 Not 
tested 
Not 
tested 
35.3 Not 
tested 
22 Not 
tested 
Not 
tested 
27.0 Not 
tested 
(Baron and 
Cassaro 
1986) 
43 36.1 64.2 Not 
tested 
Not 
tested 
49 59.3 87.6 Not 
tested 
Not 
tested 
(Scott et al. 
1990) 
13 34.1 Not 
tested 
28.1 Not 
tested 
13 45.7 Not 
tested 
30.1 Not 
tested 
(Wali 2002) 21 Not 
tested 
Not 
tested 
31.0 54.8 21 Not 
tested 
Not 
tested 
31.0 52.3 
(Murphy 
and Hands 
2008) 
10 Not 
specified 
Not 
tested 
Not 
specified 
Not 
tested 
39 33.8 Not 
tested 
29.3 Not 
tested 
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1.6.4. Oxygen Tension of Varicose and Non-Varicose Vein Wall 
Literature search only found one study that measured and compared vein wall oxygen 
tension between varicose and non-varicose veins in vivo. In this study Taccoen and colleagues 
compared the vein wall oxygen tension of 31 varicose saphenous veins from 21 patients during 
venous surgery with 7 non-varicose saphenous veins in patients undergoing femoro-popliteal 
bypass surgery. The authors reported that the average minimum values in the media was 
significantly lower in varicose compared to non-varicose veins; 7.9mmHg (1%) versus 
13.4mmHg (1.8%); P<0.05 (Taccoen et al. 1996). Although study samples were small, this was 
the only study that measured the vein wall oxygen tension directly and it reported that the wall of 
varicose veins is hypoxic. 
1.6.5. Molecular Studies 
1.6.5.1. Expression studies 
Venous stasis may cause oxidative stress by initiating a series of haemodynamic, 
metabolic, and nutritional changes including tissue hypoxia (Thomas et al. 1988; Smith 1999; 
Takase et al. 2000b). In a study of 45 patients with varicosities, down-regulation of cytochrome-
oxidase C and increased pyruvate expression in varicose compared to non-varicose portions of the 
veins suggested a reduction of oxidative phosphorylation in varicose veins (Lengyel and Acsady 
1990). Varicose vein wall has also been shown to consume less oxygen and glucose (Niebes 
1996), and generate more reactive oxygen metabolites (ROMs), including increased thiobarbituric 
acid reactive substances, myeloperoxidase and xanthine oxidase than non-varicose veins 
(Glowinski and Glowinski 2002). 
Elevated ROMs has been associated with vein wall injury and CVI (Thomas et al. 1988; 
Smith 1999; Takase et al. 2000b; Flore et al. 2003). Moreover, leukocytes in the blood of varicose 
veins produced more ROMs than arm veins in patients with CVI (Stvrtinova and Ferencikova 
1992; Whiston et al. 1994). Leukocyte trapping and oxygen free radical (superoxide dismutase 
and superoxide anions) retention in lower limbs were also significantly increased in patients with 
varicose veins compared to those without in gravity dependent positions (Ciuffetti et al. 1994). 
Interestingly, levels of ROMs from foot veins of patients with incompetent GSV were 
significantly reduced and returned to normal levels following GSV stripping (Flore et al. 2003), 
suggesting that venous reflux caused elevated ROM concentrations. 
Jacob and colleagues investigated the effect of blood stasis on the expression of 12 
biological markers and measured the oxygen tension of blood sampled from varicose veins and 
paired brachial veins (controls) of 22 patients (Jacob et al. 2002). Several plasma endothelial and 
leukocyte activation markers including ICAM-1, VCAM-1, angiotensin converting enzyme 
(ACE), pro-MMP and L-selectin were significantly elevated by postural blood stasis (limbs in the 
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dependent position compared to lying flat) in varicose veins. Such elevations were not observed 
in blood sampled from brachial veins. Furthermore, up-regulation of these markers in varicose 
veins was inversely proportional to the oxygen tension of the blood sampled. This study 
demonstrated that venous endothelium and leukocytes were activated by blood stasis. These 
changes were associated with reductions in oxygen tension in varicose veins. 
1.6.5.2. In vitro studies 
Venous endothelial response to hypoxia has often been studied in cell cultures including 
human umbilical vein endothelial cell culture (HUVEC). Venous endothelial cell culture studies 
have demonstrated that hypoxia altered venous metabolic regulatory pathways including 
reduction of adenosine triphosphate (ATP) and oxidative phosphorylation, and increases in 
glycolysis (Arnould et al. 1992; Janssens et al. 1995). Increased intracellular calcium ion (Ca
2+
) 
concentration has also been shown in hypoxic venous endothelial cells leading to activation of 
phospholipid A2 and elevated prostaglandin synthesis (Michiels et al. 1993b; Michiels et al. 
1994). Alteration to these cellular processes is thought to cause the release of inflammatory 
mediators (Michiels et al. 2002a). Activation of venous endothelial cells by hypoxia also 
increases the release of bFGF and prostaglandin F2 which are known to stimulate SMC migration 
and proliferation, a feature commonly observed in varicosity (Michiels et al. 1994; Calvani et al. 
2006; Lim and Davies 2009). In vitro studies using venous endothelial cell culture have 
demonstrated that hypoxia increased angiogenesis by up-regulating the release of pro-angiogenic 
factors such as VEGF and bFGF (Calvani et al. 2006; Zhu et al. 2008). 
Venous endothelial cells also respond to hypoxia by up-regulating HIFs (Coulet et al. 
2003; Haider et al. 2005; Jiang et al. 2009). HIFs are nuclear transcriptional factors that regulate 
the transcription of many genes involved in oxygen homoeostasis which will be discussed in 
details below (Semenza 2009b). The transcriptional activity of HIF in venous endothelial cells has 
been shown to be elevated during hypoxia. Examples of genes regulated by HIF that have been 
shown to be increased in hypoxic venous endothelial cells include VEGF and endothelial isoform 
of nitric oxide synthase (eNOS) (Coulet et al. 2003; Haider et al. 2005; Jiang et al. 2009). 
Increased PGI2 and cyclo-oxygenase-2 (COX-2) expression in hypoxic venous endothelial cells 
has also been shown to be HIF-dependent (Cook-Johnson et al. 2006). 
Besides cell culture, vein organ cultures have also been used to study whole venous tissue 
behaviour in relation to hypoxia. An early study of oxidative metabolism and glucose transport in 
varicose vein organ cultures suggested that the oxygen consumption of human varicose veins was 
relatively low and comparable to healthy veins investigated in other studies (Matagne and Gilles 
1977). However, in the absence of a control group, it is difficult to draw firm conclusions 
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regarding oxygen consumption between varicose and non-varicose veins from this study 
(Matagne and Gilles 1977). 
Leukocyte infiltration has been found to be more common in histological specimens of 
varicose than non-varicose veins (Aunapuu and Arend 2005; Somers and Knaapen 2006). 
Adhesion molecules expression such as VCAM-1, ICAM-1 and vWf which activate leukocytes 
were found to be up-regulated in varicose compared to non-varicose veins (Aunapuu and Arend 
2005; Somers and Knaapen 2006). Activated leukocytes secrete high levels of superoxide anions 
and proteases which degrade ECM (Michiels et al. 2002a). To investigate if such phenomenon 
can be caused by hypoxia, HUVEC were exposed to hypoxia and treated with non-stimulated 
polymorphonuclear (PMN) cells (Michiels et al. 1993a; Arnould et al. 1996; Bougelet et al. 
1998). Such model demonstrated a clear increase in PMN adherence to HUVEC when the PO2 
decreased below 25mmHg (Michiels et al. 2002a). Both HUVEC and PMN were activated by 
hypoxia with up-regulation of adhesion molecules including CD-18 dependent adhesion 
molecules and ICAM-1, superoxide anions, and leukotriene B4 (LTB4) (Arnould et al. 1993; 
Michiels et al. 1993a; Arnould et al. 1994; Arnould et al. 1995). Similar findings were also 
observed in whole vein explants exposed to hypoxia. Michiels and colleagues described an in 
vitro model that assessed the effect of hypoxia on saphenous vein explants in the presence of non-
stimulated PMN (Michiels et al. 1997). Non-varicose segments of GSV incubated in hypoxic, and 
normoxic environments were perfused with radio-labelled PMN. This study demonstrated 
increased number of activated PMN retained in veins incubated in hypoxic than normoxic 
conditions. PMN in hypoxia were also found to produce more superoxide anions and LTB4. Such 
in vitro models revealed similar histological appearances and behaviours as varicose veins in vivo, 
hence prompting the authors to postulate that hypoxia, as a result of blood stasis, was the trigger 
for endothelial cell responses that could cause alterations of the venous wall and varicose vein 
development (Michiels et al. 2002a). 
1.7. HYPOXIA-INDUCIBLE FACTORS 
Oxygen is required for oxidative phosphorylation in the mitochondria for the efficient 
production of ATP in all aerobic organisms. An adequate and efficient ATP production is 
essential to maintain normal cellular functions. Inefficient oxidative metabolism during hypoxia 
will also increase the generation of reactive oxygen species (ROS) such as superoxide anions and 
hydrogen peroxide which in excess may cause cellular damage or even death (Semenza 2009b). 
On the other hand, hypoxia can be important in normal physiology and development. For 
example, in embryonic development oxygen tension is related to neural tube closure, mediation of 
apoptosis, and normal morphological development during gestation (Ziello et al. 2007). Since 
oxygen tension in the macro- and microenvironment of organisms and cells changes very 
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frequently, it is important for an organism to be able to sense and respond to changes of its 
surrounding oxygen tension. One such cellular „oxygen sensing‟ mechanism that has evolved in 
metazoan cells is the HIF (Semenza 2009b). The identification of HIF has helped us to advance 
our understanding of cellular responses and adaptations to hypoxia significantly, in the context of 
both normal physiology and pathophysiology. 
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Figure 1-11 Summary of varicose vein wall hypoxia and potential therapeutic targets 
Schematic diagram of potential mechanisms that induce hypoxia and lead to varicose vein formation, and 
possible pharmacological targets. Potential targets are numbered with Arabic numerals with their 
corresponding group of drug pharmacological agents shown in the gray box. (eNOS: endothelial nitric 
oxide synthase; VEGF: vascular endothelial growth factor; bFGF: basic fibroblast growth factor; PDGF: 
platelet-derived growth factor; MMP: matrix metalloproteinase; TIMP: tissue inhibitor of matrix 
metalloproteinase, COX-2: cyclo-oxygenase-2; NSAID: non-steroidal anti-inflammatory drug) 
The identification of a hypoxia response element (HRE; 5‟(A/G)CGTG-3‟) in the 3‟ 
enhancer of the gene for erythropoietin (EPO) led to the discovery of the HIF protein which binds 
to HRE under hypoxia (Semenza and Wang 1992). HIFs are nuclear transcriptional factors which 
regulate genes involved in oxygen homoeostasis. HIFs are heterodimers consisting of a labile 
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HIF- subunit and a constitutively expressed HIF- subunit (also known as aryl hydrocarbon 
receptor nuclear translocator or ARNT) (Wang et al. 1995; Semenza 2009a). HIF- and HIF- are 
members of the bHLH-PAS (basic helix–loop–helix-Per-Arnt/AhR-Sim) superfamily of nuclear 
transcriptional factors (Wang et al. 1995; Gaber et al. 2005; Ke and Costa 2006; Semenza 2009b). 
The bHLH and PAS motifs are required for HIF- and HIF- subunit to form heterodimer. 
Meanwhile, the downstream basic region binds specifically to the HRE DNA sequence of its 
target genes. HIF- is highly inducible by hypoxia (Crews 1998; Ke and Costa 2006). Oxygen 
regulates the stability of HIF- through the oxygen-dependent degradation domain (ODD), 
consisting of approximately 200 amino acids (Pugh et al. 1997; Huang et al. 1998; Gaber et al. 
2005). The ODD overlaps with the N-terminal transactivation domain or NTAD (Ruas et al. 2002; 
Gaber et al. 2005; Ke and Costa 2006). Meanwhile, a second transactivation domain, CTAD is 
located at the C-terminal half of HIF- (Jiang et al. 1997; Patiar and Harris 2006). The CTAD 
interacts with transcriptional co-activators including CREB binding protein (CBP) and p300 to 
activate target gene transcription (Lando et al. 2002b; Ziello et al. 2007). 
So far, three HIF- isotypes (HIF-1, -2 and -3) have been identified (Gaber et al. 
2005; Ke and Costa 2006). HIF-1α is the most studied and characterised isotype. HIF-2α is also 
known as endothelial PAS-1 (EPAS-1) protein, HIF-like factor (HLF), HIF-related factor (HRF), 
and member of the PAS superfamily 2 (MOP2) (Ke and Costa 2006). HIF-1 and HIF-2 share 
relatively similar gene sequence, protein structure, biochemical properties and regulatory 
pathways (Ema et al. 1997; Tian et al. 1997; Gaber et al. 2005; Ke and Costa 2006). For e.g. HIF-
2α shares 48% amino acid sequence identity with HIF-1α (Ke and Costa 2006). Like HIF-1α, 
HIF-2α also dimerises with HIF-1β and binds on HRE (Gaber et al. 2005; Ke and Costa 2006). 
However, HIF-1α and HIF-2α have unique tissue distributions, embryonic deletion phenotypes 
and effects on tumorigenesis (Gaber et al. 2005; Ke and Costa 2006; Patel and Simon 2008; 
Semenza 2009a). HIF-1α is expressed in all nucleated cells while the expression of HIF-2α is 
restricted to specific cell types, including vascular endothelial cells, renal interstitial cells, 
hepatocytes, cardiomyocytes, and astrocytes (Talks et al. 2000; Wiesener et al. 2003). However, 
very little HIF-1α and HIF-2α proteins are detectable in normal tissues in normoxia (Talks et al. 
2000). Meanwhile, HIF-3α which is less closely related to HIF-1α and HIF-2α is also expressed in 
many tissues (Gaber et al. 2005; Ke and Costa 2006). However, the regulation and function of 
HIF-3 remain unclear although it may be involved in the negative regulation of HIF-induced 
gene transcription (Gaber et al. 2005; Ke and Costa 2006). 
Studies using knockout mice have revealed that the expression of HIF-1α and HIF-1β is 
required for the normal development of the circulatory system including the heart, blood vessels, 
and blood cells (Maltepe et al. 1997; Iyer et al. 1998; Ryan et al. 1998). HIF also mediates a 
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multitude of cellular and systemic physiological and pathophysiological responses to hypoxia or 
ischaemia in postnatal life (Semenza 2009a). 
1.7.1. Regulation of HIF-α 
1.7.1.1. Oxygen-dependent regulation of HIF-α 
The expression of HIF-α in many tissues increases exponentially as oxygen concentration 
declines (Semenza 2009a). Both the stability and transcriptional activity of HIF-1 and HIF-2 
are negatively regulated by oxygen-dependent hydroxylation. The regulation of HIF- is 
summarised in Figure 1-12. Under normoxia, the proline residue 402 and/or 564 of HIF-1 and 
HIF-2 protein subunits is hydroxylated by prolyl hydroxylase domain (PHD) enzymes, 
particularly PHD-2 (Huang et al. 2002; Muz et al. 2009; Semenza 2009b). The PHDs require 
oxygen and -ketoglutarate as substrates to catalyse a dioxygenase reaction in which one oxygen 
atom is inserted into -ketoglutarate to form succinate and CO2 (Chowdhury et al. 2008; Kaelin 
and Ratcliffe 2008). Hydroxylation of the proline residue is essential for the binding of VHL 
protein which interacts with Elongin C, facilitating the recruitment of ubiquitin ligase complex. 
Ubiquitination of HIF-1 and HIF-2 marks them for proteosomal degradation (Salceda and Caro 
1997; Maxwell et al. 1999; Kamura et al. 2000; Kaelin and Ratcliffe 2008; Semenza 2009b). 
Besides prolyl hydroxylation by PHDs, HIF-1 and HIF-2 are also subjected to hydroxylation 
of the asparagine residue 803 by factor-inhibiting HIF-1 (FIH-1) during normoxia (Mahon et al. 
2001). Asparaginyl hydroxylation negatively regulates HIF-1 and HIF-2 transactivation 
activity by blocking the interaction of the transactivation domain with the co-activator p300 or 
CBP (Lando et al. 2002a; Muz et al. 2009; Semenza 2009b). 
In hypoxia, both oxygen-dependent hydroxylation activity of PHD and FIH-1 are 
suppressed as a result of substrate (oxygen) deprivation (Patiar and Harris 2006; Semenza). 
Furthermore, hypoxia also increases ROS production in the mitochondria. ROS may inhibit the 
PHDs and FIH-1 by oxidising a ferrous ion in the catalytic site (Gruber et al. 2007; Kaelin and 
Ratcliffe 2008). Inhibition of the hydroxylation in hypoxia thereby increases HIF-1 and HIF-2 
stabilisation and transactivation (Gaber et al. 2005; Ke and Costa 2006). HIF-1 and HIF-2 
dimerise with HIF- in the nucleus The dimeric complexes bind the HRE in the target genes 
activating their transcription (Hervouet et al. 2007; Moon et al. 2007; Taylor 2008). Figure 1-12 
summarises oxygen-dependent regulation of HIF-. 
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Figure 1-12 Oxygen-dependent regulation of HIF-α 
Summary of oxygen-dependent regulation of HIF-α protein. Blue arrows represent the sequence of events 
that occur during normoxia, whereas red lines/arrows indicate those that happen during hypoxia. 
1.7.1.2. Oxygen-independent regulation of HIF-α 
The expression of HIF-α is not only limited to oxygen-dependent regulation. Oxygen-
independent pathways may regulate the synthesis and degradation of HIF-. Oxygen-independent 
mechanisms for regulation of HIF- also play important physiological and pathological roles 
(Semenza 2004). Many of the oxygen-independent mechanism for HIF- regulation are also 
involved in cell survival, growth and proliferation which will inevitably lead to increase in 
oxygen demand and consumption. Therefore, it is not surprising that these mechanisms also 
regulate the expression of HIF- to enable the cells with increasing oxygen demand to cope 
despite the ambient oxygen tension is normal (Zhong et al. 2000; Laughner et al. 2001; Fukuda et 
al. 2002; Treins et al. 2002). 
Extracellular signals such as mechanical stretch, hormones, growth factors, cytokines and 
metallic ions have been shown to regulate the synthesis of HIF- (Gaber et al. 2005; Milkiewicz 
et al. 2007a; Semenza 2009b). The regulation of HIF- synthesis by these factors remains not 
fully understood but is thought to involve the activation of phosphatidylinositol-3-kinase (PI3K) 
and mitogen-activated protein kinase (MAPK) pathways (Chang et al. 2003; Gaber et al. 2005; 
Milkiewicz et al. 2007a). Hormones, growth factors, cytokines and other ligands binds cognate 
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receptors tyrosine kinases and G-protein-coupled receptors on the cell membrane causing the 
stimulation of PI3K and MAPK pathways (Semenza 2009b). Meanwhile, integrins have been 
shown to transduce mechanical stretch to initiate signalling cascades and cause MAPK activation 
(Oktay et al. 1999). Also, mechanical stretch may increase the generation of ROS which are 
capable of activating MAPK (Hishikawa et al. 1997; Ungvari et al. 2003). Furthermore, 
mechanical stretch may stimulate PI3K by activating Ca
2+
 influx through transient receptor 
potential ion channels such as TRPV4 (Thodeti et al. 2009). 
Activation of PI3K phosphorylates the serine-threonine kinase AKT, a protein kinase B. 
Activated AKT then activates the mammalian target of rapamycin (mTOR) which in turn 
phosphorylates p70 S6 kinase (p70
S6K
) and eIF-4E binding protein 1 (4E-BP1), both are key 
translational regulators. Activation of p70
S6K
 leads to the phosphorylation of ribosomal protein 
S6. Meanwhile, phosphorylation of 4E-BP1 blocks its ability to interact with and inhibit eIF-4E, a 
critical regulator of cap-dependent mRNA translation. These actions of mTOR, which can be 
specifically inhibited by rapamycin, increase the rate of translation of a subset of cellular mRNAs 
(Jefferies et al. 1994; Hay and Sonenberg 2004; Semenza 2009b). Figure 1-13 summarises the 
oxygen-independent regulation of HIF-1α synthesis. 
RACK1 protein can bind to HIF-1α, substituting VHL protein in recruiting an E3-
ubiquitin –protein ligase complex and causing proteosomal degradation of HIF-1α (Liu et al. 
2007a). Unlike the PHD-2-VHL induced HIF-1α degradation which requires O2, RACK1 
mediated ubiquitination of HIF-1α is oxygen-independent. RACK1 has been shown to compete 
with heat shock protein 90 (HSP90) for the binding to the PAS-A subdomain of HIF-1α (Liu et al. 
2007a). Inhibition of HSP90 will therefore, cause unopposed RACK1 binding, increasing 
ubiquitination and proteosomal degradation of HIF-1α even when VHL is lacking (Isaacs et al. 
2002; Liu et al. 2007a; Liu et al. 2007b). Phosphorylation of RACK1 has been shown to promote 
dimerisation of RACK1 monomers which is required for the recruitment elongin C to HIF-1α. 
The binding of calcineurin, a Ca
2+
/calmodulin-dependent serine/threonine protein phosphatase, to 
RACK1 mediates the dephosphorylation, thereby preventing HIF-1α ubiquitination and 
proteosomal degradation (Liu et al. 2007b; Semenza 2009b). 
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Figure 1-13 Oxygen-independent regulation of HIF-1α synthesis 
Schematic diagram summarising the pathways of oxygen-independent regulation of HIF-1α synthesis by 
extracellular signals including hormones, cytokines, metallic ions, mechanical stress and radiation. 
Schematic diagram was modified from (Semenza 2009b). 
1.7.2. Adaptive Responses and Genes Mediated by HIF 
Cells mediate various adaptive responses to hypoxia in order to increase their survival. 
HIF has been found to be the master-switch for most of these responses. These adaptive responses 
include glucose and energy metabolism, angiogenesis, erythropoiesis, pH regulation, matrix 
metabolism, vascular tone, cell survival and apoptosis, and cell motility (Semenza 2003; Hervouet 
et al. 2007; Muz et al. 2009; Semenza 2009a; Semenza 2010b). Table 1-4 summarises examples 
of genes that are known to be regulated by HIFs (Semenza 2003; Gaber et al. 2005; Petrella et al. 
2005; Carroll and Ashcroft 2006; Ke and Costa 2006; Patiar and Harris 2006; Patel and Simon 
2008; Muz et al. 2009; Semenza 2009b). 
1.7.2.1. Glucose and energy metabolism, and pH regulation 
Inadequate oxygen supply during hypoxia causes cells to switch from tricarboxylic acid 
(TCA) cycle and oxidative phosphorylation that produces 38 ATP per cycle, to glycolysis which 
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only synthesises 2 ATPs per cycle as the main source of ATP (Ke and Costa 2006). Therefore, 
virtually all the enzymes involved in glycolysis are increased by HIF (Wenger 2002; Ke and 
Costa 2006). Furthermore, HIF also increases the transportation of glucose molecules into the 
hypoxic cells to meet the demand of increases in glycolysis by up-regulating the expression of 
glucose transporter-1 and -3 (GLUT-1 and -3) (Chen et al. 2001). Increases in glycolysis also 
elevate the production of pyruvate and lactate that reduce the pH of the cellular environment. 
Therefore, HIF also mediates pH buffering enzymes such as carbonic anhydrase 9 (CA9) which 
regulates the surrounding pH (Potter and Harris 2004; De Simone and Supuran 2010). 
1.7.2.2. Angiogenesis 
Angiogenesis is a process of new blood vessels formation. Angiogenesis is activated 
during ischaemia to increase the formation of new blood vessels for the delivery of more oxygen 
to hypoxic cells. As cells grow and proliferate, the increasing oxygen demand of the cells is met 
by angiogenesis which ensures that more blood vessels are formed to deliver more oxygen. HIF is 
known to regulate the expression of various angiogenic growth factors including VEGF, stromal-
derived factor-1 (SDF-1), placental growth factor (PlGF), angiopoietin (ANGPT)-1 and -2, and 
PDGF-B (Forsythe et al. 1996; Kelly et al. 2003; Ceradini et al. 2004; Bosch-Marce et al. 2007; 
Simon et al. 2008; Paleolog 2009). These angiogenic growth factors stimulate various cells 
involved in new blood vessels formation including vascular endothelial and SMC, endothelial 
progenitor cells, and mesenchymal stem cells (Semenza 2009b). Blood vessels formation is 
impaired in HIF1a
-/- 
embryos (Iyer et al. 1998; Ryan et al. 1998), whereas in HIF1a
+/- 
adult mice, 
neovascularisation fails following arterial occlusion (Tian et al. 1998; Kotch et al. 1999; Peng et 
al. 2000; Bosch-Marce et al. 2007). 
1.7.2.3. Vascular tone 
Vascular tone is important in determining blood perfusion of an organ. Therefore, blood 
and oxygen delivery can be regulated by altering vascular tone. During hypoxia, vascular tone of 
different vascular beds may vary depending on the type and site of the blood vessels. Variations 
in vascular tone in different organs during hypoxia enable the limited blood and oxygen supply 
being diverted from less important organs (such as skin) to more vital organs (such as heart and 
brain). HIF regulates the expression and activity of various vasoactive substances including α1β-
adrenergic receptor, adrenomedulin (ADM), endothelin-1 (ET1), Haem oxygenase 1 (HO-1), and 
nitric oxide synthase-2 (NOS2) (Kelly et al. 2003; Gaber et al. 2005; Ke and Costa 2006). 
Recently, some MMPs including MMP-2 which is known to be regulated by HIF, were also been 
found to cause venous relaxation, in addition to their well-known matrix metabolism function 
(Raffetto et al. 2007). 
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1.7.2.4. Cell proliferation, survival and apoptosis 
During hypoxia, cell cycle is altered to ensure increase in survival and decrease in 
apoptosis of some cell types. Paradoxically, hypoxia can also cause increased apoptosis and 
decreased survival in other cell types. HIF regulates the expression and activity of various growth 
factors required for cell proliferation including insulin-like growth factor-2 (IGF2) and 
transforming growth factor-α (TGF-α) (Feldser et al. 1999; Krishnamachary et al. 2003; Ke and 
Costa 2006). Meanwhile, cell survival and apoptosis depend on the balance of pro- and anti-
apoptotic proteins (Greijer and van der Wall 2004). Examples of pro-apoptotic proteins that are 
known to be regulated by HIF are caspase-3, caspase-9, bax, Fas, Fas ligand, Bcl-2/adenovirus 
EIB 19-kDa interacting protein 3 (BNIP3), and NIP3-like protein X (NIX) (Carmeliet et al. 1998; 
LeBlanc et al. 2002; Greijer and van der Wall 2004; Ke and Costa 2006). Anti-apoptotic proteins 
known to be regulated by HIF include Bcl-2 (Greijer and van der Wall 2004; Ke and Costa 2006). 
Genes involved in cell cycle regulation that are known to be regulated by HIF include p53 and 
p21 (Carmeliet et al. 1998; Ke and Costa 2006). 
1.7.2.5. Matrix metabolism 
Several genes involved in the synthesis, maintenance and degradation of matrix proteins 
are known to be regulated by HIF (Denko et al. 2003; Hofbauer et al. 2003; Myllyharju and 
Schipani). For example, the rate of collagen synthesis has been shown to be increased by hypoxia 
(Norman et al. 2000; Horino et al. 2002; Myllyharju and Schipani). In addition, various MMPs 
and TIMPs expression and activity is known to be regulated by HIF (Semenza 2003; Fujiwara et 
al. 2007; Ahn et al. 2008; Misra et al. 2008b). Regulation of matrix metabolism by HIF has been 
shown to be important in normal development including in foetal growth plate and joint 
development (Schipani et al. 2001; Amarilio et al. 2007; Provot and Schipani 2007; Myllyharju 
and Schipani). During hypoxia, regulation of matrix metabolism is also important for the 
migration of various cells including those involved in angiogenesis (Gaber et al. 2005; Surazynski 
et al. 2008; Muz et al. 2009). However, matrix metabolism mediated by HIF has also been shown 
to contribute to tumorigenesis and metastases in cancers (Surazynski et al. 2008; Semenza 2010a). 
1.7.2.6. Erythropoiesis 
Erythropoiesis is the process of erythrocyte production. Erythrocytes deliver oxygen in 
the blood from the lungs to all the other cells in the body. EPO is a glycoprotein hormone 
produced in the peritubular capillary endothelial cells in the kidney. EPO stimulates erythroid 
progenitor cells to undergo erythropoiesis. Erythropoiesis was found to be dysfunction in HIF1a
-/-
 
embryos (Yoon et al. 2006; Semenza 2009b). EPO was in fact the first gene found to be regulated 
by HIF (Semenza and Wang 1992). During ischaemia, elevated expression of HIF up-regulates 
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the synthesis of EPO leading to increased erythrocytes to deliver oxygen to hypoxic cells 
(Semenza 2009b). 
Table 1-4 Examples of HIF target genes 
Adaptive responses and their corresponding genes which are known to be regulated by HIFs  
 
Adaptive Response Genes 
Matrix metabolism MMP-1, MMP-3, MMP-2, CATHD, MT1-MMP, TIMP-1, 
Collagen Type V (α1), FN1, PAI1, Prolyl-4 hydroxylase-α, 
UPAR, PHD-2 and PHD-3 
Glucose and energy 
metabolism 
Hexokinas-1 (HK1), HK2, AMF/GPI, ENO1. GLUT-1, GLUT-
2, GAPDH, LDHA, PFKBH3, PFKL, PGK1, PKM, TPI, 
Aldolase-A, Aldolase-C, 6-Phosphofructo-2-kinase/fructose-
2,6-biphosphatase-3, and Leptin (LEP) 
Amino acid metabolism Transglutaminase 2 
Vascular tone α1β-adrenergic receptor, ADM, ET1, HO-1, and NOS2, MMP-2 
Angiogenesis VEGF, ENG, LEP, LRP1, TGF-β3, VEGF, ADM, 
Angiopoietin-1 and -2, PAI-1, SDF-1, PlGF and TGF-α,  
Erythropoiesis EPO 
Cell adhesion MIC2 
Apoptosis BNIP3, NIX, and RTP801 
Cell survival ADM, EPO, IGF2, IGF-BP1, IGF-BP2, IGF-BP3, NOS2, TGF-
α, VEGF, and CYCLIN D1 
Motility AMF/GPI, c-MET, LRP-1, and TGF-α 
Cell proliferation Cyclin G2, IGF2, IGF-BP1, IGF-BP2, IGF-BP3, WAF1, TGF-
α, TGF-β3, p21, and NOS-2 
Cytoskeletal structure KRT14, KRT18, KRT19, VIM 
pH regulation Carbonic anhydrase 9, and 12 
Transcriptional regulation DEC1, DEC2, ETS-1, NUR77, Embryonic transcription factors, 
Oct-4 (Pou5f1, Oct-3/4), and c-Myc 
Iron metabolism Caeruloplasmin, Transferrin (Tf), and Transferrin receptor (Tfr) 
Regulation of HIF-1 
activity 
P35srj 
Epithelial homeostasis Intestinal trefoil factor 
Drug resistant MDR1 
Nucleotide metabolism Adenylate kinase 3, and Ecto-5‟-nucleotidase 
 
1.7.3. Pathophysiology of HIF-α 
Immunohistochemistry studies have detected very little HIF-1α and HIF-2α proteins in 
virtually all normal human tissues except for bone marrow (Talks et al. 2000). This is not 
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surprising since HIFs are rapidly degraded in the presence of oxygen in which normal tissues are 
exposed to. However, increased HIF-α expression has been found in various pathological 
conditions including several cancers (Heddleston et al.; Semenza 2010a), rheumatoid arthritis 
(Akhavani et al. 2009; Muz et al. 2009), atherosclerosis (Sluimer and Daemen 2009; Semenza 
2010b), aneurysm (Choke et al. 2006), pulmonary hypertension (Semenza 2004), stroke (Shi 
2009) and myocardial infarction (Shohet and Garcia 2007; Loor and Schumacker 2008). 
In diseases such as cancers, rheumatoid arthritis and atherosclerosis (Sluimer and Daemen 
2009; Semenza 2010a; Semenza 2010b), the up-regulation of HIF-α is thought to be destructive 
(Akhavani et al. 2009; Muz et al. 2009). Over expression of HIF-α in these diseases increases the 
survival and proliferation, and facilitates the activities of the diseased cells, thereby causing 
further destruction. For example, HIF-α protects malignant cells from hypoxia as a result of 
growing tumour cell population by activating angiogenesis and reducing apoptosis. Furthermore, 
it is thought that HIF-α also facilitates metastases by various processes including altering 
surrounding tissue matrix metabolism, protecting malignant cells from the host immune system, 
and increasing cellular migration (Heddleston et al. 2010; Semenza 2010a). 
On the other hand, increases in HIF-α expression are thought to be beneficial in some 
diseases especially those that involve arterial blood supply disruption such as stroke (Shi 2009), 
myocardial infarction (Shohet and Garcia 2007; Loor and Schumacker 2008) and peripheral 
arterial diseases (Semenza 2010b). In these diseases, HIF-α increases the survival of normal cells 
such as cardiomyocytes in myocardial infarction, neurons in stroke, and skeletal muscle cells in 
peripheral arterial diseases during ischaemic event (Shohet and Garcia 2007; Loor and 
Schumacker 2008; Shi 2009; Semenza 2010b). HIF-α is also thought to be neuroprotective 
against neurodegenerative diseases including Alzheimer‟s and Parkinson disease (Correia and 
Moreira 2010). 
1.7.4. HIF and Varicose Veins 
Very little is known about the role of HIF in varicose veins. Only very recently, HIF-1α 
expression in varicose compared to non-varicose veins was reported. Using 
immunohistochemistry, Hossein-Ghaderian and colleagues identified HIF-1α expression in 
endothelial cells of the intima and vasa vasorum of 5 out of 20 varicose vein specimens but none 
of the 20 non-varicose saphenous vein tissues. The authors also found that the expression of HIF-
1α was strongly correlated with the ICAM-1 positive staining of the same specimens (Hossein 
Ghaderian et al. 2010). However, in this study the author did not assess the HIF pathway in 
detailed including the expression of HIF-2α and HIF target genes, and their regulation by hypoxia 
and other stresses.  
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There are good reasons to suggest that HIF pathway is activated in varicose veins. First, 
there is some evidence that the overall oxygen tension measured in vivo in varicose vein wall was 
significantly lower than in non-varicose veins (Taccoen et al. 1996). Secondly, patients with 
Chuvash polycythaemia, a congenital disorder of inappropriate increased expression of HIF-α due 
to VHL gene mutation, were more likely to have varicose veins compared to those without the 
polycythaemia (Gordeuk et al. 2004). Thirdly, many changes observed in varicose vein wall 
including imbalances of MMP/TIMP, impaired vascular tone, dysregulated apoptosis, altered 
angiogenesis and abnormal glucose metabolism (Lim and Davies 2009) were also those of the 
adaptive responses regulated by HIF although the direct relationships between HIF and these 
changes have never been shown. Fourthly, it has been shown that internal spermatic veins of 
patients with varicocoele, i.e. varices in the testes, expressed significantly more HIF-1α than those 
of patients without the disease (Lee et al. 2006). 
Furthermore, my predecessor Beverly Saunders has reported in an MD (Res) thesis, for 
the first time, that HIF-1α and HIF-2α mRNA were expressed in varicose and non-varicose veins 
using real-time polymerase chain reaction (Q-PCR) (Saunders 2009). She also demonstrated in 
varicose and non-varicose veins, HIF-1α mRNA significantly correlated with MMP-2 (P=0.0154), 
TNF-α (P=0.0188) and IL-1β (P=0.0049), whereas HIF-2α mRNA significantly correlated with 
MT1-MMP (0.0047) and TNF-α (P=0.0313) (Sharp et al. 2007; Saunders 2009). These findings 
suggested matrix metabolism and inflammatory cytokines in varicose and non-varicose veins 
were associated with HIF-1α and HIF-2α expression. 
All the available evidence clearly point at the activation of HIF pathway in varicose 
compared to non-varicose veins. Therefore, this research project investigated the role of HIF 
pathway in the pathogenesis of varicose veins. 
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1.8. HYPOTHESIS AND AIMS 
1.8.1. Hypothesis 
Varicose vein is associated with increased expression of hypoxia-inducible factors (HIF-
1α and -2α), and their target genes, which are regulated by oxygen-dependent and oxygen-
independent factors including mechanical stress. 
1.8.2. Aims 
1. To demonstrate that varicose and non-varicose veins are structurally different using 
special histological stains. 
2. To investigate the expression of HIF-1α and HIF-2α, their target genes, and HIF 
regulatory enzymes in varicose compared to non-varicose veins 
3. To develop and use a varicose and non-varicose vein organ culture to assess the 
regulation of HIF-1α and HIF-2α, and their target genes by oxygen tension, and the 
effects of doxycycline and micronised purified flavonoid fraction (MPFF) at a 
concentration corresponding to their physiological therapeutic dose on the HIF pathway 
4. To study the effects of prolonged increases in vein wall tension on the expression of HIF-
1, HIF-2 and MMPs, and venous tone 
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2. MATERIALS AND METHODS 
The research described in Chapters 3 and 4 was conducted in the Imperial College London, 
UK where human varicose and non-varicose vein tissues were studied. The research described in 
Chapter 5 was carried out in Harvard University, Boston, Massachusetts, USA where inferior 
vena cava (IVC) of male Sprague-Dawley rats were studied. There were variations in the 
materials and methods used in these two sites. Therefore, they are described separately in this 
chapter. 
2.1. MATERIALS AND METHODS USED IN IMPERIAL COLLEGE LONDON 
2.1.1. Ethical Approval 
Ethical approval had been obtained for the research from the Riverside Research Ethics 
Committee (RREC 3092). The research has also been registered to the Imperial College London 
Research Services, and the Imperial College Healthcare NHS Trust Research and Development 
Department. All the specimens collected were anonymised according to the rules set out in the 
Human Tissue Bill (2004). Informed consent was obtained from the patients after explaining to 
them about the nature of the study. 
2.1.2. Patients Selection And Tissue Sampling 
2.1.2.1. Varicose veins 
Varicose veins were retrieved from patients who were treated with open surgery with or 
without phlebectomies, or with phlebectomies performed as the primary procedure or following 
endovenous thermal ablation at Charing Cross Hospital and St. Mary‟s Hospital, both part of the 
Imperial College London Healthcare NHS Trust. The patients were initially assessed in the 
outpatient department at their respective hospitals in consultant-led clinics for varicose veins to 
determine whether or not they required surgery or endovenous treatment for definitive 
management of their condition. These patients were assessed with a full history taking and 
clinical examinations by the clinicians and nurse practitioners caring for them pre-operatively. All 
the patients were also assessed with duplex ultrasonography performed by accredited vascular 
scientists and/or the vascular surgeons treating them. Duplex ultrasonography allowed the 
mapping of the anatomy of the venous system of the affected legs, and assessment of the direction 
of blood flow including the presence of any venous reflux or valvular incompetence (Figure 2-1). 
Figure 2-2 depicts a typical example of a pre-operative duplex ultrasonography report of the 
venous system of the lower limbs from the Vascular Laboratory at the Charing Cross Hospital. 
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Figure 2-1 Colour duplex of an incompetent saphenofemoral junction 
(a) Saphenofemoral junction of a patient with varicose veins on an ultrasonogram. (b) Colour flow Doppler 
demonstrates forward or anterograde blood flow from GSV to CFV through the SFJ during augmentation 
(by compressing the calf muscles). (c) Colour flow Doppler shows reverse or retrograde blood flow from 
CFV to GSV (reflux) after augmentation. (CFV: common femoral vein; GSV: great saphenous vein; SFJ: 
saphenofemoral junction) 
(Photograph taken by Mary Ellis) 
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Figure 2-2 Example of a pre-operative duplex ultrasonography report 
A typical example of a pre-operative duplex ultrasonography report of the venous system of the lower limbs 
from the Vascular Laboratory at the Charing Cross Hospital 
 
The types of open surgery during which varicose veins were routinely removed and 
therefore available for research use include ligation of SFJ or often known as “high-tie” with 
stripping of GSV, ligation of SSV with and without stripping of SSV, multiple phlebectomies, 
and a combination of these procedures. Therefore, in open surgery, varicose veins were sampled 
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from truncal veins (GSV and SSV) of different level of the leg, anterior thigh vein, Giacomini 
vein, and other tributaries as long as there were clinically varicose with evidence of reflux on 
duplex ultrasonography. Meanwhile, for patients who were treated with endovenous thermal 
ablation, only varicose veins obtained from phlebectomies were used. These veins were not 
ablated with laser or radiofrequency. The patients had their surgery, phlebectomies and 
endovenous thermal ablation performed under general and/or local anaesthetics. 
2.1.2.2. Control or non-varicose veins 
Control veins were obtained from patients undergoing any surgery which involved 
routine removal of non-varicose veins that were later discarded. These veins were only collected 
from operations performed in the Department of Vascular Surgery, Charing Cross Hospital. 
Examples of such operations include vascular bypass requiring vein graft, carotid endarterectomy, 
inguinal hernia repair, arterio-venous (AV) fistula formation, and limb amputation. Commonly 
obtained non-varicose veins were shown in Table 2-1. Patients in this group were assessed with a 
full history and clinical examinations. Although duplex ultrasonography was performed to 
identify and map the anatomy of the veins in some of the patients pre-operatively such as those 
who were undergoing bypass graft and AV fistula formation, generally the assessment of venous 
reflux was not routinely performed in most patients in this group. Therefore, the suitability of the 
patients in this group was often identified solely from clinical assessment based on history taking 
and examinations. 
Table 2-1  Common sources of non-varicose veins 
Surgery Non-varicose vein 
Arterial bypass graft (e.g. femoro-
popliteal, femoro-distal and popliteal-
pedal bypass graft) 
Great saphenous vein 
Carotid endarterectomy Facial and external jugular vein 
Open inguinal hernia repair Inferior epigastric vein and superficial groin veins 
Arterio-venous fistula formation Brachial and cephalic vein 
Lower limb amputation Great and small saphenous vein and tributaries, 
and deep vein 
Abdominal and gastrointestinal surgery Mesenteric vein 
 
Non-varicose superficial veins of the leg such as GSV and SSV might appear to be the 
obvious choice of control veins for varicose vein research since they were anatomically matched 
with varicosities of the legs. However, the majority of such veins that were available for research 
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were those harvested during arterial bypass surgery or retrieved during leg amputation. Although 
these veins were non-varicose, significant pathological changes such as intimal hyperplasia and 
fibrosis (phlebosclerosis), and muscular hypertrophy were often observed in these veins (Milroy 
et al. 1989; Langes and Hort 1992; Davies et al. 1993; Wilson et al. 1996). Several reasons 
explaining such pathological changes in these so-called „normal‟ veins have been postulated 
including ageing, recurrent episodes of thrombophlebitis, inherently defective endothelium and 
focal increase in hydrostatic pressure in the veins (Langes and Hort 1992; Davies et al. 1993). 
Besides saphenous veins, similar phlebosclerotic changes have also been reported in other veins 
including cephalic (Davies et al. 1993), mesenteric (Tsai et al. 2008), and portal (Isabel Fiel et al. 
2007) veins, although these were much rarer. 
Patients who underwent arterial bypass graft and leg amputation were patients with 
peripheral arterial disease. These patients were likely to be demographically different from 
patients who underwent varicose vein surgery. For example, patients with peripheral arterial 
disease were more likely to be older than those in the varicose vein group. Patients with 
peripheral arterial disease often suffered from other cardiovascular associated co-morbidities 
including diabetes mellitus, hypertension, hypercholesterolaemia and ischaemic heart disease. 
These co-morbidities were less often seen in patients in the varicose vein group. Therefore, 
patients with peripheral arterial disease were more likely to be on more regular prescriptions 
especially drugs for cardiovascular related diseases such as aspirin, statins, anti-hypertensives and 
anti-coagulants than those in the varicose vein group (Aravind 2007; Saunders 2009). 
To overcome some of these limitations, non-varicose veins of different sources other than 
saphenous veins harvested for arterial bypass graft were also included as controls (Table 2-1). 
Using heterogeneous sources of veins as controls helped to dilute some of the histological 
abnormalities and demographic differences between the varicose vein and control group. Another 
advantage of using heterogeneous sources of non-varicose veins was to increase the sample size 
of control veins in the study. One of the major limitations of using heterogeneous sources of veins 
as controls was some of these veins were not anatomically matched with varicose veins. Even if 
heterogenous sources were used, the problem remains since patients who required carotid 
endarterectomy and those needed AV fistula formation for haemodialysis, two important sources 
of non-varicose veins in this study, were also known to be associated with cardiovascular related 
co-morbidities. 
2.1.2.3. Inclusion and exclusion criteria 
Figure 2-3 summarises the inclusion and exclusion criteria for the overall study. All 
patients with unilateral or bilateral primary varicose veins were included in the study. Patients 
with recurrent varicosities and therefore had previous varicose vein surgery and/or intervention 
were also included in the study. To standardise both study groups (varicose and non-varicose 
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vein), the same exclusion criteria were used for both groups with a few exceptions. For example, 
patients with present and past history of varicose veins were not included in the non-varicose vein 
group, even if the varicosity had been successfully treated, i.e. they must have no history of 
varicose veins. There was evidence to suggest that patients with varicose veins demonstrated 
systemic alteration of extracellular matrix including in the skin and could therefore affect other 
veins even if they were non-varicose (Sansilvestri-Morel et al. 2007). 
Varicose and non-varicose veins of the affected limbs of patients with a history of deep 
vein thrombosis (DVT) were excluded from the study although veins from the other parts of their 
body would still be included. Meanwhile, patients with congenital diseases associated with 
varicose veins including KTS and AV malformation were also excluded from the study. Patients 
with secondary varicose veins were excluded from the study because their varicose veins arose 
from a known aetiology which was different from primary varicosity. Therefore, the varicose vein 
wall of these patients were likely to be structurally and biochemically different from those of 
primary varicose veins. For example, varicose veins secondary to DVT were known to be 
associated with venous obstruction (with or without reflux) secondary to thrombus formation, but 
this was not the case in primary varicosity which was only associated with reflux (Phillips and 
Sarkar 2007). The release of inflammatory mediators including various cytokines and growth 
factors, and early increase in neutrophil infiltration in vein walls contributing to vein wall and 
valvular injury, inflammation and fibrosis in patients with DVT were associated with thrombus 
formation and resolution, but not in primary varicose veins (Downing et al. 1996; Phillips and 
Sarkar 2007; Henke and Wakefield 2009). 
Besides secondary varicose veins, patients with rheumatoid arthritis, connective tissue 
disorders and vasculitis were also excluded from the study. Patients with rheumatoid arthritis and 
connective tissue disorders are known to demonstrate systemic abnormalities of the extracellular 
matrix including the quality and quantity of collagen and elastin (Holbrook and Byers 1982; 
Aravind 2007; Saunders 2009). For example, systemic sclerosis was characterised by diffuse 
vascular lesions and fibrosis of the skin and major organs including lungs, heart and kidneys 
(Kahan and Allanore 2006). Meanwhile, patients with Marfan Syndrome, another connective 
tissue disease, were known to demonstrate systemic disarray of ECM including in the joint, bone, 
ocular, skin, dura and cardiovascular system (Keane and Pyeritz 2008). In terms of cardiovascular 
manifestations, patients with Marfan Syndrome often presented with aortic aneurysm and cardiac 
valvular abnormalities (Keane and Pyeritz 2008). Vasculitic diseases referred to conditions 
involving systemic inflammation of the blood vessels such as Kawasaki‟s disease, polyarteritis 
nodosa and Behcet‟s disease (Monach and Merkel 2010). In histology vasculitis was defined as an 
inflammatory cell infiltration and destruction of blood vessels identified upon histological 
examination (Kluger and Frances 2009). Another interesting example of vasculitis was Mondor‟s 
disease which was characterised by thrombophlebitis of the subcutaneous veins particularly 
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anterolateral of the thoracoabdominal wall (Alvarez-Garrido et al. 2009). Although varicose veins 
were not a common manifestation of these diseases, the structural and biochemical properties of 
the vein wall of patients with these conditions were likely to be affected and therefore, it was 
more appropriate for these patients to be excluded in the study. 
Patients with cancers and had previous radiotherapy treatment were not included in the 
study. Radiotherapy is known to alter ECM and cause tissue fibrosis including in vascular 
structures (Protack et al. 2007) (Fajardo 2005). Patients with human immunodeficiency virus 
(HIV)-positive were also excluded from the study. There was evidence to suggest that in HIV-
positive patients, chronic infection, inflammation, disruption of immune balance, and antiviral 
therapy might potentially alter vascular structure and function (Boccara 2008).  
Patients who were taking regular systemic steroids such as glucocorticoids were also 
excluded from the study since they altered vascular inflammation and remodelling (Walker 2007). 
Patients on oestrogen and/or progesterone therapy such as oral contraceptive pills and hormone 
replacement therapy were also excluded. Oestrogen and progesterone were known to affect 
various biochemical and metabolic changes, and venous tone of the vascular wall (Stevenson 
1998; Lim and Davies 2009). 
Although several other drugs including HMG-CoA reductase inhibitors or statins 
(Nomura et al. 2005), warfarin (Dao et al. 2002), angiotensin converting enzyme inhibitors 
(ACEIs) (Bertrand 2004) , and aspirin (Renna et al. 2009) might potentially affect the biochemical 
and structural properties of the vein wall, we did not exclude them from the study. Many of these 
drugs were commonly prescribed to many patients with cardiovascular related diseases such as 
ischaemic heart disease, hypertension and peripheral arterial disease. Therefore, excluding them 
would significantly reduce the pool of patients suitable for the study especially the non-varicose 
vein group which comprised of many patients with cardiovascular related diseases. 
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Patients with varicose veins 
including those with recurrent 
diseases ;C2-C6 (Charing 
Cross and St. Mary‟s Hospital)
Patients with no history 
of primary varicose veins 
(Charing Cross Hospital)
Surgery involving routine removal 
of veins (e.g. arterial bypass graft, 
carotid endarterectomy, arterio-
venous fistula formation, open 
inguinal hernia repair, and limb 
amputation)
Varicose vein open 
surgery or endovenous 
treatment involving 
multiple phlebectomies
Exclusion criteria:
• Secondary varicose 
veins / DVT
• Connective tissue 
disease
• Vasculitis
• Rheumatoid arthritis
• Regular systemic 
steroids, oestrogen or 
progesterone therapy
• MPFF / Daflon®
• Doxycycline
• HIV-positive
• Cancer / Radiotherapy
Non-varicose veins Varicose veins
EXCLUDED
INCLUDED
 
 
Figure 2-3 Summary of the inclusion and exclusion criteria for patients recruited in 
the study 
2.1.2.4. Demographic data 
Clinical and demographic details such as age, sex, past medical history, drug history and 
smoking status of all patients were recorded. Past medical history that was specifically assessed 
through history taking and case notes were diabetes mellitus, hypertension, DVT, hypertension, 
connective tissue disease, vasculitis, peripheral arterial disease, cancers, and rheumatoid arthritis. 
Past medical history of varicose veins was also elicited in all patients. CEAP classification of all 
patients with varicose veins was clinically determined. Duplex ultrasonographic reports of all 
patients in the varicose vein group were also scrutinised for the distribution of superficial and 
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deep venous reflux. All the demographic and clinical data were recorded. 
2.1.3. Tissue Collection and Storage 
Once harvested from the donor, varicose and non-varicose vein tissues were immediately 
collected, transported, and processed or stored appropriately depending on the type of analysis or 
experiment intended to be performed on the tissues. The allocation of the tissues to the different 
types of analysis or experiment was done in random and independent to the patient factors to 
avoid any bias. 
Whole varicose and non-varicose vein tissues that were collected for HIF and target genes 
expression assessment using reverse transcription and real time polymerase chain reaction (Q-
PCR), and Western blot were immediately snap frozen in liquid nitrogen in a portable Thermo-
Flask® (Thermo-Fischer) in the operating theatre. Snap frozen tissues were then transported to 
the laboratory and stored in a -80°C freezer. Meanwhile, whole vein tissues that were collected 
for histological analysis including with special stains and immunohistochemistry were 
immediately fixed in 4% formalin in the operating theatre before being transported to the 
Department of Histopathology of Charing Cross Hospital for paraffin embedding. Immediate snap 
freezing or formalin fixation of whole vein tissues was necessary to preserve the tissues 
constituents and morphology to as close to what they were in vivo as possible. Immediate snap 
freezing or formalin fixation of whole vein tissues was also essential to prevent as little 
degradation and alteration to the molecules of interest as possible secondary to exposure to the ex 
vivo environment. For example, HIF-1α protein has a half-life of only about 5-8 minutes in 
normoxic conditions (Berra et al. 2001). Therefore, tissues that were intended for HIF-1α assay 
should be snap frozen or formalin fixed immediately to prevent any significant degradation once 
exposed to the normoxic room air. 
Varicose and non-varicose veins that were collected for vein organ culture preparation 
were transported in Dulbecco‟s Modified Eagle‟s Medium (DMEM) with high glucose (4.5g/L), 
L-glutamine, and sodium pyruvate (PAA Laboratories GmbH, Pasching, Austria) to the 
laboratory immediately. These veins were processed for vein organ culture preparation within an 
hour from the time of retrieval from the patient in the operating theatre. Therefore, only veins 
obtained from the Charing Cross Hospital were used for organ culture preparation due to the close 
proximity of the operating theatre and the laboratory. 
2.1.4. Tissue Pulverisation and Homogenisation 
The first step of RNA and protein isolation involved pulverisation and homogenisation of 
frozen whole vein tissues. Similar pulverisation and homogenisation technique was used for RNA 
and protein isolation. All the equipment was washed thoroughly with tap water, and rinsed with 
double-distilled water (ddH2O; produced using Arium® 611DI, Sartorius, Goettingen, Germany) 
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prior to pulverisation and homogenisation of every specimen. For RNA isolation, the equipment 
was also cleaned with RNase AWAY® (Molecular BioProducts) to inactivate RNAse activity 
every time before a specimen was pulverised and homogenised. 
Frozen whole vein tissues were pulverised in liquid nitrogen into powder with a mortar 
and a pestle which were pre-cooled by immersing the hammer part of the pestle and the well 
portion of the mortar in liquid nitrogen. The powder was collected into Cryovial® (Simport 
Plastics, Quebec, Canada) which were then kept frozen in dry ice temporarily or stored for longer 
in the -80°C freezer prior to homogenisation. Homogenisation of the pulverised whole vein 
tissues was then performed using the IKA-Ultra-Turrax® T8 homogeniser (IKA®-Werke GMBH 
& CO.KG, Staufen, Germany) which ground and mixed the tissues with the RNA or protein 
isolating solution. During the homogenisation the Cryovial® containing the specimen was 
constantly kept cool at 4°C. 
2.1.5. RNA Study 
2.1.5.1. RNA isolation 
RNA from whole varicose and non-varicose veins was isolated using RNA-Bee
TM 
(AMS-
Biotechnology (Europe) Ltd, Oxon, UK) according to the manufacturer‟s protocol with a few 
modifications. The powder obtained from pulverisation of whole tissues were homogenised in 
RNA-Bee
 TM
 solution; 0.8ml RNA-Bee
 TM
 for every 1-10mg of tissue. The homogenate was 
transferred to a 1.5ml eppendorf and 160µl of chloroform was added. The eppendorf was 
vortexed vigorously for 1 minute and then was left at 4°C for 5 minutes. The content was then 
centrifuged at 12,000g for 15 minutes at 4°C in a chilled centrifuged (Centrifuge 5415R; 
Eppendorf AG, Hamburg, Germany). After 15 minutes of centrifugation, the mixture separated 
into three phases, i.e. the lower blue phenol-chloroform phase, whitish grey interphase, and upper 
clear aqueous phase. The RNA remained exclusively in the aqueous phase, whereas DNA and 
proteins were in the interphase and organic phase. The clear aqueous phase which would have a 
volume of about 50% of the initial volume of RNA-Bee
TM
 used was transferred into an RNAse 
free 1.5ml eppendorf with a pipette. During this, care was taken not to disrupt the interphase and 
organic phase which were discarded. An equal volume of isopropanol was added to precipitate the 
RNA. The samples were mixed by gentle vortex, and incubated at 4°C for 30 minutes or 
overnight. Following RNA precipitation, the sample was centrifuged at 12,000g for 10 minutes at 
4C. Once centrifuged, each sample was checked for the presence of a small white RNA pellet at 
the bottom of the eppendorf. The supernatant was carefully pipetted and discarded. The RNA 
pellet was washed by adding 300µl of 70% ethanol. The RNA pellet was dislodged in the ethanol 
by flicking the eppendorf. The sample was then centrifuged at 7,600g for 10 minutes at 4C. The 
supernatant was then carefully pipetted and discarded. The RNA pellet was left to dry at room 
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temperature for 10 minutes. The RNA pellet was then resuspended with an appropriate volume of 
0.1% di-ethyl pyrocarbonate or DEPC (Sigma Aldrich, St. Louis, MO 63103, USA) –treated 
ddH2O, usually about 20 - 40µl depending on the size of the pellet obtained. The ddH2O was 
treated with DEPC to inactivate RNases. The re-suspended RNA was mixed by gentle vortex. 
The concentration of RNA was measured using NanoDrop® 1000 spectrophotometer 
(Thermo Scientific, Wilmington, DE, 19810 USA). The NanoDrop® ND-1000 version 3.7 
(Thermo Scientific, Wilmington, DE, 19810 USA) software used the modified Beer-Lambert 
equation to calculate RNA concentration, i.e. 
c = (A x e)/b 
c: nucleic acid concentration (ng/μl) 
A: absorbance in AU 
e: wavelength-dependent extinction coefficient (ng-cm/μl) 
b: path length (cm) 
Nucleotides, RNA, single-stranded DNA (ssDNA) and double-stranded DNA (dsDNA) 
absorbed light at 260nm, hence nucleic acids were measured at this wavelength. Meanwhile, 
protein, phenol and other contaminants absorbed light strongly at or near 280nm. The 260/280 
ratio was checked each time to assess the purity of the RNA. A 260/280 ratio of 2.0 was 
considered to be „pure‟ for RNA although a ratio of 1.6 and above was accepted for analysis. 
Figure 2-4 showed representative RNA concentrations and 260/280 ratios measured for RNA 
isolated from whole vein tissues using the method described above. After RNA concentration was 
measured, RNA samples were stored at -80C or used for analysis. 
 
 
Figure 2-4 Representative RNA concentration (ng/µl) and 260/280 ratios of RNA 
isolated in the study 
2.1.5.2. Polymerase chain reaction 
Polymerase chain reaction (PCR) is a widely used molecular technique to amplify a 
single or few copies of DNA exponentially. PCR selectively replicates specific sequences of DNA 
quickly and reliably, requiring only small amount of tissue. The technique involves thermal 
cycling, consisting of cycles of rapid heating and cooling to optimal temperatures for the reaction 
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for DNA melting and enzymatic replication. As PCR progresses, the DNA generated is itself 
acting as a template for replication, setting in motion a chain reaction in which the DNA template 
is exponentially amplified (Kubista et al. 2006). 
A PCR reaction will require a mixture consisting of a special buffer containing 
deoxynucleotide triphosphates (dNTPs), two specific primers, DNA polymerase and the DNA 
strand of interest. Primers are oligonucleotides containing sequences complementary to the 3‟ 
ends of each sense and antisense strand of the DNA of interest. Primers are required for the 
initiation of the DNA synthesis. The DNA polymerase used in PCR is almost always heat-stable 
such as Taq polymerase, an enzyme originally isolated from the bacterium Thermus aquaticus. By 
using the separated single-stranded DNA of interest as a template, DNA polymerase 
enzymatically builds a new complementary DNA strand from the dNTPs (Kubista et al. 2006). 
In general, there are three stages in a PCR cycle. 
1. Denaturation: The DNA strand of interest is heated to 95C to separate its double helix. 
2. Annealing: Specific primers will anneal into the complementary regions in the DNA of 
interest at a temperature calculated from the melting temperature, forming a double 
strand. The temperature is usually between 50C and 65C. 
3. Elongation: A complementary DNA strand will be formed with a thermostable DNA 
polymerase at 72C. 
The whole cycle will then be repeated by incubating the newly formed DNA strands at 
95C to separate the double helix, followed by primers annealing and DNA elongation. 
Successive cycles of this process allow exponential amplification of the target DNA sequence 
which will then be used for further analysis. Various modifications to the basic PCR have also 
been made for specific purposes including the two variants used in my study, i.e. reverse 
transcription PCR (RT-PCR) and quantitative real-time PCR (Q-PCR). Primer sequences are 
outlined in Appendix 1. 
2.1.5.3. RT-PCR 
RT-PCR is a molecular technique combining reverse transcription and PCR. Reverse 
transcription is a process of creating a single stranded cDNA from an RNA template using reverse 
transcriptase, an enzyme also known as RNA-dependent DNA polymerase. The enzyme also 
helps the formation of a double stranded cDNA. The mRNA of many genes of interest is usually 
expressed in very small amount and therefore needed to be amplified for analysis. RNA is 
relatively unstable and it could not be directly amplified using PCR. Therefore, converting RNA 
to dsDNA is necessary for the mRNA of the gene of interest to be analysed by either conventional 
PCR or Q-PCR. 
The reverse transcription protocol used in the study has previously been validated and 
used in our laboratory to convert RNA to cDNA in cells and whole tissues. In this protocol, 500ng 
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of purified RNA of each sample was mixed with 1µl of 1/60 volume of random primers 3µg/µl 
(Invitrogen™, Paisley, UK) in a 200µl eppendorf (Corning® Incorporated, Corning, NY, USA) at 
4C. Then 0.1% DEPC-treated ddH2O was added into the mixture to a final volume of 12µl. The 
eppendorfs containing the RNA and random primers were then placed in a Personal Thermocycler 
(Biometra GmbH, Goettingen, Germany) which had been programmed to run the subsequent 
steps of reverse transcription. These steps involved rapid heating and cooling of the samples to 
specific temperatures for fixed durations optimal to the reactions involved. A master mix 
containing the enzymes, dNTPs and buffer required for reverse transcription was prepared as 
shown in Appendix 2. The Moloney-murine leukaemia virus (M-MLV; Promega, Southampton, 
UK) reverse transcriptase with RNase H deletion was needed to carry out the reverse transcription 
of the RNA to cDNA. The RNasin 40U/µl (Promega, Southampton, UK) inhibited any RNA 
contamination in the cDNA. The dNTP mix (Promega, Southampton, UK), consisting of equal 
volume of sodium salt of dATP (2'-deoxyadenosine 5'-triphosphate), dCTP (2'-deoxycytidine 5'-
triphosphate), dGTP (2'-deoxyguanosine 5'-triphosphate) and dTTP (2'-deoxythymidine 5'-
triphosphate), were the nucleotide building blocks for the cDNA synthesis. The 5x RT buffer 
(Promega, Southampton, UK), containing Tris-hydrochloride, potassium chloride and magnesium 
chloride and dithiothreitol (DTT) was essential for the reaction. Once 8µl master mix was added 
to every sample, the TPersonal Thermocycler was reactivated to continue running the 
programmed step 3 to 6 automatically to produce the required cDNA. After step 7, the cDNA 
obtained was diluted 5 times (volume) i.e. with 80µl of ddH20 to make a final volume 100ul of 
cDNA solution. The cDNA was stored at -20C. 
2.1.5.4. Q-PCR 
Q-PCR collects data throughout the PCR process for the direct detection of PCR product, 
therefore combining amplification and detection in one single step. The detection process is 
achieved using a variety of fluorescent chemistries that correlate PCR product concentration to 
fluorescence intensity (Wong and Medrano 2005). Examples of detection chemistries used in Q-
PCR are DNA binding dyes (e.g. SYBR Green I), hybridisation probes, hydrolysis probes, hairpin 
probes and scorpions (Giulietti et al. 2001; Wong and Medrano 2005). 
There are four main phases in the Q-PCR reaction i.e. linear ground, early exponential, 
log-linear (or exponential) and plateau phase (Appendix 3). The linear ground phase reflects the 
baseline or background fluorescence. During this phase, the amount of the PCR product is very 
small and the fluorescence emission at each cycle has not yet risen above background. The early 
exponential phase occurs when the intensity of fluorescence has exceeded a threshold where it is 
significantly higher than the background level, usually 10 times the standard deviation of the 
baseline. The cycle at which this phase occurs is known as the cycle threshold (Ct) or crossing 
point (CP). Consequently, the Ct value associated with the initial DNA or mRNA quantity, i.e. the 
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greater the starting DNA or mRNA, the faster the fluorescent signal significantly crossed the 
background signal threshold, yielding a lower Ct. Therefore, Ct value is representative of the 
starting DNA or mRNA copy number and is used for results analysis (Heid et al. 1996; Livak and 
Schmittgen 2001). The log-linear phase reflects the time when the PCR reaches its optimal 
amplification with the PCR product doubles after every cycle in ideal reaction conditions. Finally, 
during the plateau phase, the reaction components become limited causing the reaction to slow 
down and eventually stop. The final product of the PCR can be checked and confirmed via 
dissociation curve analysis, where the presence of different PCR products is reflected in the 
number of first-derivative melting peaks (Ririe et al. 1997), or gel analysis (Lekanne Deprez et al. 
2002). 
Q-PCR can be used for absolute and relative DNA and RNA quantification. Absolute 
quantification uses serially diluted standards of known concentrations to generate a standard 
curve. The standard curve produces a linear relationship between Ct and initial amounts of total 
RNA or cDNA. Therefore, measuring the Ct values of the study sample in parallel with the 
standards enables the determination of their absolute concentration (Heid et al. 1996). This 
method assumes the standards and samples have approximately equal amplification efficiencies 
(Souaze et al. 1996). In relative quantification, changes in sample gene expression are measured 
in relation to an external standard or a reference sample (untreated control or time zero samples), 
known as a calibrator and the results are expressed as a target to reference ratio. 
Besides calibration, normalisation of gene expression data is important to correct sample-
to-sample variation. Nucleic acids obtained from different individuals or samples may vary in 
tissue mass or cell number, RNA integrity or quantity, or experimental variables. In cell culture 
works, mRNA levels can be standardised to cell number under ideal conditions. When using 
whole tissue samples, normalisation to cell number and type is virtually impossible 
(Vandesompele et al. 2002). Therefore, in most Q-PCR, normalisation of the results against a 
control gene that may also serve as a positive control for the reaction is performed. The 
expression of the ideal control gene should be unaltered regardless of experimental conditions, 
tissue or cell types, developmental stage, or sample treatment (Wong and Medrano 2005; Mane et 
al. 2008). 
Examples of commonly used normalisation control genes include housekeeping genes or 
mRNA (e.g. glyceraldehyde 3-phosphate dehydrogenase or GAPDH and β-actin), ribosomal RNA 
(e.g. 18S, and 28S), and total RNA. So far, all available control genes are not ideal and have their 
inherent problems. The expression of many commonly used housekeeping genes or mRNA could 
be affected by different experimental conditions or treatments, biological processes, and even 
different tissues or cell types (Barber et al. 2005; Mane et al. 2008). For example it has been 
shown that the expression of GAPDH and cyclophilin in cells was affected by oxygen tension, 
and therefore not suitable for studies on the effects of hypoxia (Zhong and Simons 1999; Foldager 
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et al. 2009). Meanwhile, the gene expression of β-actin and GAPDH has been shown to be 
different in varicose compared to non-varicose veins (Lee et al. 2005b; Cario-Toumaniantz et al. 
2007). Therefore, both GAPDH and β-actin were not suitable control genes for this study. 
Ribosomal RNA has the disadvantage of being transcribed by different polymerase than mRNA 
(Barbu and Dautry 1989; Spanakis 1993). Changes in polymerase activity may not affect both 
mRNA and rRNA expression uniformly. Meanwhile, using total RNA as reference has the 
problem of the total RNA level being affected by cellular processes, RNA quality, and reverse 
transcription efficiency (Wong and Medrano 2005). To overcome some of these problems, 
multiple control genes are sometimes used although this method may be laborious (Wong and 
Medrano 2005). The 18S rRNA has previously been validated against several different reference 
genes by our laboratory in studies related to the effects of hypoxia. Hence, 18S rRNA was used in 
as the control gene in this study. 
In this study, the thermocycler Rotor-Gene™ 6000 Multiplexing System (Corbett 
Research) was used to perform Q-PCR. The thermocycler used a sensitive camera to detect the 
fluorescence in each tube during reaction. The fluorescence detection chemistry used was the 
SYBR® Green I which emitted fluorescence when bound to dsDNA. The fluorescence intensity 
increases proportionally to dsDNA concentration which accumulated during the PCR (Wittwer et 
al. 1997; Giulietti et al. 2001; Wong and Medrano 2005). SYBR® Green I bound to any dsDNA 
and therefore was not specific to a particular DNA sequence. It has the advantage that one dye 
could be used for various gene assays. However, its non-sequence specific property also has the 
disadvantage of being prone to false positives (Simpson et al. 2000; Wong and Medrano 2005). 
Therefore, the end products were checked with dissociation curve analysis, where the presence of 
different PCR products was reflected in the number of first-derivative melting peaks (Ririe et al. 
1997). The dissociation curve analysis was programmed into and performed automatically by the 
thermocycler. 
The Q-PCR protocol used in this study had previously been validated by our laboratory. 
In each 0.1ml Q-PCR Qiagen tube (Qiagen Sciences, Maryland, USA), 3µl of cDNA sample was 
mixed with 10µl Q-PCR mixture containing SYBR® Green JumpStart™ Taq Ready Mix™ 
(Sigma-Aldrich, St. Louis, USA) containing dNTP (dATP, dCTP, dGTP, and dTTP), Taq DNA 
Polymerase, Jumpstart Taq Antibody and SYBR Green I dye. Primer mix (MWG-Biotech AG, 
Ebersberg, Germany) and ddH2O were added to a total volume of 13µl (Appendix 2). Each 
sample was analysed in triplicate. The mixtures were then placed on the Rotor-Gene™ 6000 
(Corbett Research, Mortlake, NSW, Australia) and the reaction was started as shown in Figure 
2-5. 
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Pre-incubation  
(50 C, 2 minutes)
Initial denaturation
(95 C, 5 minutes)
PCR cycles 
(40X) 
Melt step
(70-99 C)
1X PCR cycle
Step 1: Denaturation 95  C
10 seconds
Step 2: Annealing 60  C
15 seconds
Step 3: Elongation 72  C
20 seconds
 
 
Figure 2-5 Steps and reactions in Q-PCR 
 
The comparative Ct method (2∆∆ Ct model) or relative quantitation was used in this 
study for relative gene expression analysis described by Livak (Livak and Schmittgen 2001): 
delta Ct (dCt) value  = Ct(target gene) -Ct (Housekeeping gene)) 
delta delta Ct (ddCt; Ct) = deltaCt sample –deltaCt calibrator 
fold change gene expression = 2
-Ct
 
As discussed earlier, this method did not require the running of standard curves every 
time, but was based on an endogenous control, also called a reference control or gene (e.g. 18S 
RNA, ARP or RPLP0). Ct values of reference control were used to normalise each sample for the 
amount of added template by comparison. These normalised values were then further standardised 
to a calibrator. For example one individual non-varicose vein sample was used as the calibrator 
when comparing gene expression between varicose and non-varicose veins in my study. The 
relative amount was calculated using the programme Rotor-Gene 6000™ Software Version 1.7 
(Corbett Research) 
2.1.6. Western Blots 
2.1.6.1. Protein extraction from whole vein tissues 
Pulverised whole varicose and non-varicose vein tissues that were intended for Western 
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blot were homogenised at 4C in urea/ sodium dodecyl sulphate (SDS) lysis buffer; about 20μl of 
buffer per mg of tissue (Appendix 4). After 30 minutes, the homogenates were centrifuged at 
13,000rpm for 5 minutes at 4C. The supernatant containing the protein was pipetted carefully 
from the pellet into a clean eppendorf. The protein extracted was assayed for the concentration or 
stored at -80C. 
2.1.6.2. Protein concentration assay 
The total protein concentration of the extracted protein was assayed using BCA™ Protein 
Assay Kit (Prod #23227; Thermo Scientific, Rockford, IL, USA). The assay combines the 
reduction of copper ion (Cu
2+
) to cuprous ion (Cu
1+
) by protein in an alkaline medium with the 
highly sensitive and selective colorimetric detection of the Cu
1+
 by bicinchoninic acid (BCA). The 
first step is the chelation of copper with protein in an alkaline environment to form a light blue 
complex known as the biuret reaction. In biuret reaction peptides containing three or more amino 
acid residues form a coloured chelate complex with cupric ions in an alkaline environment 
containing sodium potassium tartrate. The second step involves BCA reacting with Cu
1+
 that is 
formed in the first step. The chelation of two molecules of BCA with one Cu
1+
 produces an 
intense purple product. The water soluble BCA/copper complex exhibits a strong linear 
absorbance at 562nm with increasing protein concentrations. The detection of the purple product 
is approximately 100 times more sensitive (lower limit of detection) than the pale blue product 
formed from the first reaction. 
The protein concentration of the tissue extracts was determined in parallel and with 
reference to a serially diluted standard of known concentrations and a blank standard to generate a 
standard curve. Serially diluted bovine serum albumin or BSA (Sigma) starting at 2% with 
urea/SDS lysis buffer was used as standards. The blank standard used was urea/SDS lysis buffer. 
The BCA™ assay was carried out according to the manufacturer‟s protocol. Briefly, 200μl of 
BCA Working Reagent (50 parts of BCA™ Reagent A mixed with 1 part of BCA™ Reagent B) 
was added to 5μl of tissue extract sample which was diluted 1/4 volume with urea/SDS lysis 
buffer, standards and blanks in a Costar® 96 well EIA/RIA plate (Corning Incorporated, Corning, 
NY, USA). Each sample, standard and blank was assayed in duplicates. The plate was then 
covered, gently mixed on a plate shaker (Orbit 300, Labnet International Incorporation) for 30 
seconds. The plate was then incubated in dark at 37C for 30 minutes. Once the plate was cooled 
to room temperature, the absorbance was read at 550nm on a plate reader (Multiskan Ascent 
model 354, Thermo Labsystem, Finland). The standard curve and protein concentration of each 
unknown tissue extract sample was determined based on the standard curve automatically plotted 
using the Ascent Software Version 2.6 for Multiskan Ascent photometric microplate reader. 
Appendix 5 demonstrates representative typical optical density (OD) readings at absorption 
A550nm, standard curve generated and protein concentration calculated for standards and protein 
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extracted from whole vein tissues in this study. 
2.1.6.3. Gel electrophoresis 
Gel electrophoresis uses electrical voltage to separate native or denatured proteins 
according to their molecular mass. Negatively charged SDS-coated proteins migrate in 
polyacrylamide gels towards the positive electrode. The gel consists of a separation gel and a 
stacking gel. The former serves for proteins separation to occur while the latter concentrates the 
applied sample. Proteins with lower molecular mass migrate faster than those with higher 
molecular mass. The gel that was used in this study was a commercial gel; NuPAGE® Novex® 
Bis-Tris 4-12% Mini Gels (Invitrogen™, Carlsbad, CA, USA). Each gel consisted of 10 wells and 
one well could hold a maximum of 30µl of sample. The gel was used with a MOPS running 
buffer (Appendix 4). 
For a typical run, protein extract of 40µg in 25µl were mixed with 5µl per well of 4x SDS 
loading buffer (Appendix 4). The mixture was heated in a water bath at 100C for 5 minutes to 
denature the proteins. This was followed by a brief centrifugation at 12,000g for 30 seconds 
before loading of the sample onto NuPAGE® Novex® Bis-Tris 4-12% Mini Gels (Invitrogen™, 
Carlsbad, CA, USA). In each gel, 10 µl of Full Range Rainbow (Amersham, GE Healthcare), a 
coloured molecular mass standard was also included in the electrophoresis. The coloured 
molecular mass standard was used for the monitoring of electrophoresis, calibration of the 
electrophoretic mobility hence the apparent mass in kDa of the test proteins, and identification of 
the protein of interest in the Western blots. In each run, a positive control sample which was 
known to express the protein of interest in abundance was also included to help identifying the 
protein in the test samples (protein extract of renal cell carcinoma cell with VHL gene deletion for 
HIF-α and target genes). The electrophoresis was performed in Xcell SureLock™ Electrophoresis 
Cell (Invitrogen, USA) in 120V for about 60 minutes. 
2.1.6.4. Transfer 
Proteins resolved by gel electrophoresis could be analysed by Western blotting by 
transferring them from the gel to a polyvinylidene fluoride (PVDF) membrane. Proteins bound to 
the surface of the PVDF membrane become accessible for immunodetection. 
To transfer the proteins from the gel to a PVDF or Immobilon-P transfer membrane (filter 
type: PVDF, Millipore), the gel was equilibrated in chilled transfer buffer (Appendix 4) for 10 
minutes after the electrophoresis. The PVDF membrane was activated by immersing it in absolute 
methanol for 20 seconds followed by ddH2O for 2 minutes, and finally equilibrating it in chilled 
transfer buffer for 10 minutes. The proteins were then transferred using the BioRad system 
(BioRad PowerPac Basic™, USA) at 4°C for about 90 minutes at 100V in transfer buffer. In this 
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process, the transfer cassette comprising pre-equilibrated gel and PVDF membrane being 
sandwiched between chromatography papers (Paper Reels-Chrom.; Sartorius Stedim Biotech 
GmBH, Goettingen, Germany) and pads. The cassette was then placed in a transfer tank, 
immersed in chilled transfer buffer, ensuring that the PVDF membrane and gel situated towards 
the positive and negative electrode, respectively. During the transfer or electrophoresis, negatively 
charged proteins would therefore migrate from the gel to the PVDF membrane. Once transfer 
ended, the membrane was ready for immunodetection 
2.1.6.5. Immunodetection 
Immunodetection involves targeting, probing and visualising the protein of interest. A 
specific monoclonal or polyclonal primary antibody was used to target and probe the protein of 
interest on the membrane. The secondary antibody was directed against the epitope on the 
primary antibody. The secondary antibody was conjugated with a reporter fluorescence or enzyme 
such as horse-radish peroxidase (HRP) and alkaline phosphatase which would produce a 
colorimetric reaction and emit light or fluorescence when exposed to an appropriate substrate. 
Following transfer, the membrane was blocked with a blocking buffer (Appendix 4) on a 
rocking platform (GyroTwister, Labnet International Incorporation) at about 30 rpm at room 
temperature for one hour. Blocking prevents non-specific antibody binding. The membrane was 
then treated and probed with primary antibody specific to the protein of interest in an appropriate 
dilution (Appendix 6) with blocking buffer for 2 hours or overnight, depending on the protein of 
interest. The membrane was then washed 3 times with a washing buffer (Appendix 4) for 10 
minutes each time. The membrane was then incubated for 90 minutes in an appropriate secondary 
antibody conjugated with HRP (DakoCytomation) diluted appropriately in blocking buffer. The 
secondary antibody used was raised against the IgG of the animal species in which the primary 
antibody had been raised. Following treatment with secondary antibody, the membrane was 
washed 5 times in washing buffer for 10 minutes each time. Binding of the antibodies was then 
visualised using an enhanced chemiluminescence system, in this case the ECL Plus™ Western 
Blotting Detection System (GE Healthcare, Buckinghamshire, UK). It consisted of a lumigen PS-
3 acridan substrate, which was converted to an acridinium ester intermediate when catalysed by 
HRP. The ester intermediate reacted with hydrogen peroxide (H2O2) in alkaline conditions and 
emitted light. The light emission could be detected by exposing the PVDF membrane to a 
photography film (Fuji Medical X-ray Film 100NIF, Fujifilm Corporation, Tokyo, Japan) which 
was then developed by a film processor (AGFA Curix 60). 
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2.1.6.6. Loading control 
Equivalent protein loading into the gel was checked by immunodetection of a 
constitutively expressed protein. An ideal loading control protein should be expressed in the same 
amount in all sample types and all experimental conditions. In this study, anti-ERK-2 (C-14) sc-
154 antibody (Santa Cruz Biotechnology Inc, Santa Cruz, USA) was used. ERK-1 and -2 have 
been previously reported to be a suitable internal control protein in studies comparing protein 
expression in varicose and non-varicose veins (Kowalewski et al. 2009; Verstraeten et al. 2009). 
Besides this, equivalent protein loading in this study was also verified with Coomasie blue or 
Ponceau S staining (Appendix 7). 
2.1.7. Histology 
Prior to histological staining with special stains and immunohistochemistry, the varicose 
and non-varicose veins were processed, cut and prepared as described in Appendix 8.  
2.1.8. Special Histological Stains 
The special stains used for histological analysis of the varicose and non-varicose veins in this 
study were haematoxylin and eosin (H&E), Masson‟s trichrome (MT), and elastic van Gieson 
(EVG). Besides aiding morphological analysis of the veins, sections stained with these stains 
were also cross-referenced with those that were immunostained especially during the assessment 
of the distribution of the antigens of interest in the vein wall.  
2.1.8.1. Haematoxylin and eosin (H&E) 
H&E stain consists of the basic component haematoxylin which coloured basophilic 
structures (e.g. nucleic acids) with blue-purple, and alcohol-based acidic eosin which stained 
eosinophilic structures (e.g. most of the cytoplasm and red blood cells) bright pink. In this study, 
the H&E stain was used to assess for the general quality of the vein sections including the 
presence of artefacts and the integrity of the endothelium. H&E also enabled the general 
assessment of the vein wall morphology and the distribution of the inflammatory cells. 
The slides were stained using a Leica auto-stainer. First, the sections were treated with 
haematoxylin which stained the nuclei. Excess stain was then washed off with tap water. The 
sections were then immersed in acid alcohol which differentiated the haematoxylin from the 
tissue before being washed off again with tap water. Ammoniated water was then used to „blue 
up‟ the haematoxylin stain. After the ammoniated water was washed off with tap water, the 
cellular components of the sections were then counterstained with eosin. Excess eosin was 
washed away with tap water. The sections were then dehydrated with an increasing gradient of 
alcohol. Finally the slides were cleared with xylene to provide the base for the anhydrous Pertex 
mounting medium. The slides were then mounted on a Leica CV5030 Auto-cover-slipper. 
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2.1.8.2. Masson’s trichrome (MT) 
MT is generally used to distinguish cells from the surrounding connective tissues by 
differentially demonstrating the latter. It employs three dyes which selectively stain collagen 
fibres, muscles, fibrin and erythrocytes. Such selective staining affinity was affected by several 
factors including the molecular sizes of the stains, tissue density, and pH. MT coloured the 
collagen green, SMC and erythrocytes red, and nuclei blue or black. Masson‟s trichrome enabled 
the assessment of the relative amount of SMC and connective tissue in the vein wall. It also helps 
to distinguish longitudinal from circular smooth muscle fibres. 
The Charing Cross Hospital Department of Histopathology protocol was used for the MT 
staining. Deparaffinised slides were treated with 1% chromazone red in 1% acetic acid for 5 
minutes. The slides were then rinsed with distilled water (dH2O), differentiated with 
phosphomolybdic acid for 5-10 minutes, and then rinsed with dH2O again. The slides were then 
treated with the trichrome mixture consisting of 2 parts of 1% chromazone red in 1% acetic acid, 
4 parts of 1% phosphomolybdic acid and 6 parts of 1% light green in 1% acetic acid for 10 
minutes. Following that, the slides were rinsed in phosphomolybdic acid. Finally, the slides were 
treated with acetic acid for 2 minutes before being mounted in portex mountant. 
2.1.8.3. Elastic van Gieson (EVG) 
EVG stain was used to demonstrate elastic fibres. Such stains had an affinity for sulphur 
compounds which might be found in elastic fibres. Elastic fibres were stained dark blue and 
muscles fibres red. In this study, besides the assessment of the elastic fibres content in the vein 
wall, EVG also helped to identify the internal and the external lamina. Identifying the elastic 
lamina helped distinguishing the different layers of the vein wall (tunica intima, media and 
adventitia), and differentiating the elastic fibres from the SMC. 
Deparaffinised slides were treated with 70% alcohol followed by Millers stain for 2 
hours. The sections were then treated in 70% alcohol followed by van Gieson stain for 5 minutes, 
and rinsed with distilled water. The sections were then blotted dried and dehydrated with absolute 
alcohol. They were then cleared and mounted. 
2.1.9. Immunohistochemistry 
Immunohistochemistry is a technique of localising and visualising the antigens or 
proteins of interest in tissue sections. Immunohistochemistry exploits the specific antigen-
antibody interactions which can be visualised by a marker or reporter such as fluorescent dye 
(immunofluorescence), enzyme (immunoenzyme) and colloidal gold conjugated on the antibody. 
The method applied in immunohistochemistry can be divided into direct and indirect. 
Direct method is a one-step staining method that involves a labelled primary antibody, such as 
FITC conjugated antiserum, reacting directly with the antigen of interest in tissue sections (Figure 
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2-6a). This technique utilises only one antibody and has the advantage of being simple and quick. 
However, this technique compromises its detection sensitivity due to relatively little signal 
amplification when only one layer of antibody is applied. Meanwhile, indirect method involves a 
layer of unlabeled primary antibody (first layer) which binds to tissue antigen of interest, and a 
labelled secondary antibody (second layer) that reacts with the primary antibody (Figure 2-6b) 
and amplifies the signal. The secondary antibody is raised against the IgG of the animal species in 
which the primary antibody has been raised. The secondary antibody can be labelled with a 
fluorescent dye (indirect immunofluorescence method) such as FITC, rhodamine or Texas red, or 
an enzyme (indirect immunoenzyme method) such as peroxidase, alkaline phosphatase or glucose 
oxidase. The sensitivity of indirect method is increased compared to direct method due to signal 
amplification through several secondary antibody reactions with different antigenic sites on the 
primary antibody. 
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Figure 2-6 The direct and indirect method of immunohistochemistry 
(a) Direct method with only one layer of antibody, and (b) Indirect method with two layers of antibodies 
There are several ways of amplifying the detection signal in the indirect method. 
Examples include the peroxidase anti-peroxidase (PAP), avidin-biotin complex (ABC), labelled 
streptavidin biotin (LSAB), and polymeric method. For example, the widely used ABC method 
involves three layers; unlabeled primary antibody, biotinylated secondary antibody and complex 
of avidin-biotin peroxidase. Avidin is a large glycoprotein that can be conjugated with peroxidase 
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or fluorescein and has a very high affinity for biotin. Meanwhile, biotin is a low molecular weight 
vitamin that can be conjugated to a variety of biological molecules such as antibodies. The 
peroxidase is then developed by the 3,3'-diaminobenzidine (DAB) or other substrates to produce 
different colorimetric end products. 
Tissue processing, deparaffinisation and rehydration steps were similar to those discussed 
in Appendix 8. 
2.1.9.1. Quenching of endogenous peroxidase activity 
Endogenous peroxidase activity in erythrocytes, leucocytes and other cells could 
sometimes cause heavy non specific background staining with the HRP conjugated antibody. This 
could lead to false positives or masking of the actual staining (false negative). Such activity was 
blocked by immersing the sections in a 2% solution of 0.3% hydrogen peroxide (Sigma-Aldrich, 
Steinheim, Germany) for 30 minutes. The sections were then washed 3 times for 5 minutes each 
time with PBS. 
2.1.9.2. Antigen retrieval 
Formalin fixation could in some cases mask antigenic sites. Therefore, prior to 
immunohistochemical staining, the demonstration of the antigens could be improved by antigens 
retrieval. This process would break the protein cross-links formed by formalin fixation and would 
thereby uncover hidden antigen sites. There are several methods of antigen retrieval including the 
application of heat (microwave, pressure cooker or steamer) to the tissue sections in a retrieval 
solution (citrate buffer or ethylenediaminetetraacetic acid (EDTA)), and the use of enzymes 
(proteinases or trypsin) 
The antigen retrieval system that was used in this study was the application of heat from a 
steamer to the tissue sections immersed in 1mM citrate buffer (pH 6.0) (AnalaR®, BDH 
Laboratory, Poole, UK) for 40 minutes. After 50 minutes, the container containing the sections 
and hot citrate buffer was placed and gradually chilled in running cold tap water.  
2.1.9.3. Blocking 
Besides endogenous peroxidase activity which could be quenched by hydrogen 
peroxidase treatment, non-specific background staining could also be caused by non-
immunological binding of the specific immune sera or antibodies by hydrophobic and 
electrostatic forces to certain sites within the tissue sections. Such non-specific binding could be 
reduced by blocking these sites with normal serum or BSA. In this study the slides were treated 
with 3% BSA (Sigma-Aldrich, St. Louis, USA) for about 30 minutes as the blocking step. 
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2.1.9.4. Primary antibody 
Following blocking, the sections were treated with the primary antibody (Appendix 9) 
against the antigen of interest at 4
o
C overnight. The primary antibody was diluted to the 
appropriate concentration with PBS. For negative controls, the sections were either treated with 
the same concentration of the respective isotype control negative IgG. 
2.1.9.5. Secondary antibody 
A polymer detection system was used in which the secondary antibody was polymerically 
conjugated with HRP or alkaline phosphatase by using a synthetic polymer carrier. This technique 
increased the number of available enzymes or ligands binding at the antigenic site, therefore 
increasing their reactivity to the reporting chromogen. Since it was biotin-free, there was no non-
specific binding to endogenous biotin. The polymer technique had several advantages over the 
three-step avidin-biotin system including its simplicity, increased sensitivity, lack of background 
staining secondary to endogenous biotin or avidin (Ramos-Vara and Miller 2006). 
Following incubation with primary antibody, the sections were washed three times with 
PBS for 5 minutes each. The sections were treated with components of the Super Sensitive 
Polymer-HRP IHC Detection System (BioGenex
 
Laboratories, Dan Ramon, CA, USA). This 
involved incubating the sections first with the Super Enhancer™ component followed by 3 
washes of 10 minutes each time with PBS mixed plus 0.1% Electran Triton® X-100 (VWR® 
International, Leicestershire, England). The sections were then treated with Polymer-HRP 
component followed by another 3 washes of 10 minutes each time with PBS plus 0.1% Electran 
Triton® X-100. The sections were then ready for substrate preparation and development. 
2.1.9.6. Substrate preparation and development 
The reaction product was revealed by treating the section with 2µg/ml of DAB solution 
(BioGenex
 
Laboratories, Dan Ramon, CA, USA). The sections were treated with about 80-150µl 
of DAB solution and left in room temperature for several minutes depending on the antibody 
used. During optimisation, the sections were examined under a low magnification (X40 and 
X100) light microscope to grossly assess the colour (brown) development before the reaction was 
stopped by washing the DAB off by immersing the slides into tap water. 
2.1.9.7. Counterstain 
Following colour development with DAB, the sections were washed gently in running tap 
water for about 5 minutes. The sections were then counterstained with haematoxylin solution. 
This was performed by immersing the sections into the Harris‟ haematoxylin solution for about 5 
seconds. The haematoxylin solution stained the nuclei blue. 
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2.1.9.8. Dehydration and clearing 
Following counterstaining, the sections were washed gently in running tap water for 5-10 
minutes to remove excess haematoxylin. The sections were then immersed in dH2O for 5 minutes. 
Then, they were taken through a series of graded IMS bath of increasing concentration (70%, 
90%, and twice absolute alcohol for 10-minute interval each) to dehydrate the sections, and 
remove aqueous fixative and any tissue water content before the clearing process. Clearing was 
achieved by sequential transfer of the tissues into two xylene baths, 10-minute interval each. 
2.1.9.9. Mounting and cover slip 
The sections were mounted with di-n-butylphthalate in xylene, DPX (vWR® BDH 
Prolab®, Leicestershire, UK) and cover slips were laid gently onto the sections preventing any air 
bubbles being trapped. 
2.1.9.10. Optimisation of an antibody 
The conditions required for the immunostaining of each antibody were optimised with a 
paraffin embedded tissue section that was known to expressed the antibody in abundant. In this 
study, three different renal cell carcinoma that was known to expressed HIF-1α, HIF-2α and HIF 
target genes were used. The conditions required were based on previously published literature and 
datasheet of the same antibody. Three different dilutions of the primary antibody and a negative 
control (PBS only) were used during optimisation, and the best dilution i.e. with the least non 
specific staining (specificity) and the clearest positive staining (sensitivity) was then selected for 
subsequent immunostaining of the varicose and non-varicose vein tissues.  
2.1.9.11.  Positive and negative controls 
During every run of immunohistochemistry of the varicose and non-varicose vein tissues, 
a positive control tissue (renal cell carcinoma) was also immunostained against the antibody of 
interest (positive control). The positive slide helped to determine if that particular run of 
immunohistochemistry against the antibody of interest was successful. Meanwhile a 
corresponding serial cross-section slide of all the varicose and non-varicose veins, and the renal 
cell carcinoma that was used as positive control was also immunostained against an isotype 
negative control antibody at the same time of each run of immunohistochemistry. The isotype 
negative control antibody used was of the same immunoglobulin isotype raised from the same 
species as the antibody of interest in the same concentration. The isotype negative control 
antibody does not react with human antigens. The isotype negative control antibody 
immunostained slides were studied along with their corresponding sections immunostained with 
antibody of interest to identify areas of non-specific staining i.e. false positive. Figure 2-7 and 
Figure 2-8 show typical examples immunohistochemistry staining of renal cell carcinoma against 
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HIF-1α, HIF-2α, CA9 and PHD-2, and their respective isotype negative controls in the dilutions 
used for subsequent vein tissues immunostaining. HIF-1α and HIF-2α were localised in the 
nuclei, CA9 in cell membrane, and PHD-2 in cytoplasm and nuclei. 
HIF-1α
HIF-2α
(a)
(b)
Isotype negative control
Isotype negative control
 
Figure 2-7 Immunohistochemistry against HIF-1α and HIF-2α of a renal cell 
carcinoma 
Representative serial cross-sections of a renal cell carcinoma that were used as positive control tissue which 
were immunostained against HIF-1α and HIF-2α on the right and their respective isotype control antibody 
on the left. HIF-1α and HIF-2α were localised in the nuclei of the renal cell carcinoma. 
Immunohistochemistry magnification X100.  
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Figure 2-8 Immunohistochemistry against CA9 and PHD-2 of a renal cell carcinoma 
Representative serial cross-sections of a renal cell carcinoma that were used as positive control tissue which 
were immunostained against CA9 and PHD-2 on the right, and their respective isotype control antibody on 
the left. CA9 was localised in the cell membrane, and PHD-2 in cytoplasm and nuclei of the renal cell 
carcinoma. Immunohistochemistry magnification X100.  
 
2.1.10. Vein Organ Culture 
2.1.10.1. Preparation of a vein organ culture 
The vein organ culture model used in the study of in vitro responses of whole varicose 
and non-varicose vein tissue to various stimuli or conditions including hypoxia and 
pharmacological agents was based on a model previously developed by Soyombo and colleagues 
in 1990 (Soyombo et al. 1990) with some modifications. Varicose and non-varicose veins 
removed during surgery were immediately transferred to the laboratory in 5ml of DMEM High 
Glucose (4.5g/L) with L-glutamine, and sodium pyruvate (PAA Laboratories GmbH, Pasching, 
Austria). On arrival to the laboratory, the subsequent steps of the vein organ culture preparation 
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were performed in a class II laminar flow safety cabinet (Heraeus® HERASafe® KS Class II 
Safety Cabinet; Thermo Electron Corporation, Langenselbold, Germany). The vein tissues were 
assessed macroscopically for undamaged segments (e.g. unclamped areas) suitable to be used for 
the organ culture. Figure 2-9 illustrates the steps involved in the preparation of a vein organ 
culture. Damaged vein segments were excised and discarded. Excess fat and adventitial tissues on 
the veins were carefully dissected from the vessels. The veins were cut open longitudinally to 
expose the luminal or endothelial surface. The veins were then cut transversely to form 
rectangular or squared segments of veins measuring 0.5cm – 1.0cm width x 0.5cm – 1.0cm 
length. The wet weight of each segment of vein was measured on a weighing scale (Sartorius 
GmbH, Goettinger, Germany). Each segment of varicose veins was then pinned out with an A1 
minuten pin (Watkins & Doncaster, Kent, UK) at each of the four corners with the luminal or 
endothelial surface uppermost, onto a 2cm x 2cm polyester mesh (#PES475/50, Sericol Limited, 
Kent, England) resting on the sylgard resin (Dow Corning, Seneffe, Belgium) in a glass Petri dish 
(DURAN® Group GmbH, Mainz, Germany; Figure 2-10). 
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Figure 2-9 Schematic diagram of vein organ preparation 
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Figure 2-10 Photographs of a vein organ culture during various steps of preparation 
Typical appearances of the vein organ culture during preparation. A piece of vein was obtained from the 
operating theatre prior to vein organ preparation (a). A segment of vein measuring about 0.5cm x 0.5cm that 
had been pinned on to a polyester mesh on a sylgard resin in a glass Petri dish with and without culture 
medium, respectively (b) and (c). 
 
Each varicose vein segment was then immersed with 5ml of DMEM High Glucose 
(4.5g/L) with L-glutamine, and sodium pyruvate (PAA Laboratories GmbH, Pasching, Austria) + 
100 unit/ml penicillin and 0.1 mg/ml streptomycin (PAA Laboratories GmbH) +/- 10% foetal 
bovine serum (FBS; Gibco™, Invitrogen Life Sciences, Paisley, UK) (Figure 2-10). The Petri 
dish was then covered with a lid. The vein organ cultures were then incubated at 37ºC, either in a 
normoxia (95% air and 5% carbon dioxide; Napco 6500 incubator) or a hypoxia (1% oxygen and 
5% carbon dioxide; Galaxy R CO2 Incubator, Wolf Laboratories, York, UK) incubator, 
respectively. 
2.1.10.2. Culture medium change 
Change of culture medium was done entirely in a class II laminar flow safety cabinet. The 
used culture medium was transferred with a pipette from the Petri dish containing the vein organ 
culture into an appropriate storage container such as Cryovial® (Simport Plastics, Quebec, 
Canada) or the Falcon® 24-well tissue culture plate (Becton Dickinson Labware, NJ, USA). The 
vein organ culture was then replenished with 5ml of fresh culture medium before being 
transferred back into the incubator. Culture medium collected during medium change was stored 
in a -80ºC freezer if required for further analysis. 
2.1.10.3. Storage of tissue and culture medium from organ culture 
At the end of a culture, the vein organ culture was transferred from the incubator to the 
class II laminar flow safety cabinet. The A1 minuten pins at the four corners of the vein segment 
were carefully removed without damaging the tissue. The vein tissue was then gently removed 
from the Petri dish. The vein was either snap frozen immediately in liquid nitrogen before being 
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stored in a -80ºC freezer. The culture medium was also collected and stored in a -80ºC freezer for 
further analysis. 
2.1.11. Cell Death 
The viability of the vein organ culture was assessed using the Cell Death Detection 
ELISA Plus® (Roche Diagnostics GmbH, Mannheim, Germany). The Cell Death Detection 
ELISA Plus® is based on a quantitative and semi-quantitative sandwich-enzyme-immunoassay 
principle, using mouse monoclonal antibodies directed against DNA and histones, respectively. 
The assay allows the specific detection and quantitation of histone-complexed DNA (mono- and 
oligonucleosomes) that are released into the cytoplasm and surrounding medium of cells 
undergoing apoptosis and necrosis, respectively (Figure 2-11). The mono- and oligonucleosomes 
are generated as a result of activation of endogenous endonucleases during apoptosis leading to 
the cleavage of dsDNA at the most accessible internucleosomal linker region. Since the DNA of 
nucleosomes is tightly complexed with the core histones H2A, H2B, H3 and H4 and is therefore 
protected from cleavage by the endonucleases (Burgoyne et al. 1974; Stach et al. 1979) , the DNA 
fragments produced during apoptosis are discrete multiples of a 180 bp subunit. The enrichment 
of mono- and oligonucleosomes in the cytoplasm of the apoptotic cell is due to the fact that DNA 
degradation occurs several hours before plasma membrane breakdown (Duke and Cohen 1986). 
 
Normal 
cell
Necrotic 
cell
Necrotic 
cell
al 
l
Necr ic 
cel
Apoptotic 
ell
Histone complexed
DNA fragments
 
Figure 2-11 Cell Death Detection ELISA Plus® assayed the histone complexed DNA 
fragments that were released during apoptosis and necrosis 
2.1.11.1. Preparation of vein tissue lysate 
Vein tissues stored in the -80ºC freezer were thawed in room temperature. Vein tissues 
were homogenised by cutting it into tiny pieces. They were then crushed (3-5 times) gently with 
the rubber end of a plunger from a 1 ml syringe. The crushed tissue of each vein was transferred 
into a 1.5 ml eppendorf before the addition of the lysis buffer; 200µl of lysis buffer per 6.6 mg of 
vein tissues. The tissues were further crushed and homogenised in the lysis buffer. The 
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homogenates were left for 30 minutes at 4ºC. After 30 minutes, the homogenates were centrifuged 
at 13,000 g for 20 minutes at 4 ºC. The supernatant (tissue lysate) of the homogenates were 
transferred into new 1.5ml eppendorfs. If needed, lysate was diluted with the incubation buffer. 
The lysate was then analysed with the Cell Death Detection ELISA Plus®. 
2.1.11.2. Preparation of culture medium lysate 
Culture medium that was stored in the -80ºC freezer was thawed in room temperature. 
Then, 1 ml of culture medium from each specimen was transferred into a Falcon® 24-well tissue 
culture plate (Becton Dickinson Labware, NJ, USA). The culture medium was centrifuged at 1200 
rpm for 10 minutes with the Napco 2028R multi-function centrifuge. The supernatant was then 
discarded, leaving the pellets containing cellular debris including the mono- and oligo-
nucleosomes. The pellet was then treated with 200µl of lysis buffer for 30 minutes. The mixture 
was then centrifuged at 1200rpm for 10 minutes. The supernatant (lysate) was then analysed with 
the Cell Death Detection ELISA Plus®. 
2.1.11.3. Cell Death Detection ELISA Plus® 
For every well, 20µl of lysate from each specimen (tissue and culture medium), positive 
control (provided in the kit), and negative control (incubation buffer only) were analysed on the 
microplate provided. Each sample was analysed in duplicates. Immunoreagent was prepared by 
mixing of 1/20 volume anti-DNA-POD and 1/20 volume anti-histone-biotin with 18/20 volumes 
incubation buffer. In each well 80µl of the immunoreagent was added. The microplate was then 
covered with an adhesive plate cover and left on a plate shaker (Orbit 300, Labnet International 
Incorporation) at 300rpm in room temperature for 2 hours. Just before the end of the 2 hours, 
ABTS solution was prepared (1 tablet in 5 ml of substrate buffer). Once the 2 hours has passed, 
the adhesive plate cover was removed and the solution in the microplate is discarded gently by 
inverting the microplate. The wells were rinse with 250µl per well of incubation buffer which was 
then discarded. The microplate was then blotted on layers of paper towel. The rinsing and blotting 
step of the microplate was repeated for 2 more times. After the microplate was blotted for the 
third time, 100µl of the ABTS solution was added into each well. The microplate was left on the 
plate shaker at 250rpm. The absorbance at wavelength of 405nm (A405nm) against the ABTS 
solution was analysed by colorimetric measurement using a plate reader at 5, 10, 15 and 20 
minutes. 
2.1.12. RNA interference 
RNA interference (RNAi) is a biological system that involves small RNA molecules in 
the regulation of the post-transcriptional activity of genes, both activation and inhibition. Small 
RNA molecules which include microRNA and small interfering RNA (siRNA) are the direct 
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products of genes, and can bind specifically to other RNAs to regulate their activity (Mohr et al. 
2010). A typical example is the inhibition of a specific mRNA to be translated to protein. The 
RNAi pathway is initiated by an enzyme known as dicer which cleaves long double-stranded 
RNA (dsRNA) molecules into short fragments of about 20 nucleotides (Merritt et al. 2010). In the 
cytoplasm, siRNA binds and activates an RNA-induced silencing complex (RISC) (Lee et al. 
2008). Unwinding of the siRNA duplex when it binds to the RISC exposes one strand of the 
siRNA, which can bind to complementary mRNA (Lee et al. 2008). Once bound, the RISC 
complex cleaves the mRNA but does not destroy the original siRNA strand (Lee et al. 2008). 
Therefore, the complex can go on to inhibiting other complementary mRNAs (Mohr et al. 2010). 
RNAi is selective and has robust effects on gene expression, making it a powerful 
research tool. Gene knockdown by synthetic siRNA is widely used in the laboratory today to 
study the function of a specific gene without the need for genomic manipulation. Gene 
knockdown with siRNA transfection is most often described in cell cultures and sometimes in 
vivo in model animals (Karshovska et al. 2007; Lee et al. 2008; Monahan et al. 2009; Mohr et al. 
2010). In vitro siRNA transfection of whole tissues or organs has also been reported although less 
predictable and successful (Lee et al. 2008; Monahan et al. 2009). 
2.1.12.1. Transfection of vein organ culture with siRNA 
Gene knockdown was performed using siRNA targeting specific genes with lipid 
mediated transfection. Vein organ cultures were prepared as discussed above. Vein organ cultures 
were incubated and equilibrated in normoxia at 37ºC for 24 hours. They were then washed with 
5ml of sterile PBS twice. Oligofectamine and nucleic acids were each diluted in Opti-MEM I 
Reduced Serum Medium (Invitrogen) before complexing. The sequences of the siRNA used are 
shown in Appendix 10. The final concentration of siRNA when added into the vein organ culture 
was 100nM. After 5 minutes cationic lipids and siRNA (or scrambled siRNA for control) were 
mixed (500µl) and incubated for 20 minutes at room temperature, while liposomes were formed. 
Such complexes were added to plate containing cells and 4.5ml of Opti-MEM and mixed gently. 
Liposomes easily merged with cell membrane, since they both are made of phospholipid bilayer, 
and released siRNA into the cell. Vein organ cultures were incubated for 20 hours at 37°C and 
then medium was changed into DMEM and 10% FBS, cultured for 6 hours in normoxia at 37°C, 
and then subjected to hypoxia or DMOG treatment. 
 
2.2. MATERIAL AND METHODS USED IN THE HARVARD UNIVERSITY 
The solutions and drugs used in the research carried out in Harvard University are 
described in Appendix 11. 
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2.2.1. Ethical Approval 
All the research followed the Ethical Research Guidelines at the Brigham and Women's 
Hospital and Harvard Medical School. All animal research experiments were conducted following 
the guidelines of the Standing Committee on Animals at Harvard Medical School. 
2.2.2. Animals and Tissues 
Male Sprague-Dawley rats (12 weeks, 250-300 g, Charles River Lab, Wilmington, MA, 
USA) were euthanised by inhalation of CO2. Euthanasia was judged by cessation of breathing and 
heart beats. The abdominal cavity was opened, and the inferior vena cava (IVC) was rapidly 
excised, placed in Krebs solution, and carefully dissected and cleaned of adventitial tissue under a 
dissecting microscope (Figure 2-12). The IVC was portioned into four 3mm wide rings in 
preparation for isometric contraction experiments.  
 
 
Figure 2-12 Dissection of a male Sprague-Dawley rat IVC 
Dissection of a male Sprague-Dawley rat IVC was performed in physiological Krebs solution which was 
continuously bubbled with 95% O2 and 5% CO2. Dark arrow indicated the abdominal aorta and IVC, and 
white arrows depicted the kidneys 
2.2.3. Isometric Contraction 
Each IVC segment was suspended between two tungsten wire hooks, one hook was fixed 
to a glass rod at the bottom of the tissue bath and the other hook was connected to a Grass force 
displacement transducer (FT03, Astro-Med Inc, West Warwick, RI, USA; Figure 2-13). Vein 
segments were stretched under a pre-determined basal tension in a temperature controlled, water-
jacketed tissue bath, filled with 50 ml Krebs solution continuously bubbled with 95% O2 and 5% 
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CO2 at 37°C. The changes in isometric contraction were recorded on a Grass polygraph (Model 
7D, Astro-Med; Figure 2-14). 
 
 
Figure 2-13 Schematic diagram and photographs of the system used for isometric 
contraction experiments 
The system used to provide mechanical stretch to and measure isometric contraction of rat IVC The system 
was connected to a Grass force displacement transducer. The dotted lined circle in the second photograph 
indicated a segment of rat IVC being stretched in between two wire hooks in culture medium. 
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Figure 2-14 Grass polygraph (Model 7D, Astro-Med) 
A Grass polygraph (Model 7D, Astro-Med) and typical contraction traces of rat IVC measured when 
stimulated with potassium chloride, KCl 96mM and phenylephrine PHE 
 
2.2.4. RNA Study and Western blots 
The principles of the techniques used for RNA study and western blots that were used in 
Harvard University were similar to those applied in the Imperial College London, as described 
earlier in 2.1.5 and 2.1.6, respectively. The variations between the techniques used in the two sites 
were mostly related to the differences in equipment and reagents available. Therefore, the 
techniques of RNA study and Western blots used in Harvard University are only briefly described 
Appendix 12. 
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3. HYPOXIA-INDUCIBLE FACTORS AND STRUCTURAL VARIATIONS IN 
VARICOSE VEINS 
3.1. INTRODUCTION 
This chapter focused on analysis of structural changes and the HIF pathway in varicose 
and non-varicose veins. It is important to understand the histology of a normal vein, in order to 
study the structural changes and remodelling in varicose vein wall during this research project. 
Like arteries, veins are classified into large, medium and small veins. Unlike arteries, veins often 
appear irregular in shape and contain less elastic tissue and SMC. 
Similar to arteries, veins are divided into three layers or tunicae; intima, media and 
adventitia in histology. Tunica intima is the innermost layer adjacent to the lumen. Tunica intima 
consists of a thin layer of SMC covered by endothelium. Underneath the tunica intima is the 
tunica media. The border of the tunica intima and media is defined by the internal elastic lamina 
which is often poorly developed in veins. The tunica media generally consists of an inconspicuous 
inner layer of longitudinally orientated SMC and a more prominent outer layer of circularly 
orientated SMC. The SMC are embedded in ECM. The tunica adventitia lies beneath the tunica 
media, hence the outermost layer. Tunica adventitia is composed of fibroblasts, collagen fibres, 
vasa vasorum, elastic tissues and clusters of longitudinal SMC (Somers and Knaapen 2006). The 
boundary of the tunica media and adventitia is defined by the external elastic lamina. Figure 3-1 
illustrates a histological section of a normal vein, in this case, an inferior epigastric vein from a 
healthy adult individual. The normal vein was stained with special stains; (a) H&E, (b) EVG and 
(c) MT to delineate the layers and some of constituents of the vein wall including SMC, elastic 
tissues and connective tissues (Figure 3-1). 
Blood vessel formation and physiological remodelling occur through three different 
mechanisms; vasculogenesis, angiogenesis, and arteriogenesis (Heil et al. 2006; Hanze et al. 
2007; Rey and Semenza). Vasculogenesis refers to blood vessel formation from bone-marrow 
derived vascular stem cells or haemangioblasts which could develop into endothelial cells, 
vascular SMC, and pericytes during embryonic development (Heil et al. 2006; Hanze et al. 2007; 
Rey and Semenza). Angiogenesis describes the sprouting and expansion of new blood vessels 
from existing vessels. Meanwhile, arteriogenesis implies the remodelling of existing blood vessels 
including the luminal enlargement to allow increased blood flow (Heil et al. 2006; Hanze et al. 
2007; Rey and Semenza). 
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Figure 3-1 Histology of a normal vein 
Cross sections of a normal inferior epigastric vein obtained from a healthy 40 year old man, and stained 
with special stains; (a) H&E, (b) EVG, and (c) MT. The vein is divided into the innermost tunica intima, 
media and outermost adventitia. The layers are defined by the internal and external elastic laminae as 
shown in (b). Tunica intima is a thin layer consisting of endothelium and SMC underneath. Tunica media is 
consisted of inner longitudinal and outer circular SMC embedded in connective tissue with some elastic 
tissues. The tunica adventitia appears to be composed with connective tissue, SMC, adventitia and vasa 
vasorum in special stains. SMC: smooth muscle cell. Magnification X40 
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HIF appears to play a role in all the three mechanisms. Since the main function of blood 
vessels is to deliver oxygen to tissues preventing ischaemia, it is not surprising that hypoxia and 
HIF play an important role in regulating vascular formation and remodelling to meet the tissue 
oxygen demand. The role of HIF-1 in vasculogenesis was demonstrated using mouse embryos 
lacking HIF-1. Although blood vessels formed in these embryos, the vascular plexus eventually 
degenerated causing embryonic death at mid-gestational stage (Iyer et al. 1998; Ryan et al. 1998). 
Mouse embryos lacking HIF-2 have also been found to be associated with abnormal vascular 
development including increased leakiness of capillaries, failure to fuse properly and assemble 
into larger vessels, leading to haemorrhage and embryonic death (Peng et al. 2000). 
HIF is an important regulator of angiogenesis. For example, increased collateral 
circulation due to angiogenesis secondary to tissue ischaemia has been shown to be associated 
with up-regulation of HIF including in coronary heart disease (Chen et al. 2008). Meanwhile, 
ligation of the femoral artery of mice also induced increased expression of HIF and various 
angiogenic factors (Bosch-Marce et al. 2007). HIF may induce angiogenesis through the 
regulation of various critical angiogenic growth factors transcriptional activity. They include 
VEGF, SDF1, ANGPT2, PlGF, PDGF-B, and stem cell factor (SCF) (Forsythe et al. 1996; Kelly 
et al. 2003; Ceradini et al. 2004; Manalo et al. 2005; Bosch-Marce et al. 2007; Hanze et al. 2007; 
Simon et al. 2008; Semenza 2009a; Rey and Semenza 2010). Besides the expression of secreted 
angiogenic growth factors, HIF also regulates many genes that encode cell surface receptors that 
are involved in endothelial cellular response to hypoxia-induced angiogenic cytokines (Manalo et 
al. 2005). Furthermore, degradation of the basement membrane surrounding the blood vessels is 
essential for the sprouting and expansion of new capillaries during angiogenesis, in which MMP 
and TIMP may contribute to this process. Many MMPs and TIMPs such as MMP-2, MMP-9 and 
TIMP-1 are known to be induced by hypoxia in a HIF-dependent manner (Norman et al. 2000; 
Ben-Yosef et al. 2002; Fujiwara et al. 2007). 
In comparison with angiogenesis, the importance of hypoxia in arteriogenesis or vascular 
remodelling remains unclear since non-hypoxic stimuli may also be involved (Rey and Semenza 
2010). Furthermore, the process of vascular remodelling and angiogenesis are thought to overlap 
(Hershey et al. 2001; Rey and Semenza 2010). For example, VEGF and PlGF are both angiogenic 
and arteriogenic (Pipp et al. 2003; Clayton et al. 2008). Following femoral artery ligation, tissue 
hypoxia attracted pro-angiogenic myeloid cells to pass through collateral blood vessels to reach 
the ischaemic site (Bosch-Marce et al. 2007). Since more blood is trying to flow through the 
collaterals, these vessels undergo remodelling to increase the blood circulation capacity (Rey and 
Semenza 2010). Therefore, increased shear stress and pressure that occur prior to vascular 
remodelling are thought to be important stimuli for vascular remodelling along with hypoxia 
(Hanze et al. 2007; Rey and Semenza 2010). 
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Various genes regulated by HIF are known to be involved in vascular remodelling. For 
example, eNOS and iNOS are involved in vasodilatation, MT1-MMP and TIMP-1 regulate ECM 
metabolism, VEGF receptors (VEGFR) VEGFR1 and VEGFR2 affect vascular permeability, and 
PDGF-B stimulates SMC proliferation and migration (Hanze et al. 2007). An example of a 
pathology demonstrating the role of HIF in vascular remodelling is pulmonary hypertension, a 
condition characterised by narrowing of the vascular lumen caused by thickening of small 
pulmonary arteries. The vascular remodelling process is characterised by increased accumulation 
of SMC and ECM, and myofibroblast formation (Jeffery and Wanstall 2001; Theo Schermuly et 
al. 2005; Stenmark et al. 2006). Acute hypoxia induces vasoconstriction causing a reversible 
increase in pulmonary vascular resistance. In pulmonary hypertension, various HIF-dependent 
mechanisms and target genes have been demonstrated to be affected including ET-1, AT1 
receptor, VEGF, PDGF-B, eNOS, iNOS and EPO (Hanze et al. 2007). Furthermore, heterozygous 
HIF-1α (HIF-1α+/-) and HIF-2 (HIF-2α+/-) knock-out mice demonstrated delayed manifestation 
or protection of against hypoxia-induced pulmonary hypertension (Yu et al. 1999; Shimoda et al. 
2001; Brusselmans et al. 2003). 
Compared to artery formation and remodelling, less is known about the role of HIF 
pathway in vein wall remodelling. Abnormal expression of HIF- has been reported in some 
venous pathology. As previously mentioned, increased HIF-1 expression has been reported in 
the internal spermatic vein of patients with varicocoeles (Lee et al. 2006). Patients with Chuvash 
polycythaemia, a congenital disorder of inappropriate increased expression of HIF- due to VHL 
gene mutation, are more likely to have varicose veins compared to those without the 
polycythaemia (Gordeuk et al. 2004). Veins distal to haemodialysis grafts and AV fistula 
requiring revision also demonstrated increased expression of HIF-1, migration inhibition factor, 
TIMP-1, pro-MMP-2 and pro-MMP-9 compared to non-stenotic control veins of patients 
undergoing haemodialysis vascular access placement (Misra et al. 2008b). All these findings 
suggest that HIF-1 may be involved in pathological venous remodelling. Only recently, 
Hossein-Ghaderian and colleagues identified HIF-1α expression in endothelial cells of the intima 
and vasa vasorum of 5 out of 20 varicose vein specimens but none of the 20 non-varicose 
saphenous vein tissues (Hossein Ghaderian et al. 2010). 
3.2. OBJECTIVES 
The objectives of this chapter were: 
1. To demonstrate structural variations between varicose and non-varicose vein tissues using 
special stains and light microscopy 
2. To study and compare the HIF pathway in varicose and non-varicose veins by assessing 
the expression of HIF- isoforms, HIF target genes, and HIF regulatory enzymes in the 
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two types of veins 
3.3. METHODS 
3.3.1. Assessment Varicose and Non-Varicose Veins with Special Stains 
To study the structural changes of varicose and non-varicose veins, 10 randomly selected 
specimens from each group were stained with H&E, EVG and MT as previously described. The 
quality of the staining was checked by Dr Ann Sandison (Consultant Pathologist, Department of 
Histopathology, Charing Cross Hospital) prior to any assessment. The slides were then examined 
under the same light microscope (Olympus BH-2 model, Tokyo, Japan) connected to a camera 
and computer (ProgRes® Capture Pro 2.5, Jenoptik, Systeme GmbH, Jena, Germany) by Mr 
Chung Sim Lim (CSL) and Mr Joseph Shalhoub (JS) on two separate occasions independently. JS 
is a clinical research fellow in Vascular Surgery who is also studying for a PhD and has 
experience in performing histological analysis on vascular tissue sections including with special 
stains. Both assessors were blinded in terms of the type of veins during the assessment. 
All three layers of the vein wall were examined each time. The tunica intima was assessed 
for the presence and severity of intimal hyperplasia. Intima hyperplasia was graded as “nil” (no 
intimal hyperplasia found), “mild”, “moderate”, or “severe”. The tunica media was examined for 
the SMC, elastic tissue and connective tissue content, and were graded as “scattered”, “patchy”, 
and “diffuse”. Similarly, tunica adventitia was also assessed for the SMC, elastic tissue and 
connective tissue content which were graded as “scattered”, “patchy”, and “diffuse”. Intra- and 
inter-observer agreement between CSL and JS was calculated as a kappa score. Only the results of 
CSL were presented. 
3.3.2. Assessment of HIF Pathway in Varicose and Non-Varicose Veins 
Varicose and non-varicose veins were collected, stored and analysed with Q-PCR, 
Western blot and immunohistochemistry as described previously in Chapter 2. Q-PCR was used 
to relatively quantify the mRNA expression of genes of interest in varicose and non-varicose 
veins. The mRNA expression for all the genes studied was measured relative to one reference 
non-varicose vein specimen, and normalised to the control 18S rRNA. Western blot analysis was 
used to compare the expression of proteins of interest between varicose and non-varicose veins. 
Immunohistochemistry was performed to localise the expression of the proteins of interest in 
varicose and non-varicose veins.  
To study the HIF pathway in varicose and non-varicose veins, the expression three groups 
of genes and proteins were studied; (1) HIF-α isoforms, (2) HIF target genes, and (3) oxygen-
dependent HIF regulating enzymes. 
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3.3.2.1. HIF-α isoforms 
As discussed in Chapter 1, so far three HIF- isoforms (HIF-1, -2 and -3) have been 
identified (Gaber et al. 2005; Ke and Costa 2006). HIF-1 and HIF-2 share relatively similar 
gene sequence, protein structure, biochemical properties and regulatory pathways (Ema et al. 
1997; Tian et al. 1997; Gaber et al. 2005; Ke and Costa 2006). Since the regulation and function 
of HIF-3 remain unclear (Gaber et al. 2005; Ke and Costa 2006), only HIF-1 and HIF-2 
isoforms were studied. The mRNA and protein expression of HIF-1 and HIF-2 were assessed 
and compared between varicose and non-varicose veins. 
3.3.2.2. HIF target genes 
HIF target genes expression is regulated by HIF. Often, their promoter region possesses 
HRE and therefore their gene transcription is directly regulated by HIF. The expression of several 
well-known HIF target genes in varicose and non-varicose veins was studied. They included 
glucose transporter-1 (GLUT-1), carbonic anhydrase 9 (CA9), BCL2/adenovirus E1B 19 kd-
interacting protein 3 (BNIP-3), VEGF and enolase-1 (ENO-1). GLUT-1 and ENO-1 are genes 
regulating glucose metabolism, and CA9 is involved in pH control. Meanwhile, BNIP3 regulates 
cell survival and apoptosis, and VEGF promotes angiogenesis. The mRNA and protein expression 
of HIF target genes were assessed and compared between varicose and non-varicose veins. 
3.3.2.3. HIF regulatory enzymes 
In this study, the HIF regulatory enzymes that were assessed in varicose and non-varicose 
veins were HIF-PHDs and FIH-1. There are three HIF-PHD isoforms; PHD-1, PHD-2 and PHD-3 
which have been identified with specific characteristics of HIF hydroxylation and localisation, 
and they are different from the collagen prolyl-4 hydroxylases (Takahashi et al. 2000; Hanze et al. 
2007). PHD and FIH-1 negatively regulate the expression and activity of HIF- through prolyl 
and asparaginyl hydroxylation of HIF-, respectively. Interestingly, the expression of PHD-2 and 
PHD-3 are also known target genes of HIF and their expression being regulated by hypoxia 
(Hanze et al. 2007). The mRNA and protein expression of oxygen-dependent HIF regulatory 
enzymes were assessed and compared between varicose and non-varicose veins. 
3.3.3. Statistical Analysis 
Graphs were plotted and statistical analysis was performed using the Graphpad Prism 
version 5.00 for Windows (Graphpad Software, San Diego California, USA). The intra- and inter-
observer agreements were measured, and kappa score was calculated for histological analysis of 
the structural differences between varicose and non-varicose veins by JS and CSL. Chi-square test 
was used to test the differences in the histological features between varicose and non-varicose 
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veins. P<0.05 was considered significant. The fold change of mRNA expression relative to a non-
varicose vein and normalised to 18S RNA was expressed as mean±SEM. The distribution of the 
data within a group (varicose or non-varicose veins) for each gene measured with Q-PCR was 
tested whether it followed a Gaussian distribution with two normality tests; Kolmogorov-
Smirrnov, and D‟Agostino and Pearson test. The latter was only allowed to be performed if the 
sample size was more than 7. In general, both tests quantify how far the data deviate from the 
Gaussian distribution in terms of symmetry and shape. Unpaired t-test and Mann Whitney U test 
were used to test the differences in gene expression between varicose and non-varicose veins for 
normally and not normally distributed data, respectively. P<0.05 was considered statistically 
significant. 
3.4. RESULTS 
3.4.1. Structural Changes in Varicose Veins 
The demographic details of the 20 patients from whom the varicose and non-varicose 
veins were harvested and used for special stain histology are summarised in Appendix 13(A). 
3.4.1.1. Intra- and inter- observer agreement 
The intra- and inter-observer agreement and kappa scores of CSL‟s and JS‟s assessment 
of the histological features were at least 0.70 (Table 3-1). 
Table 3-1 Intra- and inter-observer agreement and kappa score (CSL and JS) 
Intra- and inter-observer agreement and kappa scores (CSL and JS) for histological semi-quantitative 
assessment of varicose and non-varicose veins 
 Intra-observer 1 
(CSL) 
Intra-observer 2 
(JS) 
Inter-observer 
(CSL and JS) 
Agreement 
(%) 
Kappa 
score 
Agreement 
(%) 
Kappa 
score 
Agreement 
(%) 
Kappa 
score 
Intimal hyperplasia 
1. Severity  
 
95 
 
0.93 
 
80 
 
0.73 
 
90 
 
0.86 
Tunica media 
1. SMC density 
2. Elastic tissue content 
3. Connective tissue content 
 
95 
90 
100 
 
0.91 
0.84 
1.00 
 
90 
85 
100 
 
0.82 
0.75 
1.00 
 
85 
85 
90 
 
0.72 
0.75 
0.81 
Tunica adventitia 
1. SMC content 
2. Elastic tissue content 
3.Connective tissue content  
 
100 
90 
100 
 
1.00 
0.78 
1.00 
 
100 
90 
100 
 
1.00 
0.78 
1.00 
 
85 
100 
85 
 
0.74 
1.00 
0.74 
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3.4.1.2. Histological variations observed between varicose and non-varicose veins using 
special stains 
Representative sections of a non-varicose and a varicose vein stained with H&E, EVG 
and MT are shown in Figure 3-2, Figure 3-3 and Figure 3-4, respectively. To study the structural 
differences between varicose and non-varicose veins, all the three layers of the vein wall stained 
with all three special stains were assessed. 
The tunica intima of the 10 varicose and 10 non-varicose veins was assessed for the 
presence and severity of intimal hyperplasia. To study the presence and severity of intimal 
hyperplasia semi-quantitatively, the intimal hyperplasia was graded as “nil”, “mild”, “moderate”, 
and “severe” as demonstrated in Figure 3-5. Intimal hyperplasia of all degree of severity was also 
seen in varicose and non-varicose veins specimens. There was no significant difference observed 
in terms of the severity of intimal hyperplasia between varicose and non-varicose veins when 
assessed semi-quantitatively using special stains (Figure 3-6). 
To study the SMC content in the tunica media semi-quantitatively, the SMC content was 
graded as “scattered”, “patchy” and “diffuse” as shown in Figure 3-7. Significant differences were 
observed in terms of SMC content in the tunica media assessed semi-quantitatively between the 
10 varicose and 10 non-varicose veins using special stains (P<0.05) as shown in Figure 3-8. In 
non-varicose veins, SMC content was found to be either scattered or patchy. Meanwhile, in 
varicose veins, patchy or diffuse SMC content was observed. 
To study the elastic tissue content in the tunica media semi-quantitatively, the elastic 
tissue content was graded as “scattered”, “patchy” and “diffuse” as shown in Figure 3-9. 
Significant differences were observed in terms of elastic tissue content in the tunica media 
assessed semi-quantitatively between the 10 varicose and 10 non-varicose veins using special 
stains (P<0.05) as shown in Figure 3-10. Although there were a couple of non-varicose vein 
specimens found to contain scattered amount of elastic tissue in the tunica media, the rest of the 
non-varicose veins demonstrated patchy and diffuse elastic tissue content in the tunica media. 
Meanwhile, in varicose veins, the majority of the specimens contained only scattered amount of 
elastic tissue in the tunica media. None of the 10 varicose vein specimens were graded to 
demonstrate diffuse elastic tissue content in the tunica media. 
To study the connective tissue content in the tunica media semi-quantitatively, the 
connective tissue content was graded as “scattered”, “patchy” and “diffuse” as shown in Figure 
3-11. No significant differences were observed in terms of connective tissue content in the tunica 
media assessed semi-quantitatively between the 10 varicose and 10 non-varicose veins using 
special stains as shown in Figure 3-12. At least half of the specimens were found to contain 
patchy amount of connective tissue in the tunica media in both varicose and non-varicose veins. 
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Figure 3-2 H&E stain of a non-varicose and a varicose vein 
Example of an H&E stained (a) non-varicose (GSV harvested for bypass), and (b) varicose vein section 
seen under light microscopy. H&E stains cytoplasm red, and nucleus dark blue. In (a) H&E stain shows no 
obvious intimal hyperplasia in non-varicose vein. However, in (b) H&E stain shows severe intimal 
hyperplasia (dark arrow) in varicose vein. H&E stain of both slides also demonstrate no obvious artefact. 
Magnification X40. 
 
a b
 
Figure 3-3 EVG stain of a non-varicose and a varicose vein 
Example of an EVG stained (a) non-varicose (GSV harvested for bypass), and (b) varicose vein section 
observed under light microscopy. EVG stains elastic tissue dark purple. In (a), the tunica media especially 
in the inner part of the non-varicose vein demonstrates diffuse elastic tissue content. Mildly severe intimal 
hyperplasia was seen in (a) which was not clear in Figure 3-2 (a). In (b) scattered amount of elastic tissue 
was present in the tunica media of varicose vein. Severe intimal hyperplasia as seen in Figure 3-2b was also 
obvious in (b). Magnification X40. 
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Figure 3-4 MT stain of a non-varicose and a varicose vein 
Example of an MT stained (a) non-varicose (GSV harvested for bypass), and (b) varicose vein section seen 
under light microscopy. MT stains connective tissue dark green, and smooth muscle cells brown. In (a), the 
tunica media of the non-varicose vein demonstrates diffuse amount of connective tissue and scattered SMC 
content. In (b) diffuse amount of SMC but scattered connective tissue content was present in the tunica 
media of varicose vein. Magnification X40. 
 
Similar to the tunica media, the tunica adventitia of the 10 varicose and non-varicose 
veins was assessed for its SMC, elastic tissue and connective tissue content, and graded as 
“scattered”, “patchy”, and “diffuse”. No significant differences were observed in terms of SMC 
(Figure 3-13), elastic tissue (Figure 3-14) and connective tissue (Figure 3-15) content in the tunica 
adventitia assessed semi-quantitatively between the 10 varicose and 10 non-varicose veins using 
special stains. 
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Figure 3-5 Photomicrographs of veins with different severity of intimal hyperplasia 
The severity of intimal hyperplasia was assessed with EVG stained slides. Photomicrographs above show 
typical examples of EVG stained veins with (a) nil, (b) mild, (c) moderate, and (d) severe intimal 
hyperplasia. Dark arrows indicate intimal hyperplasia. Magnification X40. 
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Figure 3-6 Semi-quantitative assessment of intimal hyperplasia severity in varicose 
and non-varicose veins 
Bar chart compares the proportion of 10 varicose and 10 non-varicose veins with nil, mild, moderate, and 
severe intimal hyperplasia (P=0.644; Chi-square test).  
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Figure 3-7 Photomicrographs of veins with different SMC content in tunica media 
The SMC content was assessed with MT stained slides. Photomicrographs above show typical examples of 
MT stained veins with (a) scattered, (b) patchy, and (c) diffuse SMC (stained dark brown) content in tunica 
media of veins. Magnification X40. 
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Figure 3-8 Semi-quantitative assessment of SMC content in tunica media of varicose 
and non-varicose veins 
Bar chart compares the proportion of 10 varicose and 10 non-varicose veins with scattered, patchy and 
diffuse SMC content in tunica media (P=0.016; Chi-square test). 
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Figure 3-9 Photomicrographs of veins with different elastic tissue content in tunica 
media 
The elastic tissue content was assessed with EVG stained slides. Photomicrographs above show typical 
examples of EVG stained veins with (a) scattered, (b) patchy, and (c) diffuse elastic tissue (stained dark 
blue) content in tunica media of veins. Magnification X40. 
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Figure 3-10 Semi-quantitative assessment of elastic tissue content in tunica media of 
varicose and non-varicose 
Bar chart compares the proportion of 10 varicose and 10 non-varicose veins with scattered, patchy and 
diffuse elastic tissue content in tunica media (P=0.043; Chi-square test) 
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Figure 3-11 Photomicrographs of veins with different connective tissue content in 
tunica media 
The connective tissue content was assessed with MT stained slides. Photomicrographs above show typical 
examples of MT stained veins with (a) scattered, (b) patchy, and (c) diffuse connective tissue (stained dark 
green) content in tunica media of veins. Magnification X40. 
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Figure 3-12 Semi-quantitative assessment of connective tissue content in tunica media 
of varicose and non-varicose veins 
Bar chart compares the proportion of 10 varicose and 10 non-varicose veins with scattered, patchy and 
diffuse connective tissue content in tunica media (P=0.270; Chi-square test). 
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Figure 3-13 Semi-quantitative assessment of SMC content in tunica adventitia of 
varicose and non-varicose veins 
Bar chart compares the proportion of 10 varicose and 10 non-varicose veins with scattered, patchy and 
diffuse SMC content in tunica adventitia (P=0.470; Chi-square test). 
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Figure 3-14 Semi-quantitative assessment of elastic tissue content in tunica adventitia 
of varicose and non-varicose veins 
Bar chart compares the proportion of 10 varicose and 10 non-varicose veins with scattered, patchy and 
diffuse elastic tissue content in tunica adventitia (P=0.223; Chi-square test). 
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Figure 3-15 Semi-quantitative assessment of connective tissue content in tunica 
adventitia of varicose and non-varicose veins 
Bar chart compares the proportion of 10 varicose and 10 non-varicose veins with scattered, patchy and 
diffuse connective tissue content in tunica adventitia (P=0.185; Chi-square test). 
3.4.2. Assessment of the HIF Pathway In Varicose And Non-Varicose Veins 
The demographic details of the patients from whom the varicose and non-varicose veins 
were harvested and used for analysis of HIF-α isoforms, HIF target genes and HIF regulatory 
enzyme mRNA and protein expression with Q-PCR and western blot, respectively were 
summarised in Appendix 13 (B). Meanwhile, the demographic details of the patients from whom 
the varicose and non-varicose veins were used for immunohistochemistry analysis of HIF-1α, 
HIF-2α and HIF target genes expression were summarised Appendix 13 (C). 
3.4.2.1. Assessment of normality 
Table 3-2 shows an example of Kolmogorov-Smirnov test and D‟Agostino and Pearson 
test results presented by the Graphpad Prism version 5.00 for Windows (Graphpad Software, San 
Diego California, USA) when the distribution of the relative mRNA expression of CA9 in 
varicose and non-varicose veins was tested if it assumed a Gaussian distribution. The results of 
the normality tests on all the genes assessed by Q-PCR were summarised in Table 3-3. Following 
the assessment of the normality, unpaired t-test was used to compare the means of two normally 
distributed populations. Meanwhile, Mann Whitney U test was used to compare the means of two 
populations when one or both of them were not normally distributed. 
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Table 3-2 Example of a normality test results of a gene measured with Q-PCR  
An example of a normality test results of relative CA9 mRNA expression in varicose and non-varicose 
veins presented by Graphpad Prism version 5.00 for Windows (Graphpad Software, San Diego California, 
USA). The normality tests used were Kolmogorov-Smirnov (KS) test and D‟Agostino and Pearson test. In 
this example, the non-varicose veins group passed the normality tests while the varicose veins group did 
not. Since at least one of the two groups did not pass the normality test, a non-parametric (Mann Whitney 
U) rather than a parametric test (unpaired t-test) was used to test the significance of the differences 
measured between varicose and non-varicose vein group. **P<0.01; ***P<0.001; ns: not significant 
 Non-varicose veins Varicose Veins 
KS normality test   
KS distance 0.2172 0.2261 
P value > 0.10 0.0086 
Passed normality test (alpha=0.05)? Yes No 
P value summary Ns ** 
D'Agostino & Pearson omnibus normality test   
K2 2.853 30.10 
P value 0.2402 < 0.0001 
Passed normality test (alpha=0.05)? Yes No 
P value summary Ns *** 
 
Table 3-3 Summary of normality test results and statistical test used 
Summary of normality test results and the statistical test subsequently used to assess the differences of gene 
expression between varicose and non-varicose veins. The data were considered to be not normally 
distributed if either varicose or non-varicose vein group, or both failed the normality test (P<0.05). NA: not 
applicable when the sample size was too small for the test to be performed. 
Gene Varicose 
veins 
Non-varicose 
veins 
Kolmogorov-
Smirnov 
D’Agostino 
and Pearson 
Statistical test used to 
compare differences 
HIF-1 11 5 Passed NA Unpaired t test 
HIF-2 11 5 Failed NA Mann Whitney U 
BNIP-3 20 10 Passed Passed Unpaired t test 
CA9 20 10 Failed Failed Mann Whitney U 
GLUT-1 20 10 Failed Failed Mann Whitney U 
VEGF 20 10 Failed Failed Mann Whitney U 
ENO-1 11 5 Failed NA Mann Whitney U  
PHD-1 11 5 Failed NA Mann Whitney U 
PHD-2 11 5 Passed NA Unpaired t test 
PHD-3 11 5 Passed NA Unpaired t test 
FIH-1 11 5 Failed NA Mann Whitney U 
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3.4.2.2. Expression of HIF-1 and HIF-2 mRNA in varicose and non-varicose veins 
Q-PCR analysis demonstrated detectable expression of HIF-1 and HIF-2 mRNA in 
whole varicose and non-varicose vein specimens. To compare the expression of HIF-1 and HIF-
2 mRNA between 11 varicose and 5 non-varicose vein tissues, the gene expression was 
measured in relation to one reference non-varicose vein tissue, and normalised to 18S RNA using 
2
-Ct
. HIF-1 mRNA was significantly up-regulated in varicose compared to non-varicose veins, 
with mean relative gene expression of 89.8±18.6 and 10.4±7.2, respectively (P=0.012; Figure 
3-16). Similarly, relative HIF-2 mRNA expression was also significantly higher in varicose than 
non-varicose veins, with mean relative gene expression of 384.9±209.4 and 8.1±4.2, respectively 
(P=0.008; Figure 3-16). 
To compare the protein expression of HIF-1 and HIF-2, protein extracts from 4 
varicose and 4 non-varicose veins were run in the same gel simultaneously with equal protein 
loading. Western blot analysis detected immunoreaction at 120kDa corresponding to HIF-1 in 
all the varicose and non-varicose vein tissues. Overall, the immunoreactive bands of HIF-1 were 
also more robust in varicose compared to non-varicose veins suggesting that the expression of 
HIF-1 was more in varicose than non-varicose veins (Figure 3-17). Western blot analysis of a 
separate gel with the protein extracts from the same 4 varicose and 4 non-varicose veins also 
demonstrated immunoreaction at 120kDa, corresponding to HIF-2 in all the varicose and non-
varicose vein specimens. Overall, the immunoreactive bands of HIF-2 were also more robust in 
varicose compared to non-varicose veins indicating that the expression of HIF-2 was elevated in 
varicose compared to non-varicose veins (Figure 3-18). 
Immunohistochemistry of varicose (n=8) and non-varicose vein (n=8) whole tissues 
demonstrated that HIF-1α was expressed only in some luminal endothelial cells in both types of 
veins (Figure 3-19 and Figure 3-20). No HIF-1α was detected in the tunica media and adventitia 
including the SMC (Figure 3-19 and Figure 3-20). HIF-1α was detected in all the varicose veins 
(100%) but only in 4 of the 8 non-varicose veins (50%). Meanwhile, immunohistochemistry of 
varicose (n=8) and non-varicose vein (n=8) whole tissues showed that HIF-2α was extensively 
expressed in all the veins examined (Figure 3-19 and Figure 3-20). HIF-2α was found to be 
expressed in the SMC of both types of veins (Figure 3-19 and Figure 3-20). The endothelial cells 
of the lumen and vasa vasorum of varicose and non-varicose veins also expressed HIF-2α (Figure 
3-19 and Figure 3-20). 
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Figure 3-16 Relative HIF-1 and HIF-2 mRNA expression in varicose compared to 
non-varicose veins 
Gene expression of HIF-1 and HIF-2 in varicose and non-varicose veins. Gene expression was assayed 
by Q-PCR, and normalised to 18S RNA. Data shown are median fold change of mRNA expression relative 
to the gene expression of a non-varicose vein specimen, using 2
-Ct
 method (represented by the horizontal 
line in the box), inter-quartile range (height of box), and range (whiskers) from 10 varicose and 5 non-
varicose veins. HIF-1α and HIF-2α expression between varicose and non-varicose veins was compared 
using unpaired t-test and Mann Whitney U, respectively. 
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Figure 3-17 Western blot analysis comparing HIF-1 expression in varicose and non-
varicose veins 
Increased expression of HIF-1 in varicose compared to non-varicose veins was detected with Western 
blot. Whole varicose and non-varicose specimens collected from surgery were immediately snap frozen in 
liquid nitrogen and stored at -80°C before protein was extracted. Protein extracts from 4 varicose and 4 
non-varicose veins were run on a gel. Immunoreaction bands were detected at 120kDa corresponding to 
HIF-1. Equivalent protein loading control was checked by immunodetection of ERK 2 at 42kDa. 
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Figure 3-18 Western blot analysis comparing HIF-2α expression in varicose and non-
varicose veins 
Increased expression of HIF-2 in varicose compared to non-varicose veins was detected with Western 
blot. Whole varicose and non-varicose specimens collected from surgery were immediately snap frozen in 
liquid nitrogen and stored at -80°C before protein was extracted. Protein extracts from 4 varicose and 4 
non-varicose veins were run on a gel. Immunoreaction bands were detected at 120kDa corresponding to 
HIF-2. Equivalent protein loading control was checked by immunodetection of ERK 2 at 42kDa. 
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Figure 3-19 Immunohistochemistry against HIF-1α and HIF-2α of a non-varicose vein  
Representative serial cross-sections of a non-varicose vein which were immunostained against (a) HIF-1α 
(in this case no HIF-1α was detected) and (b) HIF-2α, and their respective isotype negative control antibody 
shown on the left. A corresponding H&E stained cross-section is shown in (c) for comparison to assist the 
localisation of HIF-1α and HIF-2α. Immunohistochemistry magnification X100.  
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Figure 3-20 Immunohistochemistry against HIF-1α and HIF-2α of a varicose vein  
Representative serial cross-sections of a varicose vein which were immunostained against (a) HIF-1α and 
(b) HIF-2α, and their respective isotype negative control antibody shown on the left. Dark arrows in (a) 
indicate HIF-1α positivity in some luminal endothelial cells. A corresponding H&E stained cross-section is 
shown in (c) for comparison to assist the localisation of HIF-1α and HIF-2α. Immunohistochemistry 
magnification X100.  
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3.4.2.3. Expression of HIF target genes in varicose and non-varicose veins 
To study and compare the expression of HIF target genes mRNA in whole varicose and 
non-varicose vein tissues, the gene expression of five different HIF target genes was measured in 
relation to one reference non-varicose vein tissue (the same reference sample used for HIF-1 and 
HIF-2 mRNA analysis above). A total of 20 varicose and 10 non-varicose vein specimens were 
used to analyse BNIP-3, CA9, GLUT-1 and VEGF expression, and 11 varicose and 5 non-
varicose vein tissues were used to study ENO-1 expression. 
The mRNA expression of all the HIF target genes assessed were significantly increased in 
varicose compared to non-varicose veins; BNIP-3 (4.5±0.7 versus 1.4±0.3; P=0.004), CA9 
(8.5±2.1 versus 2.8±1.2; P=0.006), GLUT-1 (8.7±2.1 versus 1.0±0.3; P<0.001), VEGF (7.5±2.1 
versus 0.9±0.2; P=0.001), and ENO-1 (11.2±2.1 versus 3.1±1.9; P=0.019) (Figure 3-21). 
The up-regulation of HIF target genes in varicose compared to non-varicose veins was 
also reflected at the protein level. The expression of CA9 was measured using Western blot. 
Protein extracts from 4 varicose and 4 non-varicose veins were run concurrently on a gel. Western 
blot analysis demonstrated immunoreactions at 54 and 58kDa, corresponding to CA9 in all the 
varicose and non-varicose vein specimens. Overall, the immunoreactive bands of CA9 were 
stronger in varicose compared to non-varicose veins indicating that the expression of CA9 was 
elevated in varicose compared to non-varicose veins (Figure 3-22).  
Immunohistochemistry of varicose (n=8) and non-varicose vein (n=8) whole tissues 
against CA9 and PHD-2 antibody, both HIF target genes, demonstrated that both proteins were 
expressed in all the veins examined (Figure 3-23 and Figure 3-24). CA9 and PHD-2 were found 
to be expressed in the SMC of all the layers of both types of veins (Figure 3-23 and Figure 3-24). 
The endothelial cells of the lumen and vasa vasorum of varicose and non-varicose veins also 
expressed CA9 and PHD-2 (Figure 3-23 and Figure 3-24). The distribution of the expression of 
the target genes also appeared to correlate more to the expression of HIF-2α than HIF-1α when 
H&E and immunostaining of the serial sections were examined. 
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Figure 3-21 HIF target genes mRNA expression in varicose and non-varicose veins 
Gene expression of HIF target genes; (a) BNIP-3, (b) CA9, (c) GLUT-1, (d) VEGF, and (e) ENO-1 in 
varicose and non-varicose veins that were immediately snap frozen and stored at -80°C once removed 
surgically. The mRNA was assayed by Q-PCR, and normalised to 18S RNA. Data shown are median 
(represented by the horizontal line in the box), inter-quartile range (height of box), and range (whiskers) of 
the fold change of mRNA relative to the gene expression of a non-varicose vein specimen of 20 varicose 
and 10 non-varicose veins for (a-d), and 11 varicose and 5 non-varicose veins for (e). The differences in 
gene expression between varicose and non-varicose veins were compared using unpaired t-test (BNIP-3) or 
Mann Whitney U test (CA9, GLUT-1, VEGF and ENO-1). 
Chapter 3 
129 
 
Varicose veinsNon-varicose veins
54 kDa
42 kDa
CA9
ERK 2
58 kDa
 
Figure 3-22 Western blot analysis comparing CA9 expression in varicose and non-
varicose veins 
Western blot analysis of CA9 in varicose and non-varicose veins analysed. Whole varicose and non-
varicose vein specimens collected from surgery were immediately snap frozen in liquid nitrogen and stored 
at -80°C before protein was extracted. Protein extracts from 4 varicose and 4 non-varicose veins were run 
on a gel. Immunoreaction bands were detected at 54 and 58kDa corresponding to CA9. Equivalent protein 
loading control was checked by immunodetection of ERK 2 at 42kDa. 
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Figure 3-23 Immunohistochemistry against HIF target genes, CA9 and PHD-2 of a 
non-varicose vein  
Representative serial cross-sections of a non-varicose vein which were immunostained against HIF target 
genes; (a) CA9 and (b) PHD-2, and their respective isotype negative control antibody on the left. A 
corresponding H&E stained cross-section is shown in (c) for comparison to assist the localisation of CA9 
and PHD-2. The immunostaining of CA9 and PHD-2 was also examined and compared with the HIF-1α 
and HIF-2α immunostaining of their corresponding serial sections. Immunohistochemistry magnification 
X100.  
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Figure 3-24 Immunohistochemistry against HIF target genes, CA9 and PHD-2 of a 
varicose vein  
Representative serial cross-sections of a varicose vein which were immunostained against HIF target genes; 
(a) CA9 and (b) PHD-2, and their respective isotype negative control antibody on the left. A corresponding 
H&E stained cross-section is shown in (c) for comparison to assist the localisation of CA9 and PHD-2. The 
immunostaining of CA9 and PHD-2 was also examined and compared with the HIF-1α and HIF-2α 
immunostaining of their corresponding serial sections. Immunohistochemistry magnification X100.  
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3.4.2.4. Expression of HIF regulatory enzymes in varicose and non-varicose veins 
The mRNA expression of four HIF regulatory enzymes; PHD-1, PHD-2, PHD-3 and FIH-
1 was measured in 11 varicose and 5 non-varicose veins in relation to one reference non-varicose 
vein tissue (the same reference sample used for HIF-1 and HIF-2 mRNA analysis above). The 
mRNA expression of PHD-2 and PHD-3, both were also known to be HIF target genes, was 
significantly increased in varicose compared to non-varicose veins; PHD-2 (5.6±1.1 for varicose 
veins and 1.7±0.7 for non-varicose veins; P=0.034) and PHD-3 (9.9±2.2 and 2.4±1.2; P=0.047; 
Figure 3-25). No significant difference was observed between varicose and non-varicose veins in 
terms of the mRNA expression of PHD-1 (3.2±0.8 and 1.6±0.9) and FIH-1 (3.6±0.7 and 4.4±2.2; 
Figure 3-25). 
The up-regulation of PHD-2 and PHD-3 in varicose compared to non-varicose veins was 
also reflected at protein level when protein expression was assessed using western blot. Protein 
extracts from 4 varicose and 4 non-varicose veins were run concurrently on a gel. Western blot 
analysis demonstrated immunoreactions at 46 and 27kDa, corresponding to PHD-2 and PHD-3, 
respectively in all the varicose and non-varicose vein specimens (Figure 3-26). Overall, the 
immunoreactive bands of PHD-2 and PHD-3 were stronger in varicose compared to non-varicose 
veins indicating that the expression of both of these oxygen-dependent HIF regulating enzymes 
were elevated in varicose compared to non-varicose veins (Figure 3-26). Meanwhile, western blot 
analysis of protein extracts from 4 varicose and 4 non-varicose veins run concurrently on a gel 
demonstrated the presence immunoreactive bands at 45kDa, corresponding to PHD-1 (Figure 
3-27). There was a small decrease in the intensity of 2 of the 4 immunoreactive bands of the non-
varicose veins compared to all the four immunoreactions of varicose veins (Figure 3-27). Western 
blot analysis of protein extracts from 4 varicose and 4 non-varicose veins run concurrently on a 
gel demonstrated the presence immunoreactive bands at 40.3kDa, corresponding to FIH-1 (Figure 
3-28). However, there was no obvious difference in the intensity of the FIH-1 immunoreactive 
bands between varicose and non-varicose veins (Figure 3-28).  
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Figure 3-25 Relative mRNA expression of HIF regulatory enzymes in varicose 
compared to non-varicose veins 
The relative mRNA expression of HIF regulatory enzymes; (a) PHD-1, (b) PHD-2, (c) PHD-3, and (d) FIH-
1 in varicose and to non-varicose veins that were immediately snap frozen and stored in -80°C freezer once 
removed surgically from patients. Gene expression was assayed by Q-PCR, and normalised to 18S RNA. 
Data shown are median fold change of mRNA expression relative to the gene expression of a non-varicose 
vein specimen, using 2
-Ct
 method (represented by the horizontal line in the box), inter-quartile range 
(height of box), and range (whiskers) from 11 varicose and 5 non-varicose veins. The differences in gene 
expression between varicose and non-varicose veins were compared using unpaired t-test (PHD-2 and 
PHD-3) or Mann Whitney test (PHD-1 and FIH-1). 
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Figure 3-26 Western blot analysis comparing PHD-2 and PHD-3 expression in 
varicose and non-varicose veins 
Western blot analysis of PHD-2 and PHD-3 in varicose and non-varicose veins. Whole varicose and non-
varicose specimens collected from surgery were immediately snap frozen in liquid nitrogen and stored at -
80°C before protein was extracted. Protein extracts from 4 varicose and 4 non-varicose veins were run on a 
gel. Immunoreaction bands were detected at 46 and 27kDa corresponding to PHD-2 and PHD-3, 
respectively. Equivalent protein loading control was checked by immunodetection of ERK 2 at 42kDa. 
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Figure 3-27 Western blot analysis comparing PHD-1 expression in varicose and non-
varicose veins 
Western blot analysis of PHD-1 in varicose and non-varicose veins. Whole varicose and non-varicose 
specimens collected from surgery were immediately snap frozen in liquid nitrogen and stored at -80°C 
before protein was extracted. Protein extracts from 4 varicose and 4 non-varicose veins were run on a gel. 
Immunoreaction bands were detected at 45kDa corresponding to FIH-1. Equivalent protein loading control 
was checked by immunodetection of ERK 2 at 42kDa. 
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Figure 3-28 Western blot analysis comparing FIH-1 expression in varicose and non-
varicose veins 
Western blot analysis of FIH-1 in varicose and non-varicose veins. Whole varicose and non-varicose 
specimens collected from surgery were immediately snap frozen in liquid nitrogen and stored at -80°C 
before protein was extracted. Protein extracts from 4 varicose and 4 non-varicose veins were run on a gel. 
Immunoreaction bands were detected at 40.3kDa corresponding to FIH-1. Equivalent protein loading 
control was checked by immunodetection of ERK 2 at 42kDa. 
3.5. DISCUSSION 
The objectives of this chapter were to demonstrate structural variations between varicose 
and non-varicose vein tissues using special stains and light microscopy, and to assess the HIF 
pathway in varicose and non-varicose veins by comparing the expression of HIF-α isoforms, HIF 
target genes, and HIF regulatory enzymes. The main findings of this chapter include (1) the 
demonstration of structural variations between varicose and non-varicose vein specimens that 
were collected and examined under light microscopy with special stains; (2) the up-regulation of 
HIF-1, HIF-2 and their target genes in varicose compared to non-varicose veins; (3) increased 
expression of PHD-2 and PHD-3 which are both HIF regulatory enzymes as well as HIF target 
genes in varicose compared to non-varicose veins; and (4) HIF-1α was expressed only in some 
endothelial cells of both types of veins, and HIF-2α and target genes (CA9 and PHD-2) were 
expressed in endothelial cell and SMC of all layers of all varicose and non-varicose veins. 
All the varicose and most of the non-varicose vein specimens were snap frozen or stored 
in formalin for research as soon as they were removed from the donors. Only a few of the non-
varicose veins harvested for arterial bypass surgery had to be measured and tested for damages by 
the surgeons before the excess tissues were snap frozen or stored in formalin for research. 
Immediate snap freezing and formalin fixing of the tissues were important to preserve as much of 
the structural and biochemical properties of the veins as what they were in the patients before 
surgical removal. 
Chapter 3 
136 
In terms of structural changes, semi-quantitative light microscopy analysis used in this 
study found increased SMC content in tunica media of varicose compared to non-varicose veins. 
Using the same method, this study also demonstrated lower elastic tissue content in the tunica 
media of varicose compared to non-varicose veins. There was no difference observed in the 
connective tissue content in tunica media of varicose and non-varicose veins. The SMC, elastic 
tissue and connective tissue content in tunica adventitia also did not differ between the two types 
of veins. Meanwhile, intimal hyperplasia was present in some but not all of the varicose and non-
varicose veins, and with different severity. Overall, there was no difference observed in terms of 
the presence and severity of intimal hyperplasia between the two types of veins. Although many 
previous studies have assessed and demonstrated various structural changes in varicose compared 
to non-varicose veins (Somers and Knaapen 2006; Raffetto and Khalil 2008b; Lim and Davies 
2009), it was important for this study to investigate if the sources of veins for the subsequent 
research on the HIF pathway also reflected similar structural variations as previously reported. 
The findings on the structural changes of varicose and non-varicose veins seemed consistent with 
many of the observations made in the previous studies. The total elastic tissue content in varicose 
veins has repeatedly been shown to be less than in non-varicose veins (Andreotti and Cammelli 
1979; Gandhi et al. 1993; Venturi et al. 1996; Elsharawy et al. 2007). The reduction of elastic 
tissue is likely to contribute to the weakening and dilatation of varicosities. Studies have also 
repeatedly reported SMC proliferation and hypertrophy in the tunica media of varicose veins, 
although regions of atrophy may also present (Milroy et al. 1989; Travers et al. 1996; London and 
Nash 2000; Wali et al. 2003; Somers and Knaapen 2006; Naoum et al. 2007). The SMC of 
varicose veins are thought to have dedifferentiated from contractile to synthetic and proliferative 
phenotype. They appear disorganised and demonstrate features of vacuolisation and phagocytosis 
(Sansilvestri-Morel et al. 2001; Wali and Eid 2001; Somers and Knaapen 2006). Such phenotypic 
change is again thought to account for the increases in proliferation and hypertrophy, weakening 
and reduced contractility leading to dilatation of varicose veins (Lim and Davies 2009). Intimal 
hyperplasia refers to areas of irregular thickening underneath the endothelial lining consisting of 
collagen deposits, SMC infiltration and plaques (Milroy et al. 1989; London and Nash 2000; Wali 
and Eid 2002; Wali et al. 2003; Somers and Knaapen 2006; Elsharawy et al. 2007). Intimal 
hyperplasia has often been observed in varicose veins (Milroy et al. 1989; London and Nash 
2000; Wali and Eid 2002; Wali et al. 2003; Somers and Knaapen 2006; Elsharawy et al. 2007). 
However, intimal hyperplasia has also been reported in phlebosclerotic lesions of non-varicose 
veins, often found in patients with cardiovascular diseases especially those who need bypass 
surgery (Milroy et al. 1989; Langes and Hort 1992; Davies et al. 1993; Wilson et al. 1996). This 
may explain our findings that there was no difference found between the two types of veins in 
terms of presence and severity of intimal hyperplasia since many of the non-varicose veins were 
obtained from patients with cardiovascular disease. 
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One of the limitations of the methodology used in the study was the semi-quantitative 
rather than quantitative nature of the special stains histological assessment. Although semi-
quantitative assessment is simpler and quicker to performed, it is more subjective and therefore 
introduces biases such as assessor bias, and potential inconsistency. These disadvantages were 
part overcome by using two independent assessors of similar level of surgical and research 
training, and both were blinded. The assessors also investigated the slides twice, both 
independently at different occasions. Overall, the intra- and inter-observer agreements, and kappa 
score of 0.7 or more (0.5 is usually considered moderate) reflected that the agreements were 
acceptable. 
Since HIFs are nuclear transcriptional factors, the expression of several of their well-
known target genes, i.e. BNIP-3, CA9, GLUT-1, VEGF and ENO-1, was studied to reflect HIF 
activity in varicose and non-varicose veins. Interestingly, the expression of all five HIF target 
genes examined was significantly up-regulated at mRNA level in varicose compared to non-
varicose veins. Increased expression of HIF target genes was also be reflected at the protein level 
as demonstrated by up-regulation of CA9 in varicose compared to non-varicose veins analysed 
with Western blot. 
It is important to stress that although in this chapter structural changes and increased HIF 
activity have been demonstrated in varicose compared to non-varicose veins, the study 
methodology was not designed to assess if a cause-and-effect or even an association relationship 
between the two was present in varicosity. However, many of the biological and cellular 
processes regulated by HIF are also known to contribute to vascular wall remodelling. HIF has 
been shown to contribute to vascular wall remodelling as described earlier (Hanze et al. 2007; 
Rey and Semenza). For example, dysregulated apoptosis is thought to contribute to SMC 
proliferation and hypertrophy observed in varicose veins, and apoptosis is a major cellular process 
regulated by the HIF pathway (Somers and Knaapen 2006; Stenmark et al. 2006; Lim and Davies 
2009). Another example is imbalances of MMPs and TIMPs, some of which are regulated by HIF, 
is known to contribute to ECM degradation and therefore vascular remodelling, a feature also 
associated with varicose veins (Ben-Yosef et al. 2002; Fujiwara et al. 2007; Raffetto and Khalil 
2008b). Therefore, it is likely that HIF may contribute to some of the structural changes and 
vascular remodelling observed in varicose veins. 
In this chapter, the expression of HIF regulatory enzymes i.e. PHD-1, PHD-2, PHD-3 and 
FIH-1 was also studied. The expression of PHD-2 and PHD-3 mRNA and protein was found 
increased in varicose compared to non-varicose veins. However, no significant differences were 
observed in the expression of PHD-1 and FIH-1 mRNA between varicose and non-varicose veins. 
All these enzymes regulate HIF- post-translational modifications and their activity on HIF is 
governed by the presence of oxygen through the oxygen-dependent regulation of HIF pathway as 
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described in Chapter 1. Furthermore, PHD-2 and PHD-3, and to a lesser extent PHD-1 have been 
shown to be strongly induced by hypoxia in many cell types (Hanze et al. 2007; Muz et al. 2009). 
Therefore, following long period of hypoxia, increased oxygen-mediated HIF- degradation has 
been observed (Marxsen et al. 2004; Pescador et al. 2005; Muz et al. 2009). Interestingly, in my 
study, the expression of PHD-2 and PHD-3 but not PHD-1 and FIH-1 was significantly increased 
in varicose compared to non-varicose veins, suggesting the possibility of hypoxia and/or HIF 
regulation. 
Several factors including vein wall hypoxia, increased mechanical strain, and cytokine 
activation are potential causes of the increases in HIF-1 and HIF-2 expression in varicose 
veins. These factors are features known to be associated with varicose veins, and have been 
shown to regulate HIF- expression (Michiels et al. 2000; Signorelli et al. 2000; Gaber et al. 
2005; Lim and Davies 2009). Hypoxia increases the expression of HIF-1 and HIF-2 protein 
but not mRNA through the oxygen-dependent regulation of HIF- pathway (Gaber et al. 2005; 
Semenza 2009b). Meanwhile, mechanical stress and cytokines regulate the expression of HIF- 
through the oxygen-independent regulation of HIF- pathway which is associated with increased 
HIF- mRNA (Gaber et al. 2005). Although increased HIF-1 and HIF-2 mRNA in varicose 
compared to non-varicose veins found in this study may suggest an oxygen-independent HIF 
regulation involvement, such assumption may not be true. The current understanding of the 
regulation of HIF- was mostly based on animal models and in vitro studies during which cells or 
tissues were subjected to experimental conditions over a relatively short period as compared to 
real-life diseases such as varicose veins which would have taken a much longer time to develop. 
In addition, varicose veins are also a heterogeneous disorder involving various risk factors, thus 
the regulation of HIF- may be much more complicated. Furthermore, a combination of oxygen-
dependent and-independent HIF- regulation may also be a possibility in varicose veins. 
Therefore, the next two chapters investigated the role of both hypoxia and mechanical stress, 
respectively in the regulation of HIF-1 and HIF-2 expression and activity in venous tissues. 
3.6. CONCLUSION 
Structural variations including increased media SMC content and reduced media elastic 
tissue content are present in varicose compared to non-varicose veins assessed histologically with 
special stains. The expression of the mRNA and protein of HIF-1α, HIF-2α and their target genes 
is increased in varicose compared to non-varicose veins. HIF-2α is more widely expressed and is 
found in SMC and endothelium as compared to HIF-1α which is only seen in some endothelial 
cells, suggesting that HIF-2α instead of HIF-1α may be the key regulator of the HIF pathway in 
varicose and non-varicose veins. 
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4. REGULATION OF HIF AND TARGET GENES EXPRESSION IN VARICOSE AND 
NON-VARICOSE VEINS BY HYPOXIA 
4.1. INTRODUCTION 
Increased expression of HIF-1α, HIF-2α and HIF target genes in varicose compared to 
non-varicose veins shown in Chapter 3 suggested the possibility of varicose vein wall hypoxia. 
Oxygen tension is the most well-known and well-reported regulatory factor of the HIF pathway 
(Milkiewicz and Haas 2005; Semenza 2009b). In this chapter, the effects of normoxia and 
hypoxia, and pharmacological manipulation of several drugs on the HIF pathway in varicose and 
non-varicose vein tissues were examined using a vein organ culture model. 
The in vitro effects of hypoxia on the HIF pathway in various cell and tissue types have 
been investigated using cell and organ cultures subjected to various oxygen tensions (Rajakumar 
et al. 2003; Wojciak-Stothard et al. 2006; Eliasson et al. 2010; Heinis et al. 2010; Lavrentieva et 
al. 2010). However, the regulation of the HIF pathway in varicose and non-varicose vein organ 
culture has not been reported so far. The effects of hypoxia on the HIF pathway can also be 
mimicked using DMOG, a cell permeable 2-oxoglutarate analogue (Elvidge et al. 2006). DMOG 
is a non-specific inhibitor of both prolyl and asparaginyl hydroxylases, thereby blocking the 
activity of PHD and FIH-1. By inhibiting PHD and FIH-1, DMOG stabilises and increases the 
activity of HIF-α, similar to the effects of hypoxia (Elvidge et al. 2006). Several studies have 
investigated the in vitro effects of DMOG on the HIF pathway using cell and organ cultures 
(Glassford et al. 2007; Heinis et al. 2010). 
Besides hypoxia and hypoxia mimetic agents, the in vitro effects of various other drugs 
on the HIF pathway have also been investigated (Adesida et al. 2007; Ishikawa et al. 2007). In 
this chapter, the effects of two drugs of interest i.e. doxycycline and MPFF on the HIF pathway in 
varicose and non-varicose veins were also examined using the vein organ culture. Both drugs are 
known to modify vascular wall remodelling but whether or not they affect the HIF pathway in 
varicose and non-varicose veins remains unknown (Lyseng-Williamson and Perry 2003; 
Nicolaides 2003; Raffetto and Khalil 2008b). 
Doxycycline, a tetracycline analogue, is a broad spectrum anti-microbial agent which has 
been used since the 1940s. Besides this, doxycycline has other functions including inhibiting 
MMP activity (Liu et al. 2003) and promoting cell apoptosis (Onoda et al. 2006). There is 
evidence supporting that doxycycline delays the progression and development of aortic aneurysm. 
This is thought to be due to its MMP inhibitory property (Aziz and Kuivaniemi 2007; Abdul-
Hussien et al. 2009). MMPs are thought to play a significant role in the destruction of ECM in 
aortic wall leading to the pathogenesis of aortic aneurysm (Aziz and Kuivaniemi 2007; Raffetto 
and Khalil 2008a). The effects of doxycycline on varicose vein wall remain unclear. Since some 
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of the MMPs and TIMPs are known to be regulated by the HIF pathway, there is a possibility that 
doxycycline may affect the HIF pathway. 
MPFF or Daflon® is a venoactive drug consisting 90% diosmin and 10% hesperidin. It 
has been used clinically to treat CVI. The efficacy of MPFF in the treatment of CVI including 
improving the rate of ulcer healing and oedema related symptoms have been demonstrated in 
several randomised controlled studies (Lyseng-Williamson and Perry 2003; Nicolaides 2003; 
Pascarella et al. 2008). MPFF has several mechanisms of action including inhibiting inflammation 
by reducing the expression of adhesion molecules, and increasing venous tone (Lyseng-
Williamson and Perry 2003; Nicolaides 2003; Pascarella et al. 2008). MPFF and other venoactive 
drugs have also been shown to reduce apoptosis in varicose veins, improve oxygen carrying in 
varicosities, and protect endothelial responses to hypoxic stress in veins (McEwan and McArdle 
1971; Matagne and Gilles 1977; Arnould et al. 1996; Bougelet et al. 1998; Janssens et al. 2000; 
Michiels et al. 2002a; Lyseng-Williamson and Perry 2003). There is also evidence that some 
flavonoids affect the HIF pathway (Newcomb 2004; Losso and Bawadi 2005; Luo et al. 2009) 
4.1.1. Organ Culture 
Organ or tissue culture (similar to ex vivo tissue explant) is an in vitro model involving 
keeping a whole organ or tissue in conditions that enable the tissue or organ to remain viable and 
behave as close to its in vivo characteristics as possible. Using an in vitro model has the advantage 
of being able to control the experimental conditions more easily compared to an in vivo whole 
body model. Therefore, like cell culture, organ culture can be used to study the effects of various 
exogenous stimuli including drugs, radiation, cytokines, growth factors, hormones and physical 
strains such as mechanical stretch (Ozaki and Karaki 2002). Organ culture can also be 
manipulated to study a particular biological pathway including HIF (Rajakumar et al. 2003; 
Risbud et al. 2003; Lee et al. 2008; Heinis et al. 2010). Furthermore, organ culture model has 
been developed as a disease model to study a particular pathology. For example, saphenous vein 
organ culture has been developed, validated and used to study the mechanism of intimal 
hyperplasia in vein graft stenosis (Soyombo et al. 1990; Porter et al. 1996). However, one major 
limitation of an in vitro model is the loss or compromised of real-life representation (Ozaki and 
Karaki 2002). 
Compared to cell culture, organ culture has the advantage of preserving the structural 
relationship and interactions between the different cell types and with the ECM. However, it is 
important to realise that despite the morphology of the organ has not changed, it is likely that the 
cells would have undergone changes and started to behave differently as soon as they were 
removed from the host. Furthermore, like cell culture, various external factors including the type 
of culture medium, external physical factors such as movement, temperature change and 
surrounding lighting, and the trauma caused during preparation are likely to alter the 
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characteristics of the organ culture. Organ culture is also generally less predictable than cell 
culture, and the interpretation of the results may be more complex due to the presence of various 
factors involving different cell types and ECM. For example, the penetration of a drug into an 
organ culture may be a factor determining the response of the organ culture to the drug. 
4.1.2. Vein Organ Culture 
Organ cultures of vascular tissues including arteries and veins have been reported in 
many vascular biology studies (Soyombo et al. 1990; Wilson et al. 1997; Franklin et al. 1999; 
Castronuovo et al. 2002; Ozaki and Karaki 2002; Thorne et al. 2004; Kumar et al. 2006). One of 
the commonly used and reported vein organ culture models was first described by Soyombo and 
colleagues in 1990 to study neointimal hyperplasia in saphenous vein graft stenosis (Soyombo et 
al. 1990). Since then this model, with and without modifications, has been widely used and 
validated. In this model, the vein organ cultures have been shown to be viable for at least 14 days 
(Soyombo et al. 1990; Angelini et al. 1991; Porter et al. 1996; Porter et al. 2002). This model has 
been used to study the pathophysiology of neointimal hyperplasia development in saphenous vein 
tissues (Angelini et al. 1991; Porter et al. 1999). For example, Porter and colleagues used this 
model to demonstrate that the development of neointimal hyperplasia was associated with 
increased production of MMP-9 (Porter et al. 1999). Besides, this model has also been used to 
study the effects of various growth factors (e.g. PDGF) (George et al. 1996) and drugs (e.g. 
simvastatin and marimastat) (Porter et al. 1998; Porter et al. 2001; Porter et al. 2002) on 
neointimal thickening in saphenous vein graft. 
Modifications of this saphenous vein organ culture model have also been described for 
varicose vein tissues (Nomura et al. 2005). Nomura and colleagues used a varicose vein version 
of this model, with some modifications, to study the effect of statins on MMPs in varicose veins 
(Nomura et al. 2005). However, this was not the only varicose vein organ culture that has been 
described. An earlier version of a varicose vein organ culture has been reported to study the 
oxidative metabolism and glucose transport, and the effects of O-(beta-hydroxyethyl)-rutoside on 
lactate dehydrogenase in varicose veins (Matagne and Gilles 1977). Another varicose vein organ 
culture model was described to assess the effect of MPFF (Daflon® 500 mg) on noradrenaline 
induced contraction of the veins (Juteau et al. 1995). 
4.2. OBJECTIVES 
The objectives of this chapter were: 
1. To prepare and validate a varicose vein organ culture by assessing its viability using a cell 
death assay. 
2. To demonstrate that hypoxia and hypoxia mimetic drug DMOG increase the expression 
of HIF-α and target genes in varicose and non-varicose vein organ culture 
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3. To assess the effects of MPFF and doxycycline on HIF-α and HIF target genes expression 
in varicose and non-varicose vein organ culture subjected to hypoxia 
4.3. METHODS 
In all the experiments described in this chapter, varicose and non-varicose vein organ 
cultures were prepared as described in Chapter 2. Hypoxia refers to 1% oxygen and normoxia 
represents 20-21% O2. The culture medium used was 5ml of DMEM High Glucose (4.5g/L) with 
L-glutamine, and sodium pyruvate (PAA Laboratories GmbH, Pasching, Austria), supplemented 
with 100 unit/ml penicillin and 0.1 mg/ml streptomycin (PAA Laboratories GmbH), and 10% 
FBS (Gibco™, Invitrogen Life Sciences, Paisley, UK) unless stated otherwise. 
4.3.1. Assessment of the Viability of Varicose Vein Organ Culture 
4.3.1.1. Cell death of varicose veins cultured for 27 days 
To assess the pattern of cell death with time, varicose vein organ cultures were incubated 
in normoxia at 37ºC for up to 27 days with culture medium changed every 48 hours. Varicose 
vein specimens obtained from every patient were used to prepare between 5-9 vein organ cultures 
each time. All the varicose vein organ cultures were incubated in normoxia at 37°C. Culture 
medium was changed on day 1 and then every 48 hours for up to 27 days. Culture medium that 
had been used in the first 14 days of culture was collected and stored in -80°C for cell death assay 
later. Varicose vein organ cultures were sampled at random and snap frozen on day 0, 2, 4, 8, 10, 
14, 15, 21 and 27 for cell death assay later to assess the pattern of cell death of the organ culture 
over 27 days. Cell death of the culture medium and vein tissue from the organ culture were 
assayed using Cell Death Detection ELISA Plus® which has been described in Chapter 2. 
4.3.1.2. The effects of sodium azide 10mM on cell death of varicose vein organ culture 
To demonstrate that the varicose vein organ culture model contained living cells, the cell 
death of varicose vein organ cultures treated with sodium azide 10nM and their untreated 
counterparts were compared. Sodium azide is known to cause cell death through apoptosis and/or 
necrosis (Duranteau et al. 1998; Leary et al. 2002; Safiulina et al. 2006; Selvatici et al. 2009). 
Varicose vein specimens obtained from every patient were used to prepare seven vein 
organ cultures. All the varicose vein organ cultures were incubated in normoxia at 37°C. On day 
1, one of the seven organ cultures selected at random was snap frozen and the culture medium 
was collected; both were stored at -80°C. The remaining six varicose vein organ cultures were 
divided into two groups; untreated and treated with sodium azide 10mM. The culture medium was 
changed on day 1, 3 and 5 with or without sodium azide 10mM treatment depending on the group 
they belonged to. On day 3, 5 and 7, one varicose vein organ culture from each group was 
sampled at random and snap frozen with the culture medium was also collected; both were stored 
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at -80°C. All the stored tissues and culture medium were later assayed with Cell Death Detection 
ELISA Plus®. 
4.3.1.3. The effects of hypoxia on cell death of varicose vein organ culture 
To assess the effects of hypoxia on the viability of this varicose vein organ culture model, 
the cell death of varicose vein organ cultures subjected to hypoxia and normoxia was compared. 
Varicose vein specimens obtained from every patient were used to prepare two vein organ 
cultures. Both varicose vein organ cultures were incubated and equilibrated in normoxia at 37°C 
for 24 hours. On day 1, the culture medium of both varicose vein organ cultures was changed. 
One of them was then incubated in normoxia and the other in hypoxia for 24 hours. Both varicose 
vein organ cultures were snap frozen and the culture medium was collected; both were stored at -
80°C. All the stored tissues and culture medium were later assayed with Cell Death Detection 
ELISA Plus®. 
4.3.2. Regulation of the HIF pathway by Hypoxia, Hypoxia Mimetic DMOG, 
Doxycycline and MPFF in Non-Varicose and Varicose Veins 
Vein organ cultures of varicose and non-varicose veins were prepared as described in 
Chapter 2. Six vein organ cultures were prepared from veins harvested from every patient. All the 
vein organ cultures were incubated and equilibrated in normoxia at 37°C for the first 24 hours. 
Then, the culture medium of all the vein organ cultures was changed. One vein organ culture was 
then subjected to one of the following conditions for 16 hours; normoxia only, normoxia and 
DMOG 1mM, hypoxia only, hypoxia and doxycycline 5µg/ml, hypoxia and DMSO 0.02% (v/v), 
and hypoxia and MPFF (Daflon®, gift from Dr Pascale Deloffre, Servier, France) 10
-5
M. DMSO 
was used as a vehicle control for MPFF. DMOG and doxycycline were both water soluble. 
Following 16 hours of exposure of the vein organ cultures to these conditions, they were 
immediately snap frozen in liquid nitrogen and stored at -80°C for analysis of HIF-1α, HIF-2α 
and HIF target genes expression with Q-PCR and Western blot. 
4.3.3. Statistics and Graphs 
Graphs were plotted and significance tests were performed using the Graphpad Prism 
version 5.00 for Windows (Graphpad Software, San Diego California, USA). Data were 
expressed as mean±SEM. The normality of the continuous data was tested with Kolmogorov-
Smirnov test. Two-way ANOVA with Bonferroni post-tests was used to test the differences 
between the cell death of varicose vein organ culture treated and untreated with sodium azide. 
Paired student t-test was used to test the differences in the mean values of cell death between 
varicose veins cultured in hypoxia and those in normoxia. In relative Q-PCR analysis of gene 
expression of varicose and non-varicose vein organ cultures exposed to normoxia only, hypoxia 
only, and DMOG in normoxia, the differences between the ∆Ct values of different groups were 
Chapter 4 
145 
tested with one-way ANOVA with repeated measures followed by Dunnett‟s test for multiple 
comparisons. The ∆Ct rather than fold change was used here because the fold change of vein 
organ cultures subjected to normoxia only was always 1 since they were used as the calibrator or 
reference samples. The use of ∆Ct values in statistical testing in relative Q-PCR has been reported 
to be an acceptable method (Yuan et al. 2006). Meanwhile, in the relative Q-PCR analysis of vein 
organ cultures exposed to hypoxia with and without the treatment of doxycycline or MPFF, the 
differences in the fold change of gene expression between the groups were tested directly with 
one-way ANOVA with repeated measures followed by Dunnett‟s test for multiple comparisons. 
P<0.05 was considered significant. 
4.4. RESULTS 
4.4.1. Viability of Varicose Vein Organ Culture 
4.4.1.1. Cell death of varicose veins cultured for 27 days 
The demographic details of the patients from whom the varicose veins were harvested 
and used for analysis of cell death of varicose veins cultured for 27 days were summarised in 
Appendix 13 (D). 
Figure 4-1 demonstrates the pattern of cell death (apoptosis) represented as optical 
density, A450nm, assayed with Cell Death Detection ELISA Plus® of tissue lysate of varicose veins 
cultured for 27 days with culture medium changed every 48 hours. Increased cell death was 
measured in the tissue lysate of varicose vein organ cultures from day 0 to day 2. The amount of 
cell death decreased rapidly from day 2 to day 4. The cell death seemed to continue to decrease 
but less rapidly after day 4, and then plateaued off from day 8 until at least day 21. The amount of 
cell death appeared to show an increasing trend again from day 21 until day 27 when the 
experiment was stopped. 
Figure 4-2 shows the pattern of cell death (necrosis) represented as optical density, A450nm 
measured in the culture medium of the varicose vein organ culture over 14 days using Cell Death 
Detection ELISA Plus® assay. Similar to tissue lysate, the cell death measured in the culture 
medium increased rapidly from day 0 to day 2. The amount of cell death decreased rapidly from 
day 2 onwards and seemed to plateau off to relatively very little cell death from day 8 onwards 
until day 14. 
Chapter 4 
146 
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28
0.0
0.5
1.0
1.5
2.0
Tissue lysate
Day
O
p
ti
c
a
l 
D
e
n
si
ty
, 
A
4
0
5
n
m
 
Figure 4-1 Cell death assay of tissue lysate of varicose veins cultured for 27 days 
Cell Death Detection ELISA Plus® assay of tissue lysate of varicose vein cultured for 27 days. Culture 
medium was changed every 48 hours. Cell death was measured as optical density, A405nm. Data represent 
mean±SEM. Varicose veins were obtained from 14 patients 
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Figure 4-2 Cell death assay of culture medium of varicose veins cultured for 14 days 
Cell Death Detection ELISA Plus® assay of culture medium sampled from varicose vein organ cultures 
cultured for 14 days. Culture medium was changed every 48 hours. Cell death was measured as optical 
density A405nm per g tissue. Data represent mean±SEM. Varicose veins were obtained from 14 patients. 
4.4.1.2. The effects of sodium azide on cell death of varicose vein organ culture 
The demographic details of the patients from whom the varicose veins were harvested 
and used to study the effects of sodium azide on cell death of varicose vein organ culture are 
summarised in Appendix 13 (D). 
Figure 4-3 compares the cell death measured in tissue lysate (apoptosis) and culture 
medium (necrosis) of varicose vein organ cultures treated and untreated with sodium azide 
10mM. The cell death, represented as optical density, A450nm, was assayed with Cell Death 
Detection ELISA Plus®. Overall, varicose vein organ cultures that were treated with sodium 
azide 10mM on day 1 onwards demonstrated significantly more cell death in the tissue lysate 
(P=0.001; Two-way ANOVA with Bonferroni post-tests). The cell death measured in tissue lysate 
(apoptosis) of varicose vein organ cultures that were treated with sodium azide on day 1 onwards 
continued to increase until day 7. Whereas, the cell death measured in tissue lysate of varicose 
vein organ cultures that were not treated with sodium azide did not increase after day 1. The cell 
death measured in the culture medium (necrosis) of varicose vein organ cultures both treated and 
untreated with sodium azide appeared similar i.e. increased from day 1 to day 3 and then declined 
from day 3 to day 7. 
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Figure 4-3 Cell death assay of varicose vein organ culture untreated and treated with 
sodium azide 
Cell Death Detection ELISA Plus® assay of (a) tissue lysate and (b) culture medium of varicose vein organ 
culture untreated (full line) and treated (dotted line) with sodium azide 10mM added from day 1 onwards. 
Cell death was measured as optical density, A405nm. Data represents mean±SEM; n=4. Varicose vein organ 
cultures were cultured in normoxia at 37°C for 7 days. Culture medium was changed on day 1 and then 
every 48 hours up to day 7. In the sodium azide group, the varicose vein organ cultures were treated with 
sodium azide 10mM from day 1 onwards. The differences in cell death measured between varicose vein 
organ cultures treated with sodium azide 10mM and those untreated were tested with two-way ANOVA 
with Bonferroni post-tests. 
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4.4.1.3. The effects of hypoxia on cell death of varicose vein organ culture 
The demographic details of the patients from whom the varicose veins were harvested 
and used to study the effects of hypoxia on cell death of varicose vein organ culture are 
summarised in Appendix 13 (D). 
Figure 4-4 compares the cell death of varicose vein organ cultures exposed to 24 hours of 
normoxia and hypoxia to assess if their viability was affected by the oxygen tension used in the 
subsequent experiments in this chapter. The cell death, represented as optical density, A450nm, was 
assayed with Cell Death Detection ELISA Plus®. There was no significant difference measured 
between cell death in the tissue lysate of varicose vein organ cultures subjected to hypoxia and 
those exposed to normoxia for 24 hours. 
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Figure 4-4 Cell death assay of varicose vein organ cultures exposed to normoxia and 
hypoxia 
Cell Death Detection ELISA Plus® assay of tissue lysate and of varicose vein organ culture exposed to 24 
hour of normoxia and hypoxia from day 1. Cell death was measured as optical density, A405nm. Data 
represents mean±SEM; n=3. The difference in cell death between varicose vein organ cultures exposed to 
normoxia and hypoxia for 24 hours was tested with paired student t-test. 
 
4.4.2. Regulation of HIF by Hypoxia and Hypoxia Mimetic DMOG 
The demographic details of the patients from whom the varicose veins were harvested 
and used to study the regulation of HIF by hypoxia and hypoxia mimetic drug are summarised in 
Appendix 13 (E). 
Exposure of non-varicose vein organ cultures to 16 hours of hypoxia significantly 
reduced the expression of HIF-1α (P<0.05) but not HIF-2α mRNA compared to those subjected to 
normoxia only (Figure 4-5). Meanwhile, treatment of normoxic non-varicose vein organ cultures 
with 16 hours of DMOG 1mM also significantly decreased the expression of HIF-1α (P<0.001) 
but not HIF-2α mRNA compared to those subjected to normoxia only (Figure 4-5).  
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Figure 4-5 Relative expression of HIF-1α and HIF-2α mRNA in non-varicose vein 
organ cultures exposed to hypoxia and DMOG 
Expression of HIF-1α and HIF-2α mRNA measured with Q-PCR relative to normoxia of non-varicose vein 
organ cultures of six patients exposed to 16 hours of normoxia only, hypoxia, or DMOG 1mM in normoxia. 
Data are expressed as mean±SEM. 
* Significantly decreased compared to non-varicose veins exposed to normoxia (P<0.05; One-way ANOVA 
with repeated measures followed by Dunnett‟s test for multiple comparisons)  
*** Significantly decreased compared to non-varicose veins exposed to normoxia (P<0.001; One-way 
ANOVA with repeated measures followed by Dunnett‟s test for multiple comparisons)  
 
Similarly, exposure of varicose vein organ cultures to 16 hours of hypoxia significantly 
reduced the expression of HIF-1α (P<0.001) but not HIF-2α mRNA compared to those subjected 
to normoxia only (Figure 4-6). Also, treatment of normoxic varicose vein organ cultures with 16 
hours of DMOG 1mM also significantly decreased the expression of HIF-1α compared to those 
subjected to normoxia only (P<0.001) but not HIF-2α mRNA (Figure 4-6).  
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Figure 4-6 Relative expression of HIF-1α and HIF-2α mRNA in varicose vein organ 
cultures exposed to hypoxia and DMOG 
Expression of HIF-1α and HIF-2α mRNA measured with Q-PCR relative to normoxia of varicose vein 
organ cultures of six patients exposed to 16 hours of normoxia only, hypoxia, or DMOG1mM in normoxia. 
Data are expressed as mean±SEM. 
*** Significantly decreased compared to varicose veins exposed to normoxia (P<0.001; One-way ANOVA 
with repeated measures followed by Dunnett‟s test for multiple comparisons)  
 
Western blot analysis of protein extracted from varicose (n=4) and non-varicose (n=4) 
vein organ cultures exposed to normoxia only demonstrated very little or no imunoreactive band 
at 120kDa corresponding to HIF-1α (Figure 4-7). However, the immunoreaction at 120kDa 
corresponding to HIF-1α detected in varicose and non-varicose vein organ cultures exposed to 16 
hours of hypoxia, and those of 16 hours of DMOG 1mM in normoxia were more robust compared 
to their respective vein organ cultures that were subjected to normoxia only (Figure 4-7).  
Similar to HIF-1α, western blot analysis of protein extracted from varicose (n=4) and 
non-varicose (n=4) vein organ cultures exposed to normoxia only showed little or no 
imunoreactive band at 120kDa corresponding to HIF-2α (Figure 4-8). Again, the immunoreaction 
at 120kDa corresponding to HIF-2α detected in varicose and non-varicose vein organ cultures 
exposed to hypoxia or DMOG in normoxia were more robust than their respective vein organ 
cultures that were subjected to normoxia only (Figure 4-8).  
Exposure of non-varicose vein organ cultures to hypoxia significantly increased the 
mRNA expression of all the HIF target genes assessed (CA9, BNIP-3, PHD-2, PHD-3, and 
GLUT-1) except VEGF compared to those subjected to normoxia (Figure 4-9). Although 
statistically not significant, an increasing trend was demonstrated for the expression of VEGF in 
non-varicose vein organ cultures exposed to of hypoxia compared to normoxia only (Figure 4-9). 
Meanwhile, treatment of normoxic non-varicose vein organ cultures with DMOG significantly 
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increased the expression of all the six HIF target genes assessed (CA9, BNIP-3, PHD-2, PHD-3, 
GLUT-1, and VEGF) compared to those subjected to normoxia only (Figure 4-9). 
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Figure 4-7 Western blots analysis of HIF-1α of varicose and non-varicose vein organ 
cultures exposed to normoxia only, hypoxia, and DMOG in normoxia 
Representative western blot analysis of HIF-1α of varicose vein organ cultures of a patient, and non-
varicose vein organ cultures of a patient without any history of varicosities, exposed to normoxia only, 
hypoxia, or DMOG 1mM in normoxia. The loading control was assessed with ERK 2. 
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Figure 4-8 Western blots analysis of HIF-2α of varicose and non-varicose vein organ 
cultures exposed to normoxia only, hypoxia, and DMOG in normoxia 
Representative western blot analysis of HIF-2α of varicose vein organ cultures of a patient, and non-
varicose vein organ cultures of a patient without any history of varicosities, exposed to normoxia only, 
hypoxia, or DMOG 1mM in normoxia. The loading control was assessed with ERK 2. 
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Figure 4-9 Relative expression of HIF target genes in non-varicose vein organ 
cultures exposed to hypoxia and DMOG 
Expression of six HIF target genes mRNA measured with Q-PCR relative to normoxia of non-varicose vein 
organ cultures of six patients exposed to 16 hours of normoxia only, hypoxia, or DMOG in normoxia. The 
HIF target genes assessed were CA9, BNIP-3, PHD-2, PHD-3, GLUT-1 and VEGF. Data are expressed as 
mean±SEM. 
* Significantly decreased compared to non-varicose veins exposed to normoxia (P<0.05; One-way ANOVA 
with repeated measures followed by Dunnett‟s test for multiple comparisons)  
** Significantly decreased compared to non-varicose veins exposed to normoxia (P<0.01; One-way 
ANOVA with repeated measures followed by Dunnett‟s test for multiple comparisons)  
*** Significantly decreased compared to non-varicose veins exposed to normoxia (P<0.001; One-way 
ANOVA with repeated measures followed by Dunnett‟s test for multiple comparisons)  
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Exposure of varicose vein organ cultures to 16 hours of hypoxia significantly increased 
the expression of all the six HIF target genes assessed (CA9, BNIP-3, PHD-2, PHD-3, GLUT-1, 
VEGF) compared to those subjected to normoxia only (Figure 4-10). Similar to non-varicose 
veins, treatment of normoxic varicose vein organ cultures with 16 hours of DMOG 1mM also 
significantly increased the expression of all the six HIF target genes assessed compared to those 
subjected to normoxia only (Figure 4-10).  
The up-regulation of HIF target genes in non-varicose and varicose vein organ cultures 
following exposure to 16 hours of hypoxia or 16 hours of DMOG 1mM in normoxia compared to 
normoxia only was also reflected at protein level measured using western blot analysis (n=4). 
Figure 4-11 demonstrated a representative GLUT-1 and PHD-3 western blot analysis of varicose 
vein organ cultures of a patient, and non-varicose vein organ cultures of a patient with no history 
varicosities, exposed to 16 hours of hypoxia or 16 hours of DMOG 1mM in normoxia. 
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Figure 4-10 Relative expression of HIF target genes in varicose vein organ cultures 
exposed to hypoxia and DMOG 
Expression of six HIF target genes mRNA measured with Q-PCR relative to normoxia of varicose vein 
organ cultures of six patients exposed to 16 hours of normoxia only, hypoxia, or DMOG in normoxia. The 
HIF target genes were CA9, BNIP-3, PHD-2, PHD-3, GLUT-1 and VEGF. Data represent mean±SEM. 
* Significantly decreased compared to varicose veins exposed to normoxia (P<0.05; One-way ANOVA 
with repeated measures followed by Dunnett‟s test for multiple comparisons)  
** Significantly decreased compared to varicose veins exposed to normoxia (P<0.01; One-way ANOVA 
with repeated measures followed by Dunnett‟s test for multiple comparisons)  
*** Significantly decreased compared to varicose veins exposed to normoxia (P<0.001 One-way ANOVA 
with repeated measures followed by Dunnett‟s test for multiple comparisons)  
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Figure 4-11 Western blots analysis of HIF target genes of varicose and non-varicose 
vein organ cultures exposed to normoxia only, hypoxia, and DMOG in 
normoxia 
Representative western blots analysis of GLUT-1 and PHD-3 of varicose vein organ cultures of a patient, 
and non-varicose vein organ cultures of a patient without any history of varicosities, exposed to normoxia 
only, hypoxia, or DMOG in normoxia. The loading control was assessed with ERK 2. 
 
4.4.3. Regulation of HIF-1α and HIF-2α by doxycycline and MPFF  
The demographic details of the patients from whom the varicose veins were harvested to 
study the regulation of HIF doxycycline and MPFF were summarised in Appendix 13 (E). 
Treatment of non-varicose vein organ cultures that were exposed to hypoxia with 
doxycycline or MPFF did not significantly alter the expression of HIF-1α and HIF-2α mRNA 
compared to those exposed to normoxia only (Figure 4-12). Meanwhile, treatment of varicose 
vein organ cultures that were exposed to 16 hours of hypoxia with doxycycline also did not 
significantly affect the expression of HIF-1α and HIF-2α mRNA compared to those exposed to 
normoxia only (Figure 4-13). However, MPFF significantly reduced the expression of HIF-1α 
mRNA in varicose vein organ cultures exposed to hypoxia compared to those that were treated 
with equal amount of DMSO, vehicle control only (Figure 4-13). Although statistically not 
Chapter 4 
157 
significant, MPFF also appeared to decrease the expression of HIF-2α mRNA in varicose vein 
organ cultures exposed to hypoxia compared to those that were treated with equal amount of 
DMSO only (Figure 4-13). The 0.02% (v/v) of DMSO that was used to dissolve MPFF did not 
significantly affect the expression of HIF-1α and HIF-2α mRNA in non-varicose and varicose 
vein organ cultures exposed to hypoxia compared to those that were not treated with DMSO 
(Figure 4-12 and Figure 4-13). 
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Figure 4-12 The effects of doxycycline and MPFF on the expression of HIF-1α and 
HIF-2α mRNA in hypoxic non-varicose vein organ cultures 
Relative expression of HIF-1α and HIF-2α mRNA measured with Q-PCR of non-varicose vein organ 
cultures of six patients exposed to 16 hours of hypoxia with or without treatment with doxycycline 5µg/ml 
or MPFF 10
-5
M. MPFF was dissolved in DMSO (0.02%; v/v) and therefore, the effects of DMSO on HIF-
1α and HIF-2α mRNA in non-varicose vein organ cultures exposed to 16 hours of hypoxia were also 
assessed for comparison with those treated with MPFF. Data are expressed as mean±SEM. One-way 
ANOVA with repeated measures followed by Dunnett‟s test for multiple comparisons was used to calculate 
for any significant differences. 
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Figure 4-13 The effects of doxycycline and MPFF on the expression of HIF-1α and 
HIF-2α mRNA in hypoxic varicose vein organ cultures 
Relative expression of HIF-1α and HIF-2α mRNA measured with Q-PCR of varicose vein organ cultures of 
six patients exposed to 16 hours of hypoxia with or without treatment with doxycycline 5µg/ml or MPFF 
10
-5
M. MPFF was dissolved in DMSO (0.02%; v/v) and therefore, the effects of DMSO on HIF-1α and 
HIF-2α mRNA in varicose vein organ cultures exposed to 16 hours of hypoxia were also assessed for 
comparison with those treated with MPFF. Data are expressed as mean±SEM. 
§ Significantly decreased compared to varicose vein organ cultures exposed to 16 hours of hypoxia and 
treated with DMSO 0.02% (v/v) only (P<0.05; One-way ANOVA with repeated measures followed by 
Dunnett‟s test for multiple comparisons)  
 
As discussed earlier, exposure of non-varicose vein organ cultures to hypoxia increased 
the intensity of the immunoreaction detected at 120kDa on western blot corresponding to HIF-1α 
compared to those subjected to normoxia only. Treatment of non-varicose vein organ cultures that 
were exposed to hypoxia with doxycycline or MPFF did not appear to alter the intensity of the 
immunoreaction at 120kDa corresponding to HIF-1α compared to those that were untreated or 
treated with DMSO 0.02% (v/v) only, respectively (n=3). Figure 4-14 demonstrates a 
representative western blots analysis of HIF-1α of non-varicose vein organ cultures of a patient 
exposed to normoxia only, hypoxia with and without treatment of doxycycline or MPFF. 
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Figure 4-14 Western blots analysis of HIF-1α of non-varicose vein organ cultures 
exposed to normoxia only, hypoxia with and without treatment of 
doxycycline and MPFF 
Representative western blot analysis of HIF-1α of non-varicose vein organ cultures of a patient exposed to 
normoxia only, hypoxia with and without treatment of doxycycline 5µg/ml or MPFF 10
-5
M. The MPFF was 
dissolved in DMSO (0.02%; v/v) and therefore, the effects of DMSO on HIF-1α mRNA in non-varicose 
vein organ cultures exposed to hypoxia were also assessed for comparison with those treated with MPFF. 
The loading control was assessed with ERK 2. 
 
As discussed before, exposure of non-varicose vein organ cultures to 16 hours of hypoxia 
also increased the intensity of the immunoreaction detected at 120kDa on western blot 
corresponding to HIF-2α compared to those subjected to normoxia only. Treatment of non-
varicose vein organ cultures that were exposed to hypoxia with doxycycline or MPFF did not 
seem to change the intensity of the immunoreaction at 120kDa corresponding to HIF-2α 
compared to those that were untreated or treated with DMSO 0.02% (v/v) only, respectively 
(n=3). Figure 4-15 shows a representative western blots analysis of HIF-2α of non-varicose vein 
organ cultures of a patient exposed to normoxia only, hypoxia with and without treatment of 
doxycycline 5µg/ml or MPFF 10
-5
M.  
The 0.02% (v/v) of DMSO that was used to dissolve MPFF did not appear to affect the 
expression of HIF-1α and HIF-2α protein expression in non-varicose vein organ cultures exposed 
to hypoxia compared to those that were not treated with DMSO (Figure 4-14 and Figure 4-15). 
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Figure 4-15 Western blots analysis of HIF-2α of non-varicose vein organ cultures 
exposed to normoxia only, hypoxia with and without treatment of 
doxycycline and MPFF 
Representative western blot analysis of HIF-2α of non-varicose vein organ cultures of a patient exposed to 
normoxia only, hypoxia with and without treatment of doxycycline 5µg/ml or MPFF 10
-5
M. The MPFF was 
dissolved in DMSO (0.02%; v/v) and therefore, the effects of DMSO on HIF-2α mRNA in non-varicose 
vein organ cultures exposed to hypoxia were also assessed for comparison with those treated with MPFF. 
The loading control was assessed with ERK 2. 
 
Similar to non-varicose veins, exposure of varicose vein organ cultures to 16 hours of 
hypoxia increased the intensity of HIF-1α protein expression compared to those subjected to 
normoxia only. Treatment of varicose vein organ cultures that were exposed to hypoxia with 
doxycycline or MPFF did not appear to alter the intensity of HIF-1α protein expression compared 
to those that were untreated or treated with DMSO only, respectively (n=3). Figure 4-16 
demonstrates a representative western blots analysis of HIF-1α of varicose vein organ cultures of 
a patient exposed to normoxia only, hypoxia with and without treatment of doxycycline or MPFF. 
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Figure 4-16 Western blots analysis of HIF-1α of varicose vein organ cultures exposed 
to normoxia only, hypoxia with and without treatment of doxycycline and 
MPFF 
Representative western blot analysis of HIF-1α of varicose vein organ cultures of a patient exposed to 
normoxia only, hypoxia with and without treatment of doxycycline 5µg/ml or MPFF 10
-5
M. The MPFF was 
dissolved in DMSO (0.02%; v/v) and therefore, the effects of DMSO on HIF-1α mRNA in varicose vein 
organ cultures exposed to hypoxia were also assessed for comparison with those treated with MPFF. The 
loading control was assessed with ERK 2. 
 
Similar to HIF-1α, exposure of varicose vein organ cultures to 16 hours of hypoxia also 
increased the intensity of HIF-2α protein expression compared to those subjected to normoxia 
only. Treatment of varicose vein organ cultures that were exposed to hypoxia with doxycycline or 
MPFF did not seem to change HIF-2α protein expression compared to those that were untreated 
or treated with DMSO only, respectively (n=3). Figure 4-17 depicts a representative western blots 
analysis of HIF-2α of varicose vein organ cultures of a patient exposed to normoxia only, hypoxia 
with and without treatment of doxycycline or MPFF. DMSO vehicle control did not affect HIF-1α 
and HIF-2α protein expression (Figure 4-16 and Figure 4-17). 
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Figure 4-17 Western blots analysis of HIF-2α of varicose vein organ cultures exposed 
to normoxia only, hypoxia with and without treatment of doxycycline and 
MPFF 
Representative western blot analysis of HIF-2α of varicose vein organ cultures of a patient exposed to 
normoxia only, hypoxia with and without treatment of doxycycline 5µg/ml or MPFF 10
-5
M. The MPFF was 
dissolved in DMSO (0.02%; v/v) and therefore, the effects of DMSO on HIF-2α mRNA in varicose vein 
organ cultures exposed to hypoxia were also assessed for comparison with those treated with MPFF. The 
loading control was assessed with ERK 2. 
 
Treatment of non-varicose and varicose vein organ cultures that were exposed to 16 hours 
of hypoxia with doxycycline did not significantly alter the expression of all the HIF target genes 
mRNA assessed (CA9, BNIP-3, PHD-2, PHD-3, GLUT-1 and VEGF) compared to those exposed 
to normoxia only (Figure 4-18 and Figure 4-19). Similarly, treatment of non-varicose vein organ 
cultures that were exposed to hypoxia with MPFF did not significantly affect the expression of all 
the HIF target genes mRNA assessed compared to those that were treated with DMSO only 
(Figure 4-18). Although not significant, there appeared to be a trend that MPFF decreased the 
expression of all the HIF target genes mRNA assessed in varicose vein organ cultures exposed to 
hypoxia compared to those that were treated with equal amount of DMSO only (Figure 4-19). 
Chapter 4 
163 
CA9
Untreated Doxycycline DMSO MPFF
0
2
4
6
8
10
R
el
at
iv
e 
C
A
9
 m
R
N
A
 e
x
p
re
ss
io
n
BNIP-3
Untreated Doxycycline DMSO MPFF
0
2
4
6
R
el
at
iv
e 
B
N
IP
-3
 m
R
N
A
 e
x
p
re
ss
io
n
PHD-2
Untreated Doxycycline DMSO MPFF
0
1
2
3
R
el
at
iv
e 
P
H
D
-2
 m
R
N
A
 e
x
p
re
ss
io
n PHD-3
Untreated Doxycycline DMSO MPFF
0
10
20
30
40
R
el
at
iv
e 
P
H
D
-3
 m
R
N
A
 e
x
p
re
ss
io
n
GLUT-1
Untreated Doxycycline DMSO MPFF
0
5
10
15
20
R
el
at
iv
e 
G
L
U
T
-1
 m
R
N
A
 e
x
p
re
ss
io
n VEGF
Untreated Doxycycline DMSO MPFF
0
2
4
6
8
10
R
e
la
ti
v
e
 V
E
G
F
 m
R
N
A
 e
x
p
re
ss
io
n
 
Figure 4-18 The effects of doxycycline and MPFF on the relative expression of HIF 
target genes mRNA in hypoxic non-varicose vein organ cultures 
Relative expression of six HIF target genes (CA9, BNIP-3, PHD-2, PHD-3, GLUT-1 and VEGF) measured 
with Q-PCR of non-varicose vein organ cultures of six patients exposed to 16 hours hypoxia with or 
without treatment with doxycycline 5µg/ml or MPFF 10
-5
M. The MPFF was dissolved in DMSO (0.02%; 
v/v) and therefore, the effects of DMSO on HIF target genes in non-varicose vein organ cultures exposed to 
hypoxia were also assessed for comparison with those treated with MPFF. Data are expressed as 
mean±SEM. One-way ANOVA with repeated measures followed by Dunnett‟s test for multiple 
comparisons was used to calculate for any significant differences. 
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Figure 4-19 The effects of doxycycline and MPFF on the relative expression of HIF 
target genes mRNA in hypoxic varicose vein organ cultures 
Relative expression of six HIF target genes (CA9, BNIP-3, PHD-2, PHD-3, GLUT-1 and VEGF) measured 
with Q-PCR of varicose vein organ cultures of six patients exposed to 16 hours hypoxia with or without 
treatment with doxycycline 5µg/ml or MPFF 10
-5
M. The MPFF was dissolved in DMSO (0.02%; v/v) and 
therefore, the effects of DMSO on HIF target genes in varicose vein organ cultures exposed to hypoxia 
were also assessed for comparison with those treated with MPFF. Data are expressed as mean±SEM. One-
way ANOVA with repeated measures followed by Dunnett‟s test for multiple comparisons was used to 
calculate for any significant differences. 
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4.5. DISCUSSION 
The main objective of this chapter was to validate and use a varicose and non-varicose vein 
organ culture to investigate the regulation of HIF and target genes expression by hypoxia, with 
and without the treatment of doxycycline and MPFF. The viability of the varicose vein organ 
culture was checked with cell death assay which confirmed that the model used contains living 
cells in normoxic and hypoxic condition used in the subsequent experiments. Exposure of 
varicose and non-varicose vein organ cultures to 16 hours of hypoxia or DMOG in normoxia was 
associated with the decreased expression of HIF-1α but not HIF-2α mRNA. However, HIF-1α and 
HIF-2α protein, and their target genes expression was increased in varicose and non-varicose vein 
organ cultures subjected to hypoxia or DMOG, compared to those in normoxia only. Doxycycline 
and MPFF at a concentration corresponding to their therapeutic physiological concentration did 
not significantly alter the expression of HIF-1α and HIF-2α protein, and their target genes. 
The vein organ culture used in this chapter was developed based on a model developed to 
study neointimal hyperplasia in saphenous vein graft stenosis (Soyombo et al. 1990). Several 
modifications to the vein organ culture were made. The original model used 6ml of Roswell Park 
Memorial Institute (RPMI) 1640 medium containing 2g/l of sodium bicarbonate, 2.5ug/ml of 
gentamicin, 100ug/ml of penicillin: streptomycin, 0.8mmol/l glutamine, and 30% (v/v) of FBS as 
the culture medium (Soyombo et al. 1990). The vein organ culture in this study used 5ml of 
DMEM containing glucose 4.5g/l with L-glutamine, and sodium pyruvate, and supplemented with 
100 unit/ml penicillin and 0.1 mg/ml streptomycin, and 10% FBS. In terms of culture medium 
volume, 5 ml instead of 6 ml was used to reduce the depth of the culture medium that the oxygen 
needed to diffuse through to reach the vein tissue situated at the bottom culture. It was unlikely 
that DMEM would cause any significant difference compared to RPMI. DMEM has been used in 
similar vein organ cultures previously including those of varicose vein tissues (Nomura et al. 
2005; Kumar et al. 2006). We also used a lower concentration of FBS than the original model. 
FBS contains various growth factors and other unidentified biological factors that stimulate cell 
differentiation and growth, and increase cell viability (Ozaki and Karaki 2002). FBS has also been 
shown to cause vascular SMC to change from contractile to proliferative phenotype (Ozaki and 
Karaki 2002). Chronic treatment of vascular tissues with high concentration of FBS has been 
reported to cause neointimal hyperplasia in models to study arterial restenosis (Voisard et al. 
1999). It was likely that the 30% (v/v) of FBS used in the original vein organ culture model was 
intended to stimulate cellular proliferation required for the development of neointimal 
hyperplasia. However, 30% of FBS was likely to be too high for this study in which FBS was 
only needed to keep the cells alive. Therefore, in my study 10% (v/v) of FBS was used instead, to 
maintain the viability of the tissue and yet prevent any excessive proliferation of cells and change 
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of contractility that might cause the vein organ culture to be less representative of varicose and 
non-varicose vein (Ozaki and Karaki 2002). 
Although this vein organ culture model has been used and validated in many occasions, and 
appeared to be reproducible by different research groups (Soyombo et al. 1990; Porter et al. 1996; 
Wilson et al. 1997; Nomura et al. 2005), the viability of the vein organ culture model used in this 
chapter was checked with cell death to ensure that the tissue remained alive after several days of 
culture. This was important because this was the first time that the model was developed and used 
in our laboratory. Furthermore, a few modifications and variations such as lowering of the FBS 
concentration and different experimental conditions including hypoxia were also used.  
In the original model, the viability of the vein organ culture was checked with ADP/ATP 
assay, measurement of [
3
H]-thymidine incorporation into DNA, and histological analysis with 
light and scanning electron microscopy. The ATP concentration in cultured veins after 7 and 14 
days was found to be approximately 30% and 20% lower than in freshly isolated vein, 
respectively. The ATP/ADP ratio was found to have increased by 25% and 45% after 7 and 14 
days in culture, respectively. Meanwhile, the DNA concentration declined by about 20% after 7 
days but recovered by 14 days in culture. Scanning electron microscopy of freshly isolated veins 
prepared for culture showed that endothelial cells were largely undamaged in the central portion 
but appeared injured and loss near the cut edges of segments. After 14 days of culture, the central 
region appeared similar although less flattened than before culturing, whereas close to the cut 
edges, cells seemed larger, some less cuboidal, and demonstrated filamentous projections on 
scanning electron micrographs. Light microscopy of silver-stained segments showed that about 
70% of the total surface was covered by endothelial cells in the freshly isolated veins prepared for 
culture compared to 80% of those cultured for 14 days (Soyombo et al. 1990; Angelini et al. 
1991; Porter et al. 1996; Wilson et al. 1997). 
Cell death assay of varicose vein organ culture in this study demonstrated that most cell 
death occurred within the first two days of the culture. The cell death then declined to a relatively 
low level and remained more or less the same until at least day 21. The spike of cell death 
observed within the first two days was likely to represent the trauma caused by the surgical 
retrieval and organ culture preparation that involved tissue handling, dissection and cutting. This 
was consistent with the endothelial injury and loss at the edges demonstrated in the original 
model. In the original model, surgically preparation of veins has also been shown to cause 
damage to the tissues leading to more neointimal hyperplasia development (Soyombo et al. 1990; 
Angelini et al. 1991). The relatively low level of cell death measured in the varicose vein organ 
culture was also consistent with the viability demonstrated in the original organ culture which was 
maintained at least up to 14 days (Soyombo et al. 1990; Angelini et al. 1991; Wilson et al. 1997). 
Sodium azide is known to cause cell death through apoptosis and/or necrosis. It inhibits 
oxidative phosphorylation by preventing electron transfer between cytochrome c oxidase or 
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mitochondrial complex IV and oxygen (Duranteau et al. 1998; Leary et al. 2002; Safiulina et al. 
2006; Selvatici et al. 2009). It also reversibly increases intracellular Ca
2+
, at least partially 
involving NMDA glutamate receptor activation (Marino et al. 2007; Selvatici et al. 2009). 
Treatment of varicose vein organ culture with sodium azide 10mM was expected to cause 
increase in cell death. This was clearly shown in this study when treatment of varicose vein organ 
culture with sodium azide 10mM from day 1 of culture onwards caused the cell death to continue 
to rise to at least day 7. Whereas, the cell death of those untreated with did not increase after day 
1. This finding also supported that the varicose vein organ culture prepared contained living cells. 
Meanwhile, the cell death measured in the culture medium of the varicose vein organ culture 
treated and untreated with sodium azide appeared similar. This finding suggested that sodium 
azide causes cell death in varicose vein organ culture through apoptosis but not necrosis. 
The cell death of the varicose vein organ culture exposed to 24 hours of normoxia and 
hypoxia was also measured and compared. This was to ascertain that the low oxygen tension of 
1% used as „hypoxia‟ in this study did not significantly affect the viability of the tissues. Similar 
level of cell death demonstrated by tissue exposed to 24 hours normoxia and hypoxia reassured 
that the effects observed in the subsequent pats of the study were not caused by tissue injury or 
cell loss secondary to hypoxia. 
Exposure of varicose and non-varicose vein organ culture to hypoxia or DMOG was 
associated with significant reduction of HIF-1α but not HIF-2α mRNA expression compared to 
those in normoxia only. However, HIF-1α and HIF-2α protein, and their target genes expression 
was increased in varicose and non-varicose vein organ cultures subjected to 16 hours of hypoxia 
or DMOG in normoxia, compared to those in normoxia only. The findings were consistent with 
previous reports where the up-regulation of HIF-α by hypoxia occurs at the protein level as 
described previously in the oxygen-dependent regulation of HIF-α.  
The down-regulation of HIF-1α mRNA by hypoxia is also consistent with previous 
reports that prolonged hypoxia could activate several negative feedback mechanisms that may 
lead to attenuation of HIF activity and adjustment of the cells to sense relative hypoxia with 
different ambient oxygen levels (Webb et al. 2009). For example, exposing embryonic stem cell-
derived embryoid bodies to ambient oxygen at or below 5% resulted
 
in stabilisation of HIF-1α 
and increased transcription of HIF target genes. HIF-1α expression was found to peak after 
approximately
 
48 hours of hypoxic exposure, and then decline to near undetectable
 
levels, despite 
constant hypoxic exposure (Cameron et al. 2008). Examples of negative feedback mechanisms 
that have been described for HIF-1α during sustained hypoxia include the generation of an 
antisense RNA to HIF-1α (aHIF) (Thrash-Bingham and Tartof 1999), production of CBP/p300-
Interacting-Transactivator-with-ED-rich-tail-2 (CITED2) that can bind and block p300 
recruitment required for HIF transcriptional activity (Bhattacharya et al. 1999; Webb et al. 2009), 
activation of PHDs transcription which negatively regulate HIF-α expression (Webb et al. 2009), 
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and induction of HIF-3α that negatively regulates HIF-1α (Ke and Costa 2006). HIF also exerts 
indirect feedbacks through its significant effects on several processes including glycolysis, 
mitochondrial metabolism and iron transport which may affect the availability of oxoglutarate, 
iron, succinate and fumarate which are known to affect the HIF hydroxylase activity (Isaacs et al. 
2005; Pollard et al. 2005; Pollard et al. 2007). Overall, these negative feedback regulations of 
HIF-α are complex and remain not fully understood. Furthermore, these negative feedback 
mechanisms are also known to have differential effects on the various components of the HIF 
pathway to adjust the balance of HIF-1α and HIF-2α activity. For example, aHIF seemed to 
preferentially act on HIF-1α while, PHD-3 has been reported to have preferential hydroxylation of 
HIF-2α (Thrash-Bingham and Tartof 1999; Webb et al. 2009). This may explain the negative 
regulation of HIF-1α but not HIF-2α mRNA by 16 hours of hypoxia or DMOG in normoxia 
observed in this study. 
The activity of the HIF pathway could be assessed by measuring the transcription of a set 
of HIF target genes. Although each individual HIF target gene may be affected by other HIF 
independent regulation (Luo et al. 2009; Takacova et al. 2009), simultaneous increases in the 
transcription of several HIF target genes are likely to represent activation of the HIF pathway. In 
this study, exposure of varicose and non-varicose vein organ cultures to hypoxia was associated 
with the up-regulation of CA9, GLUT-1, BNIP-3, VEGF, PHD-2 and PHD-3; all are known to be 
regulated by HIF. This finding supported that HIF pathway was activated in varicose and non-
varicose vein organ cultures exposed to hypoxia or DMOG in normoxia consistent with the HIF-
1α and HIF-2α protein finding. 
There is little agreement about what constitutes „normoxia‟ and „hypoxia‟ (Muz et al. 
2009). The physiological oxygen tension in vivo may be different from the atmospheric oxygen 
tension (Muz et al. 2009). Many in vitro studies considered the atmospheric oxygen tension of 
21% as „normoxia‟ while some studies defined „physiological normoxia‟ at 5% to 7% oxygen 
(Elvidge et al. 2006; Muz et al. 2009; Abaci et al.). „Hypoxia‟ has often been defined as oxygen 
tension of less than 5% in many studies (Muz et al. 2009). The oxygen tension of a tissue may be 
much lower compared to the blood circulation surrounding it (Muz et al. 2009). For example 
venous blood in the leg measured about 4% to 8% (Holling et al. 1938; Baron and Cassaro 1986; 
Scott et al. 1990; Wali 2002), However, the mean oxygen tension measured in varicose and non 
varicose veins in vivo in patients who were undergoing surgery has been reported as 1.0% and 
1.8%, respectively (Taccoen et al. 1996). In this study, „normoxia‟ was defined as 20–21% 
oxygen, and „hypoxia‟ as 1% oxygen. Since the objective of the study was to demonstrate that the 
HIF pathway could be activated by low oxygen tension in varicose and non-varicose veins, a 
larger difference in oxygen tension between „normoxia‟ and „hypoxia‟, and yet remained within 
the general acceptable range, would be preferred and more likely to demonstrate a clearer 
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outcome. After all, the oxygen tension of varicose vein tissues has been shown to be about 1% 
(Taccoen et al. 1996). 
In this study, varicose and non-varicose vein organ cultures were exposed to hypoxia and 
DMOG for 16 hours. This duration was long enough for the inhibition of prolyl- and asparaginyl 
hydroxylation, thus HIF stabilisation and activation leading to HIF target genes transcription to 
occur. It has also been reported that 16 hours of exposure of cell culture to hypoxia (1% oxygen) 
or to DMOG in normoxia demonstrated striking concordance between the patterns of gene 
expression (Elvidge et al. 2006). This result indicates the central involvement of prolyl- and 
asparaginyl hydroxylases (i.e. PHDs and FIH-1) in oxygen regulation of gene expression (Elvidge 
et al. 2006). However, such striking concordance is unlikely to sustain in prolonged hypoxia or 
DMOG treatment especially when other factors that might be regulated independently by hypoxia 
and DMOG become apparent (Elvidge et al. 2006). 
Doxycycline 5μg/ml did not significantly affect the expression of HIF-1α, HIF-2α, and 
HIF target genes expression in varicose and non-varicose vein organ cultures exposed to 16 hours 
of hypoxia. The concentration of doxycycline used in this study was based on previous in vivo 
and in vitro studies on abdominal aortic aneurysm since its effect on varicosity has never been 
reported. In one study, 14 patients diagnosed with abdominal aortic aneurysm were prescribed 
with 100mg twice a day for at least 3 months. Blood samples of these patients were analysed with 
liquid chromatography. The levels of circulating doxycycline ranged from 1.8 to 9.4μg/ml (mean, 
4.1±0.56) (Prall et al. 2002). In another study, doxycycline at a concentration of 5µg/ml was 
found to significantly reduce the production of MMP-2 in vascular SMC culture and infrarenal 
aortic tissue explants, corresponded to the normal therapeutic serum concentration (Liu et al. 
2003). Therefore, doxycycline concentration of 5μg/ml was used in this study.  
Meanwhile, the concentration of MPFF used in this study was based on in vitro studies 
that assessed the effects of MPFF or diosmin on vein cultures (Savineau and Marthan 1994; 
Juteau et al. 1995). In one study, MPFF at the concentration of 10
-5
M significantly increased the 
noradrenaline induced contractility of varicose and non-varicose vein organ culture (Juteau et al. 
1995). In another study, diosmin at the concentration of 0.5-10μM was found to shift the Ca2+ 
concentration-tension response curve to the left in chemically (β-escin) skinned strips from the rat 
femoral vein (Savineau and Marthan 1994). Diosmin was dissolved in DMSO of less than 0.1% 
(v/v) and was found to have no effect on the contractility of the venous tissues (Savineau and 
Marthan 1994). Based on the findings of these studies, MPFF at concentration of 10
-5
M was used. 
MPFF was dissolved in DMSO to make a final concentration of 0.02% (v/v) in the culture to 
minimise any toxicity from the solvent. 
MPFF significantly reduced the mRNA expression of HIF-1α but not HIF-2α in varicose 
vein organ cultures exposed to hypoxia compared to those untreated. There was also a statistically 
insignificant reduction of HIF target genes mRNA expression in the organ cultures exposed to 
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hypoxia compared to those untreated. Such observation was however, not obvious in non-varicose 
vein organ cultures treated similarly, i.e. MPFF did not significantly alter the HIF-1α, HIF-2α, 
and HIF target genes expression in non-varicose vein organ cultures exposed to hypoxia. This 
could be a novel mechanism of action of MPFF previously not known. MPFF is known to 
regulate vein wall remodelling, protect vein wall from hypoxia, and has been shown to be 
beneficial to some patients with CVI. Furthermore flavonoid has been previously shown to inhibit 
HIF-1α activity (Losso and Bawadi 2005). It has also been reported that the inhibition of HIF-1α 
activity by some flavonoids involves the oxygen-independent HIF-α regulation pathways 
including the MAPK and mTOR/p70S6 kinase/4E-BP1 (Garcia-Maceira and Mateo 2009; 
Mylonis et al. 2010). However, these pathways are complex and therefore this needs to be further 
investigated before any firm conclusion about the effects of MPFF on the HIF pathway in 
varicose and non-varicose veins can be made.  
The findings from this chapter suggest that increased expression of HIF-1α, HIF-2α and 
HIF target genes in varicose compared to non-varicose veins observed in Chapter 3 might be 
associated with varicose vein wall hypoxia. However, increased expression and activity of HIF-1α 
and HIF-2α can also be affected by other factors including mechanical stress which like hypoxia, 
is also related to CVD. Therefore, in the next chapter the effects of mechanical stretch on the HIF 
pathway were investigated in rat venous tissue.  
4.6. CONCLUSION 
Varicose and non-varicose vein wall hypoxia is associated with increased expression of 
HIF-1α, HIF-2α and HIF target genes, i.e. activation of the HIF pathway. Doxycycline 5μg/ml 
does not significantly alter the expression HIF-1α, HIF-2α and HIF target genes in hypoxic 
varicose and non-varicose veins. Meanwhile, MPFF 10
-5
M significantly reduces the expression of 
HIF-1α but not HIF-2α mRNA, and seems to cause a statistically insignificant reduction in HIF 
target genes expression in varicose vein organ cultures exposed to 16 hours of hypoxia.  
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5. REGULATION OF HIF AND VENOUS TONE BY VEIN WALL TENSION 
5.1. INTRODUCTION 
5.1.1. Venous Hypertension 
Venous hypertension or increased venous hydrostatic pressure is an important feature 
associated with CVD including in patients with varicose veins (Eberhardt and Raffetto 2005; 
Bergan et al. 2006). Venous hypertension and dilatation in CVD is thought to be caused by 
venous reflux and blood stasis in the lower limb (Raffetto and Khalil 2008b). Most, if not all, of 
the symptoms and signs associated with CVD are thought to be related to venous hypertension 
(Bergan et al. 2006). Venous hypertension is thought to activate the endothelial lining of the vein 
wall causing increased vascular permeability and extravasation of fibrinogen, α2-macroglobulin 
and erythrocytes into the dermal interstitium (Burnand et al. 1982; Thomas et al. 1988; Leu 1991; 
Herrick et al. 1992; Higley et al. 1995; Meissner et al. 2007a). Degradation of the interstitial 
erythrocytes and protein stimulates chronic injury and inflammatory responses including 
increased expression of ICAM-1 on endothelial cells of the microcirculation, and recruitment of 
macrophages, mast cells and lymphocytes (Leu et al. 1995; Pappas et al. 1997). Leukocytes in the 
extra-cellular space are found to surround the capillaries and postcapillary venules with matrix 
proteins, forming a perivascular cuff (Burnand et al. 1982; Leu 1991; Wilkinson et al. 1993; 
Higley et al. 1995; Leu et al. 1995; Pappas et al. 1997; Bishop 1998). The cuff is thought to 
prevent diffusion of nutrients and oxygen into the dermis (Bishop 1998; Meissner et al. 2007a). 
These inflammatory processes are thought to ultimately cause symptoms and signs of CVD 
including skin changes and venous ulcers (Raffetto 2009). 
5.1.2. Contribution of Venous Hypertension to the Initiation and Progression of 
Varicose Vein Formation 
Although valvular incompetence may precede vein dilatation in many cases, there is a 
significant body of evidence supporting the view that vein dilatation can also precede venous 
reﬂux, and that valvular dysfunction may be an epiphenomenon of vein wall dilatation (Gandhi et 
al. 1993; Labropoulos et al. 1999; Kirsch et al. 2000a; Kirsch et al. 2000b; Raffetto and Khalil 
2008b). Clinical studies using duplex ultrasonography have demonstrated that venous 
insufﬁciency can occur in varicosities without axial reﬂux of the superﬁcial, deep, or perforator 
veins (Labropoulos et al. 1997; Labropoulos et al. 1999). Furthermore, imbalances in ECM 
proteins may cause connective tissue changes prior to valvular insufﬁciency (Gandhi et al. 1993). 
Thus, venous hypertension and vein wall dilatation may contribute to the initiation and 
progression of varicose veins (Raffetto and Khalil 2008b; Lim and Davies 2009). Venous 
hypertension may damage the vein wall and valves directly through mechanical stress leading to 
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increases in vein wall tension. Alternatively, venous hypertension may also cause dilatation of the 
vein, separating the valves which in turn become incompetence. Either way, this would then cause 
venous reflux leading to further blood stasis and venous hypertension, creating a vicious cycle of 
progressive varicose vein formation. 
The potential for venous hypertension to initiate vein wall and valvular damage leading to 
venous insufficiency has been shown in animal models. In one rat model, acute venous 
hypertension was created through an AV fistula between the femoral artery and vein (Takase et al. 
2004; Pascarella et al. 2005; Misra et al. 2008a; Pascarella et al. 2008). The limbs with the AV 
fistula developed venous reflux and oedema which worsened over time (3-6 weeks) compared to 
the legs without AV fistula. Valvular and vein wall injury and fibrosis were also observed in the 
veins from the legs with AV fistula (Takase et al. 2004; Pascarella et al. 2005). Increased 
infiltration of inflammatory cells including granulocytes, monocytes and macrophages, and up-
regulation of P-selectin and ICAM-1 expression were found in the saphenous vein walls in the 
presence of AV fistula compared to those without (Takase et al. 2004; Pascarella et al. 2008). 
Furthermore, over expression of MMP-2 and MMP-9 were also measured in the veins subjected 
to venous hypertension (Pascarella et al. 2005; Misra et al. 2008a; Pascarella et al. 2008). 
Interestingly, rats that received oral treatment with MPFF demonstrated reduced leg oedema and 
venous reflux caused by the AV fistula (Pascarella et al. 2008). 
Although experimental AV fistula formation with the intention to cause varicose veins in 
human subjects is unlikely to gain ethical approval, venous hypertension can be indirectly induced 
through postural blood stasis (Saharay et al. 1998) or temporary venous occlusion using inflated 
blood pressure cuff (Signorelli et al. 2000). Venous hypertension induced by these methods has 
been shown to activate inflammatory processes in the venous system including endothelial 
activation. For example, postural venous stasis was found to augment the expression of adhesion 
molecules including endothelial leukocyte adhesion molecule-1 (ELAM-1 or E-selectin), ICAM-1 
and VCAM-1 in the plasma obtained from leg veins of patients with and without varicose veins 
(Saharay et al. 1998). In another study, venous hypertension induced through venous occlusion 
with an inflated cuff was shown to elevate the expression of IL-1β, IL-6 and TNF-α in patients 
with and without varicose veins, and more so in the former (Signorelli et al. 2000). Inflammation 
is an important feature of varicose veins. Increased expression of inflammatory markers such as 
VCAM-1, ICAM-1 and vWf by the endothelium of varicose compared to non-varicose veins have 
been measured (Aunapuu and Arend 2005; Somers and Knaapen 2006). Significantly more mast 
cells, monocytes and macrophages infiltration have been observed in varicose compared to non-
varicose veins (Yamada et al. 1996; Kakkos et al. 2003; Sayer and Smith 2004). Furthermore, 
cytokines including TNF-α, IL-1 and IL-6 have also been found to be elevated in patients with 
varicose compared to non-varicose vein (Signorelli et al. 2000; Takase et al. 2000a). Therefore, 
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similarities between inflammatory processes observed in varicose veins and those activated by 
experimental venous hypertension in non-varicose veins indirectly support that venous 
hypertension may contribute to the initiation and progression of varicose vein formation. 
5.1.3. Regulation of MMP by Mechanical Stretch 
As discussed earlier in Chapter 1, varicose vein wall demonstrated alteration in the MMP 
and TIMP balance. The expression and/or activity of MMP-1, -2, -3, -9, -12, and -13, and TIMP-1 
and -3 have been shown to be up-regulated in varicose compared to non-varicose veins (Raffetto 
and Khalil 2008b; Lim and Davies). The cause of the imbalances of MMP and TIMP in varicose 
veins remains unclear although several factors including hypoxia, mechanical stretch and low 
shear stress are likely to contribute (Michiels et al. 2002a; Somers and Knaapen 2006; Raffetto et 
al. 2008; Lim and Davies 2009). 
There is good evidence to support the regulation of MMPs by mechanical stress in many 
cell types. Studies have shown that human endothelial cells from muscle and lung tissues exposed 
to mechanical stretch or pressure were associated with over expression of MMP-2 (Haseneen et 
al. 2003; Milkiewicz and Haas 2005; Milkiewicz et al. 2007b). Increased release of MMP-9 has 
also been measured in immortalised human keratinocytes exposed to mechanical stretch (Reno et 
al. 2009). The expression of MMP-2, -9, and -14 have been reported to be up-regulated in 
ﬁbroblasts, endothelial cells, and SMC from human arteries and veins subjected to mechanical 
stretch (Asanuma et al. 2003; Grote et al. 2003; Zhou et al. 2005). 
Mechanical stretch of whole vascular tissues have also been implicated to alter the 
expression of MMPs. Increased MMP-9 has been observed in carotid arteries isolated from pigs 
and subjected to ex vivo increases in axial strain (Nichol et al. 2009). In another porcine model, 
increases in pressure distension caused up-regulation of MMP-2 and MMP-9 expression in the 
internal jugular vein graft (Chung et al. 2005). Meanwhile, thoracic aortic rings isolated from 
mice demonstrated significant increases in MMP-2 and MT1-MMP promoter activity when 
subjected to elevated vascular wall tension (Ruddy et al.). In human abdominal aortic aneurysm, 
the expression of aortic wall MMP-9 was associated with the diameter of the aneurysm suggesting 
the regulation of MMP-9 by mechanical stress in aortic wall (McMillan et al. 1997). 
5.1.4. Regulation of Venous Tone by Prolonged Increases in Vein Wall Tension and 
MMP 
Previous experiments on rat IVC carried out in our laboratory in Harvard University have 
shown that increases in the magnitude and duration of vein wall tension were associated with 
reduced contraction and over expression of MMP-2 and MMP-9 (Raffetto et al. 2008). MMP-2 
and MMP-9 were also found to induce significant relaxation of rat IVC, possibly through SMC 
hyperpolarisation and activation of large conductance Ca
2+
-dependent potassium channel 
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(Raffetto et al. 2007). These studies suggested that MMPs may play a role in the early stages of 
venous dilation secondary to venous hypertension (Raffetto et al. 2007). However, the upstream 
mechanisms linking the increases in vein wall tension to MMPs expression and venous dilation 
remain unclear. 
5.1.5. Regulation of HIF by Mechanical Stretch 
In addition to the regulation of HIF-α by oxygen tension, other factors such as hormones, 
cytokines and metallic ions as well as mechanical stretch may induce HIF-α expression (Gaber et 
al. 2005; Semenza 2009b). In terms of mechanical stress, HIF-1α and HIF-2α mRNA and protein 
expression were found to be increased in capillary endothelial cells of skeletal muscle fibres 
exposed to stretch (Milkiewicz and Haas 2005; Milkiewicz et al. 2007a; Milkiewicz et al. 2007b). 
Tendon fibroblasts and cartilage discs subjected to mechanical strain were also shown to express 
significantly more HIF-1 than those not being stretched (Petersen et al. 2004; Pufe et al. 2004). 
Also, HIF-1α was reported to be over expressed in rat cardiac and thoracic aortic vascular SMC 
exposed to mechanical stretch (Kim et al. 2002; Chang et al. 2003). 
The pathways involved in the induction of HIF-α by mechanical stretch may be different 
from those involved in oxygen-dependent HIF-α regulation. While the regulation of oxygen-
dependent HIF-α appears to occur at the level of protein stabilisation, the induction of HIF-α by 
mechanical stretch seems to occur at the level of gene transcription and translation and likely 
involves the PI3K and MAPK pathways (Milkiewicz et al. 2007a; Semenza 2009b). 
5.2. OBJECTIVES 
To investigate upstream mechanisms involved in the regulation of MMP-2 and MMP-9 
expression, and in the reduced venous contraction following prolonged increases in vein wall 
tension, the study described in this chapter aimed to test the hypothesis that increases in venous 
pressure or wall tension are associated with over expression of HIF-1α and HIF-2α, leading to up-
regulation in specific MMP expression in the vein wall and decreased venous contraction. Male 
Sprague-Dawley rat IVC segments were used to address the following objectives: 
1. To determine whether prolonged increases in vein wall tension are associated with 
increased expression of HIF-1α and HIF-2α 
2. To assess whether the increased expression of HIF-1α and HIF-2α in stretched veins is 
associated with increased MMP-2 and MMP-9 expression and decreased venous 
contraction 
3. To investigate whether blockade of the expression or activities of HIF-1α and HIF-2α 
prevents MMP over expression and improves contraction in stretched veins. 
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5.3. METHODS 
5.3.1. Basal Vein Wall Tension and Isometric Contraction Protocols 
Previously, Raffetto and colleagues have demonstrated that in rat IVC segments subjected 
to step-wise increases in basal tension (0.0625, 0.125, 0.25, 0.5, 1, 2 and 3g) for short duration of 
30 minutes, membrane depolarisation by 96mM KCl caused tension-dependent increases in IVC 
contraction that reached a maximum at 0.5g basal tension (Raffetto et al. 2008). Increases in basal 
tension to 1g and 2g did not show any further increase in KCl contraction compared with 0.5g. 
When the basal tension was increased to 3g, the KCl contraction was reduced significantly 
(Raffetto et al. 2008). Based on these findings, 0.5g was selected as the normal control basal 
tension that produces maximum contraction. Meanwhile, 2g was used as the maximum basal 
tension that would still produce maximum contraction without causing excessive vein wall stretch 
and tissue damage.  
All the vein segments that have been harvested were initially stretched under 0.5g basal 
tension and allowed to equilibrate for 1 hour. To determine the initial control contraction 
properties of the IVC, the tissue segments were stimulated twice with KCl 96mM solution and 
then once with PHE 10
-5
M. Each control IVC contraction was followed by three washes 10 
minutes each in Krebs solution. The bathing solution was then changed to Minimum Essential 
Medium (MEM) 1X with Hanks salts and L-glutamine (Gibco/Invitrogen, Grand Island, NY, 
USA) supplemented with 100 units/ml penicillin G sodium, 100 g/ml streptomycin sulphate and 
0.25 g/ml amphotericin B (Gibco/Invitrogen). The IVC segments were then subjected to one of 
the experimental conditions shown in Table 5-1. The assignment of the vein segments to these 
experimental conditions was performed randomly to reduce any potential bias. 
Table 5-1 Experimental conditions 
Condition Tension (g) Duration (hour) HIF-modulating agent 
1 0.5 18 Nil 
2 2 18 Nil 
3 2 18 U-0126 10
-5
 M 
4 2 18 Echinomycin 10
-6
 M 
5 2 18 17-DMAG 10
-5
 M 
6 2 18 DMOG 10
-4
 M 
7 Experiment was stopped straight after the initial basal KCl- and PHE-
contraction were elicited 
 
Previously, prolonged increases in rat IVC wall tension for 24 hour were shown to be 
associated with decreased contraction and increased expression of MMP-2 and MMP-9. In the 
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present study we used a slightly shorter 18 hour period of stretch to avoid possible negative 
feedback mechanisms that could down-regulate HIF-α (Webb et al. 2009). Previous studies on 
hypoxia regulation of HIF-α used a duration of about 16 hour to avoid the negative feedback 
mechanisms that may complicate the findings (Elvidge et al. 2006).  
After 18 hour of incubation at the specific basal tension, the IVC segments were washed 
in Krebs solution three times 10 minutes each, and contraction to KCl 96mM and PHE 10
-5
M was 
elicited. The fold change of contraction was calculated by dividing the contraction to PHE and 
KCl after prolonged tension for 18 hour by the corresponding initial control contraction at 0.5g 
tension for 1 hour. At the end of the contraction experiment, the vein tissues were stored at -80°C 
in RNAlater® (Ambion, Foster City, CA, USA) for RT-PCR and Q-PCR, and in Krebs solution 
for western blot analysis. Figure 5-1 summarises the experimental protocol used 
 
18 hours in culture 
medium with or 
without HIF 
modulating agent
KCl KCl PHE
PHEKCl KCl
0.5g
Experiment 
stopped and 
tissues stored
a b c d
1 hour of basal 
tension
0.5g or 2g
3 x 10mins 
wash
3 x 10mins 
wash
3 x 10mins 
wash
3 x 10mins 
wash
3 x 10mins 
wash
3 x 10mins 
wash
Magnitude of 
contraction
Time   
Figure 5-1 Isometric contraction experimental protocol used in my study 
Schematic diagram summarises the isometric experimental protocol, drawn not to scale. The height of a, b, 
c and d corresponds to the maximum contraction of the vein segment when stimulated with KCl 96mM or 
PHE 10
-5
M. Fold change of contraction of KCl- and PHE-induced contraction can be calculated as c/a and 
d/b, respectively. 
 
5.3.2. Selection of HIF Inhibitors 
Various pharmacological agents with different modes of action, both already in clinical 
use and still being tested in the laboratory, have been found to inhibit the expression and/or 
activity of HIF-α (Table 5-2). A literature review was performed which found that all of these 
agents, or at least those that were commercially available, possess other non-HIF related 
activities. For example, YC-1 is known to inhibit the expression of HIF-1α (Yeo et al. 2003). 
However, since YC-1 is a soluble guanylyl cyclase (sGC) stimulator, it can also cause vascular 
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relaxation through the activation of the sGC/nitric oxide pathway (Gunnett et al. 2005), hence not 
suitable to be used in the current study. 
Since there was no pharmacological agent that inhibits the expression or activity of HIF 
without causing other non-HIF related activity, three different HIF inhibitors acting at different 
level of HIF regulation were used. The HIF inhibitors selected were the MAPK inhibitor (U0126), 
heat shock protein (HSP) 90 inhibitor (17-DMAG) and DNA-binding activity blocking agent 
(echinomycin). The decision on the number and types of HIF inhibitors used was based on 
findings from literature search, discussion with supervisors, and advice from Dr Greg Semenza, a 
leading expert of HIF who described HIF-1α. 
5.3.3. Statistical Analysis 
The data were presented as meansSEM, with n=number of experiments. The data were 
first analyzed using ANOVA. When a statistical difference was observed, the data were further 
analysed using Student‟s t-test for unpaired data for comparison of two means (Graphpad Prism 
5.00, Graphpad Software, San Diego, CA). Differences were considered statistically significant 
when P<0.05. 
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Table 5-2 Various types and examples of HIF inhibitors 
Mechanism of action or class Examples 
Topoisomerases Topoisomerase I: Topotecan, Topoisomerase II: NSC644221 
Cyclin-dependent kinases Flavopiridol 
VHL tumour suppressor  Bioengineered VHL tumour suppressor complex  
PI3K-AKT-mTOR and RAS-RAF-
MEK-ERK pathways 
 
BCR-ABL: imatinib/Gleevec 
EGFR: Gefitinib/Iressa, Erlotinib/Tarceva, Cetuximab/C225 
HER2neu: Transtuzumab/Herceptin 
mTOR: Temsirolimus/CCI-779, Everolimus/RAD-001, Rapamycin 
Farnesyltransferase: Lonafarnib/SCH66336 
Tyrosine kinase: Genistein 
MEK: PD98059, U0126 
COX2: NS398, Ibuprofen, Celecoxib 
PI3K inhibitors: Wortmannin, LY294002, ZSTK474, SU5416 
Heat shock protein (HSP)-90 
inhibitor 
 
Geldanamycin, 17-AAG (Geldanamycin analogue), 
Radicicol/KF58333, 17-DMAG /NSC 707545, Dimethyl-bisphenol 
A 3,3‟,5,5‟-tetra-tert-butyl-4,4‟bis(hydroxyphenyl), Apigenin, 
Vitexin/apigenin-8-C-β-D-glucopyranoside 
Thioredoxin 1-methylpropyl-2-imidazolyl-disulfide / PX12, Pleurotin 
sGC activator YC-1  
Microtubule modifier 
 
Oestrogen: 2-methoxyestradiol, 2-hydroxy oestradiol  
Vinca alkaloid: Vincristine, Vinblastine 
Taxane: Taxol, Taxotere 
Epothilone B, Colchicine 
FIH-1 activation Bortezomib 
Activation of proteosome Pseudolaric acid B  
Activation of PHD R59949, Ciclosporin A 
Blockade of HIF induction NSC-134754, NSC-607097  
Decrease HIF protein stability and 
transactivating activity 
CAY10585, Sphingomyelin synthase/Phosphatidylcholine 
Phospholipase C (PC-PCL) inhibitor/ D609 (tricyclodecan-9-
ylxanthogenate), Amphotericin, PX-478 
Inhibition of NADPH oxidase 
(NOX) activity  
Diphenyleneiodonium chloride, Rotenone, Myxothiazol, and NaCN 
Histone deacetylases LAQ824, FK228, SAHA/Vorinostat, Trichostatin A 
Inhibition of synthesis and decrease 
of HIF stability 
Chrysin, 5,7-Dihydroxyflavone 
 
Regulation of oxidative-stress 
mediated pathway 
Artemisinin 
 
Disruption of the binding of p300 to 
HIF subunit 
Chetomin 
 
Modulating the oxygen sensing Emetine dihydrochloride, Klugine, Isocephaeline  
RNA antagonist EZN-2968/SPC2968 
Block HIF mediated transcription SNS-032, D609 (Tricyclodecan-9-yl xanthogenate) 
Inhibits HIF DNA binding capacity Echinomycin (NSC-13502), Polyamides, DJ12 (150umol/L) 
Inhibition of HIF protein 
accumulation (unknown 
mechanism) 
4-O-methylsaucerneol, Manassantins, D-Glucosamine, 1-butanol (1-
BtOH), Berberin, Laurenditerpenol 
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5.4. RESULTS 
5.4.1. KCl-Induced Contraction 
KCl was chosen to determine the tension-contraction relation because KCl 96mM 
produces maximum and reproducible vein contraction that could be repeated multiple times. KCl 
causes contraction by allowing Ca
2+
 entry into the cells when the potassium-dependent Ca
2+
 
channel is activated. KCl-induced contraction is also receptor-independent, i.e. not dependent on 
α-adrenergic or angiotensin II receptors, thus avoiding possible receptor saturation or 
desensitisation with repeated agonist stimulation which could signiﬁcantly affect the maximum 
vein contraction at the speciﬁc basal tension. 
When assessing for KCl-induced contraction, each IVC was stimulated twice with KCl 
96mM with three washes in between the two stimulations. The second contraction measurement 
was measured and used for analysis. Since the vein tissue equilibrated for an hour under basal 
tension of 0.5g, this might not allow the first KCl treatment to open all of the voltage-gated 
channels activated by KCl. Stimulating the vein tissue to initially contract and then returning to 
the resting membrane potential, usually around -70mV, allows the full recruitment of voltage-
gated channels for maximum contraction, hence the second KCl contraction was performed and 
measured for analysis. This also explains the observation that the second KCl-induced contraction 
was often larger and more robust than the first. Vein A in Figure 5-2 demonstrates a typical 
example of two consecutive initial basal KCl-induced isometric contractions of a rat IVC 
segment. 
5.4.2. PHE-Induced Contraction 
PHE is an α1-adrenergic receptor agonist which is known to cause vasoconstriction. In rat 
IVC, PHE stimulates venous contraction. Stimulating IVC segments with PHE 10
-5
 M enabled the 
assessment of rat IVC contraction specific to α1-adrenergic receptor. PHE-induced contraction 
was smaller in magnitude than the KCl-induced contraction as observed in Figure 5-2. Venous 
tone regulation by α1-adrenergic receptor was investigated because previous studies have 
demonstrated that PHE-induced contraction was absent in severe varicose veins (Brunner et al. 
2001). Figure 5-2 (Vein A) demonstrates a typical example of basal PHE-induced isometric 
contractions of a rat IVC segment.  
5.4.3. Tissue Viability 
One of the advantages of using this system was that the functional viability of each 
segment of vein harvested was able to be assessed simultaneously while carrying out the isometric 
contraction experiment. The presence of a measurable KCl- and PHE-induced contraction 
indicated that the vein segments were functionally viable. Meanwhile, segments of veins that did 
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not produce any initial basal contraction were excluded from further analysis as they were 
presumed non-viable or dead, most likely secondary to trauma from the tissue dissection during 
harvesting. The functional viability of the vein segments following prolonged tension of 18 hours 
with or without the presence of HIF modulating agent was also reassured with the presence of 
measurable contraction when stimulated with KCl and PHE. Figure 5-2 demonstrates typical 
initial control isometric contraction traces of a functionally viable (Vein A) and a non-viable vein 
(Vein B) segment when stimulated with KCl and PHE. 
 
Figure 5-2 Initial control KCl- and PHE-induced contraction of a viable and non-
viable vein segment in a same experiment 
Real traces of initial KCl- and PHE-induced contraction of two IVC segments performed in a same 
experiment. Vein A was clearly functionally viable by demonstrating measurable contraction when 
stimulated with KCl and PHE. In contrast, vein B was clearly non-viable since there was no measurable 
contraction observed when stimulated with KCl and PHE 
 
5.4.4. Effect of Prolonged Increases in Basal Tension on KCl Contraction 
In IVC segments under 0.5g basal tension for 1 hour, membrane depolarisation by high 
KCl 96mM caused significant venous contraction (Figure 5-3). To study the effect of prolonged 
low basal tension on KCl-induced contraction, some of the vein segments (n=7) were subjected to 
18 hours of 0.5g of basal tension and KCl contraction was then measured. Compared to the initial 
control IVC contraction at 0.5g tension for 1 hour, the fold change of contraction to KCl after 
prolonged basal tension at 0.5g was 1.1±0.06 (Figure 5-3). Therefore, prolonged low basal tension 
of 0.5g did not seem to alter the magnitude of the KCl-induced contraction compared to the 
control KCl-contraction in rat IVC. 
KCl KCl PHEWash Wash Wash Wash Wash Wash Wash
Vein A
Vein B
timeMagnitude of 
contraction
Time
Chapter 5 
182 
To assess the effect of prolonged high tension on KCl-induced contraction, some of the 
IVC segments (n=10) were exposed to 18 hours of basal tension at 2g. The IVC contraction 
induced by KCl after prolonged increases in basal tension at 2g was significantly reduced 
compared to those that were stretched with 0.5g for 18 hours, with a fold change of 0.72±0.05 
(P<0.001; Figure 5-3). This finding indicated that prolonged increases in vein wall tension caused 
significantly less venous contraction in rat IVC when stimulated with KCl. 
5.4.5. Effect of HIF Inhibitors on KCl-Induced Contraction of IVC Segments Exposed to 
Prolonged Stretch 
To study if the expression of HIF was associated with the reduction of KCl-induced 
contraction following prolonged increases in vein wall tension, HIF expression was inhibited in 
some of the rat IVC segments during the 18 hour of mechanical stretch. Since there was no 
available HIF inhibitor that was specific, the effects of three different HIF inhibitors; U0126, 17-
DMAG and echinomycin on KCl-induced contraction in IVC segments exposed to prolonged 2g 
of mechanical stretch were examined. The reduction of KCl contraction in IVC segments exposed 
to prolonged 2g basal tension for 18 hour was reversed by U0126 10
-5
M (fold change of 
1.14±0.05; n=7, P<0.001; Figure 5-3) and echinomycin 10
-6
M (fold change of 1.11±0.15; n=7, 
P=0.0068; Figure 5-3). On the other hand, treatment with the HIF inhibitor 17-DMAG 10
-5
M did 
not restore the reduced KCl-induced contraction in IVC segments exposed to prolonged 2g 
tension for 18 hour, with a fold change of contraction of 0.48±0.06 (n=7, P=0.0068; Figure 5-3). 
All three HIF inhibitors used in the study significantly altered the KCl-induced 
contraction in rat IVC subjected to prolonged increases in vein wall tension. This observation 
suggested that the expression of HIF might be regulated by mechanical stretch in rat IVC and 
associated with alteration in venous tone. However, only two of the three HIF inhibitors used 
reversed the reduction of KCl-induced contraction in rat IVC exposed to prolonged mechanical 
stretch, while the third agent caused further venous relaxation. The inconsistency was likely to be 
due to the non-specificity of the HIF inhibitors, a problem that had already been anticipated when 
selecting the HIF inhibitors. 
5.4.6. Effect of HIF Stabilisation on KCl-Induced Contraction of IVC Segments Exposed 
to Prolonged Stretch 
Since HIF inhibition with pharmacological agents had been anticipated to be limited by 
their non-specificity, the effect of HIF stabilisation by the PHD inhibitor DMOG on KCl-induced 
contraction of rat IVC segments exposed to prolonged 2g stretch was examined. Treatment with 
DMOG further reduced KCl-induced contraction in IVC segments exposed to prolonged 2g basal 
tension for 18 hour compared to those untreated (fold change of 0.57±0.01; n=8, P=0.0105; 
Figure 5-3). This observation further supported that stabilisation or up-regulation of HIF 
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expression were associated with the reduction of KCl-induced contraction in rat IVC following 
prolonged increases in vein wall tension. 
 
Figure 5-3 Effects of prolonged increases in basal tension and HIF modulators on 
KCl-induced contraction in rat IVC 
IVC segments were subjected to initial 0.5g basal tension for 1 hour and a control contraction to membrane 
depolarisation by KCl 96mM was elicited. The veins were then subjected to either 0.5g or 2g tension for 18 
hour and a second KCl 96mM contraction was elicited. Some of the veins subjected to 2g tension were also 
treated with the HIF inhibitor U0126 10
-5
M, 17-DMAG 10
-5
M, or echinomycin 10
-6
M, or with the PHD 
inhibitor DMOG 10
-4
M. The second KCl contraction was measured as fold change compared to the initial 
control contraction at 0.5g basal tension for 1 hour. The top drawings are representative contraction traces 
drawn to scale when an IVC segment was stimulated with KCl 96mM. Data columns represent 
means±SEM of 7 to 10 experiments. 
* Significantly reduced (P<0.05) compared to veins under 0.5g tension for 18 hour (dotted column). 
§ Significantly enhanced (P<0.05) compared to veins under 2g tension for 18 hour (black column). 
 
5.4.7. Effect of Prolonged Increases in Basal Tension on PHE Contraction 
In IVC segments under 0.5g basal tension for 1 hour, -adrenergic receptor stimulation 
with PHE 10
-5
M caused significant contraction (Figure 5-4). To study the effect of prolonged low 
basal tension on PHE-induced contraction, some of the vein segments (n=7) were subjected to 18 
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hours of 0.5g of basal tension and PHE-contraction was then measured. Compared to the initial 
control IVC contraction at 0.5g tension for 1 hour, the fold change of contraction to PHE after 
prolonged basal tension at 0.5g for 18 hour was 2.0±0.35 (Figure 5-4). Therefore, prolonged low 
tension seemed to increase the magnitude of the PHE-induced contraction in rat IVC by two-fold. 
To assess the effect of prolonged high tension on PHE-induced contraction, some of the 
IVC segments (n=10) were exposed to 18 hours of basal tension at 2g. Under this condition, the 
PHE-induced contraction was significantly decreased compared to those that were stretched with 
0.5g for 18 hours (fold change of 0.87±0.13; P=0.0021; Figure 5-4). Therefore, this observation 
supported that prolonged increases in vein wall tension caused significant reduction in venous 
contraction in rat IVC treated with PHE. 
5.4.8. Effect of HIF Inhibitors on PHE-Induced Contraction of IVC Segments Exposed 
to Prolonged Stretch 
To study if the expression of HIF was associated with the reduction of PHE-induced 
venous contraction observed following prolonged increases in vein wall tension, the effects of the 
three different HIF inhibitors described earlier were then examined. The PHE-induced contraction 
of IVC segments exposed to prolonged 2g basal tension for 18 hour was restored by U0126 10
-5
M 
(fold change of 1.38±0.15; n=7, P=0.0216; Figure 5-4) and echinomycin 10
-6
M (fold change of 
2.02±0.34; n=7, P=0.0027; Figure 5-4). On the other hand, treatment with the HIF inhibitor 17-
DMAG 10
-5
M did not restore the reduced PHE-induced contraction, with a fold change of 
contraction of 0.34±0.04 (n=7, P=0.0018; Figure 5-4). 
All the three HIF inhibitors used in my study significantly altered the PHE-induced 
contraction in rat IVC subjected to prolonged increases in vein wall tension. Only two of the three 
HIF inhibitors used restored the PHE-induced contraction in rat IVC exposed to prolonged 
mechanical stretch, while the third agent caused further venous relaxation. These findings were 
similar to those observed in KCl-induced contraction earlier. Again, the inconsistency was likely 
to be due to the non-specificity of the HIF inhibitors. 
5.4.9. Effect of HIF Stabilisation on PHE-Induced Contraction of IVC Segments 
Exposed to Prolonged Stretch 
In the next step, the effect of HIF stabilisation by DMOG on PHE-induced contraction of 
rat IVC segments exposed to prolonged stretch was also examined. Treatment of IVC segments 
exposed to prolonged 2g basal tension for 18 hour with DMOG 10
-4
M further decreased PHE-
induced contraction compared to those untreated (fold change of 0.47±0.06; n=8, P=0.0058; 
Figure 5-4). 
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Figure 5-4 Effects of prolonged increases in basal tension and HIF modulators on 
PHE-induced contraction in rat IVC 
IVC segments were subjected to initial 0.5g basal tension for 1 hour and a control PHE 10
-5
M contraction 
was elicited. The veins were then subjected to either 0.5g or 2g tension for 18 hour and a second PHE 10
-5
 
M contraction was elicited. Some of the tissues subjected to 2g tension were also treated with the HIF 
inhibitor U-0126 10
-5
M, 17-DMAG 10
-5
M, or echinomycin 10
-6
M, or with the HIF stabiliser DMOG 10
-4
M. 
The second PHE contraction was measured as fold change compared to the initial control contraction at 
0.5g basal tension for 1 hour. The top drawings are representative contraction traces drawn to scale when an 
IVC segment was stimulated with PHE 10
-5
M. Data columns represent means±SEM of 7 to 10 experiments. 
* Significantly reduced (P<0.05) compared to veins under 0.5g tension for 18 hr (dotted column). 
§ Significantly enhanced (P<0.05) compared to veins under 2g tension for 18 hr (black column). 
 
5.4.10. Q-PCR Analysis of HIFs 
Q-PCR analysis demonstrated detectable expression of HIF-1α and HIF-2α mRNA in 
control IVC under 0.5g basal tension for 1 hour. Small but significant increases in the expression 
of HIF-1α and HIF-2α mRNA were observed in IVC segments exposed to 0.5g basal tension for 
18 hour. On the other hand, significant and robust increases in the mRNA expression of HIF-1α 
and HIF-2α were observed in IVC segments exposed to prolonged 2g basal tension for 18 hour 
(Figure 5-5). The increases in HIF-1α and HIF-2α mRNA expression in stretched veins were 
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reversed in IVC treated with the HIF inhibitor U0126, and to a less extent with 17-DMAG or 
echinomycin, but not with the HIF stabiliser DMOG (Figure 5-5). 
 
 
Figure 5-5 Effects of prolonged increases in basal tension and HIF modulators on the 
expression of HIF-1 and HIF-2 mRNA in rat IVC 
IVC segments were subjected to 0.5g basal tension for 1 hour, 0.5g tension for 18 hour, high 2g tension for 
18 hour, and prolonged 2g tension plus the HIF inhibitor U-0126 10-5M, 17-DMAG 10-5M, or 
echinomycin 10-6M, or the HIF stabiliser DMOG 10-4M. The veins were rapidly frozen for mRNA 
analysis. Q-PCR analysis was performed to measure the expression of HIF-1 (A) and HIF-2 mRNA (B) 
relative to the house keeping gene -actin. Data represent means±SEM, n=4. 
* Significantly increased (P<0.05) compared to veins under 0.5g tension for 18 hour (dotted column). 
§ Significantly reduced (P<0.05) compared to veins under 2g tension for 18 hour (black column). 
 
5.4.11. Q-PCR Analysis of MMPs 
Q-PCR analysis also demonstrated prominent expression of MMP-2 and MMP-9 mRNA 
in control IVC under 0.5g basal tension for 1 hour. In IVC segments exposed to 0.5g tension for 
18 hour, small increases in the expression of MMP-2 and MMP-9 mRNA were observed. In 
contrast, in IVC segments exposed to prolonged 2g basal tension for 18 hr significant and robust 
increases in the expression of MMP-2 and MMP-9 mRNA were observed (Figure 5-6). The 
increases in MMP-2 or MMP-9 mRNA expression in stretched veins were reversed in IVC treated 
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with the HIF inhibitor U0126, 17-DMAG or echinomycin, but not with the HIF stabiliser DMOG 
(Figure 5-6). 
 
 
Figure 5-6 Effects of prolonged increases in basal tension and HIF modulators on the 
expression of MMP-2 and MMP-9 in rat IVC 
IVC segments were subjected to 0.5g basal tension for 1 hour, 0.5g tension for 18 hour, high 2g tension for 
18 hour, and prolonged 2g tension plus the HIF inhibitor U-0126 10
-5
M, 17-DMAG 10
-5
M, or echinomycin 
10
-6
M, or the HIF stabiliser DMOG 10
-4
M. The veins were rapidly frozen for mRNA analysis. Q-PCR 
analysis was performed to measure the expression of MMP-2 (A) and MMP-9 mRNA (B) relative to the 
house keeping gene -actin. Data represent means±SEM, n=4. 
* Significantly increased (P<0.05) compared to veins under 0.5g tension for 18 hour (dotted column). 
§ Significantly reduced (P<0.05) compared to veins under 2g tension for 18 hour (black column). 
 
5.4.12. Western Blot Analysis of HIFs and MMPs 
Western blot analysis in control IVC revealed little immunoreaction at 100kDa 
corresponding to HIF-1α, but a robust immunoreactive band In IVC segments under prolonged 2g 
tension for 18 hour (Figure 5-7A). A band at 116kDa corresponding to HIF-2α was detected in 
control IVC under 0.5g tension for 1 hour, and was significantly increased in IVC under 
prolonged 2g tension for 18 hour (Figure 5-7B). Western blot analysis also revealed an 
immunoreactive band at 72kDa corresponding to proMMP-2 and a second band at 63kDa 
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corresponding to active MMP-2 in control IVC, that were significantly increased in IVC under 
prolonged 2g tension for 18 hour (Figure 5-7C). In control IVC, a little immunoreaction at 92kDa 
corresponding to MMP-9 could be detected. In IVC segments exposed to prolonged 2g tension for 
18 hour a significant and robust MMP-9 immunoreactive band was observed (Figure 5-7D). 
 
 
 
Figure 5-7 Effects of prolonged increases in basal tension on the protein expression 
of HIF-1, HIF-2, MMP-2 and MMP-9 in rat IVC 
IVC segments were subjected to 0.5g basal tension for 1 hour, or high 2g tension for 18 hour, Western blot 
analysis was performed to measure the protein amount of HIF-1 (A), HIF-2 (B), MMP-2 (C) and MMP-
9 (D) relative to the house keeping protein -actin. Data represent means±SEM, n=4 to 8 experiments. 
*Significantly increased (P<0.05) compared to control veins under 0.5g basal tension for 1 hour. 
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5.5. DISCUSSION 
This study demonstrated the novel finding that prolonged increases in vein wall tension 
were associated with over expression of HIF-1 and HIF-2 in rat IVC. The up-regulation of 
HIF-1 and HIF-2 secondary to prolonged increases in rat IVC wall tension was associated with 
increased MMP-2 and MMP-9 expression and reduced venous contraction. 
We have estimated the venous pressure corresponding to the basal tension on IVC 
segments using the formula P=F/A, where P=pressure in gram force/cm
2
, F=force, A=area, and 
assuming an average IVC diameter of 1.5mm as detected by histology. At 0.5g tension the 
pressure generated is 28.4 gram force/cm
2
 or 20.8 mmHg, and at 2g tension the pressure 
generated is 113.2 gram force/cm
2
 or 83.4 mmHg (Raffetto et al. 2008). These pressures are in 
accordance with the venous pressures observed in the lower extremity of humans, which could 
vary between 10 and 100 mmHg depending on posture and muscular contraction. Although the 
estimated pressure generated by 0.5g and 2g tension appeared similar to lower extremity venous 
pressure in humans, it is important to note that the present study was conducted on rat IVC and, 
therefore, any extrapolation of the findings in the rat veins to human varicose veins should be 
interpreted with extreme caution. 
Previous studies demonstrated an increase of MMP-2 expression in mechanically 
stretched skeletal muscle fibres (Milkiewicz and Haas 2005). Also, previous experiments on rat 
IVC have demonstrated that increases in the magnitude and duration of vein wall tension were 
associated with reduced contraction and increased protein amount of MMP-2 and MMP-9 
(Raffetto et al. 2008). Raffetto et al. have previously performed immunohistochemistry studies 
and demonstrated that MMP-2 and MMP-9 were expressed in tunica intima, media and adventitia 
of rat IVC. Significant increases in MMP-2 and MMP-9 immunostaining were observed in the 
tunica intima of IVC subjected to 2g basal tension for 24 hours as compared to tissues under 0.5g 
basal tension. Also, a relative increase in the MMP immunostaining in the media vascular SMC 
could be observed in tissues under 2g tension for 24 hours (Raffetto et al. 2008). These data 
suggested that the endothelium and vascular SMC may function as sources/targets of MMPs in rat 
IVC. Other studies have shown the expression of MMP-9 in vascular SMC of rat aorta (Knipp et 
al. 2004) and human saphenous vein (Turner et al. 2005).  
MMP-2 and MMP-9 have also been shown to cause significant relaxation of Ca
2+
-
dependent contraction in rat IVC (Raffetto et al. 2007). Consistent with previous reports (Raffetto 
et al. 2008), both the PHE-induced α-adrenergic receptor-mediated contraction and the KCl-
induced receptor-independent response were reduced in rat IVC exposed to prolonged mechanical 
stretch. Because membrane depolarisation by KCl mainly stimulates Ca
2+
 entry (Khalil and van 
Breemen 1988), the reduced contraction in IVC segments under prolonged stretch is likely to be 
due to reduction in the Ca
2+
-dependent pathways or downstream mechanism of vascular SMC 
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contraction. The present observations that prolonged increases in the magnitude and duration of 
basal tension were associated with decreased IVC contraction and increased expression of MMP-
2 and MMP-9 are consistent with the previous reports and further support a relationship between 
vein wall tension secondary to stretch, MMP expression and decreased venous contraction. 
In search for the upstream mechanisms linking the increases in vein wall tension to the 
changes in MMP-2 and MMP-9 expression and the reduction in venous contraction, this study 
demonstrated HIF-1α and HIF-2α as potential candidates for several reasons. First, the reduction 
in venous contraction associated with prolonged vein wall stretch was reversed by the HIF 
inhibitors U0126 and echinomycin. Secondly, the reduction in venous contraction associated with 
prolonged vein wall stretch was enhanced in the presence of the HIF stabiliser DMOG. Thirdly, 
prolonged increases in vein wall stretch were associated with increased expression of HIF-1α and 
HIF-2α. Finally, the increased expression of MMP-2 and MMP-9 associated with prolonged vein 
wall stretch were reversed in veins treated with HIF inhibitors. 
In this study, the potential involvement of HIF in the decreased venous contraction 
associated with prolonged vein wall stretch was first examined using HIF inhibitors (Figure 5-8). 
In order to circumvent potential lack of specificity, three different HIF inhibitors with different 
mechanisms of action were used. U0126 is a MAPK inhibitor which has been shown to inhibit the 
increases in HIF-α mRNA expression and protein amount in response to mechanical stretch of rat 
skeletal muscle microvascular endothelial and aortic vascular SMC (Chang et al. 2003; 
Milkiewicz et al. 2007a). Echinomycin is a small molecule inhibitor of HIF-1 DNA binding 
activity. Echinomycin specifically inhibits the binding of HIF to the HRE sequence on the 
promoter of HIF target genes (Kong et al. 2005). In this study, U0126 and echinomycin restored 
venous contraction of rat IVC exposed to prolonged increases in vein wall tension, suggesting a 
role of HIF in the reduced venous contraction associated with prolonged vein wall stretch. 
To further examine the role of HIF in the decreased venous contraction associated with 
prolonged increases in vein wall tension, the effect of stabilising HIF with DMOG on venous 
contraction was investigated. DMOG is known to inhibit PHD and FIH-1, which mediate the 
oxygen-dependent degradation and destabilisation of HIF- protein. Therefore, DMOG increases 
the amount and activity of HIF-α protein even in normoxia (Gelse et al. 2008). The IVC segments 
treated with DMOG during prolonged increases of vein wall tension demonstrated further 
reduction in venous contraction, consistent with a role of HIF in the reduced venous contraction 
associated with prolonged vein wall stretch. 
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Figure 5-8 Potential relation between mechanical vein wall stretch, HIF and MMP 
expression 
A schematic diagram depicting the potential relation between mechanical vein wall stretch, HIF and MMP 
expression, and vein relaxation. Also, shown are different HIF modulators and their site of action 
 
To directly examine if HIF-α in the reduced venous contraction is associated with 
prolonged increases in vein wall tension, the effects of prolonged vein wall stretch on HIF 
expression were examined. Studies have shown that HIF-1α and HIF-2α are expressed in vascular 
endothelial cells (Hodges et al. 2005; Hossein Ghaderian et al. 2010) and vascular SMC (Schultz 
et al. 2006; Lambert et al. 2010). Also increased expression of HIF-α in response to mechanical 
stretch has been demonstrated in several tissues and cell types including myocardium (Kim et al. 
2002), fibroblasts (Petersen et al. 2004), vascular SMC (Chang et al. 2003), and skeletal muscle 
fibres (Milkiewicz and Haas 2005; Milkiewicz et al. 2007a). In support of transcriptional 
regulation of HIF-1α by mechanical stress, Chang and colleagues reported up-regulation of HIF-
1α mRNA by about two-fold in vascular SMC subjected to cyclic stretch for 4 hour (Chang et al. 
2003). Also, Milkiewicz and colleagues demonstrated increased HIF-1α and HIF-2α mRNA and 
proteins in rat capillary endothelial cells of skeletal muscle fibres exposed to prolonged 
mechanical stretch (Milkiewicz et al. 2007a). Other studies have supported that the protein 
amount and activity of HIF-1α and HIF-2α are regulated by mechanical stretch (Chang et al. 
2003; Ke and Costa 2006; Milkiewicz et al. 2007a). Kim and colleagues have demonstrated an 
Proteosomal
degradation
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up-regulation of HIF-1α protein in response to increased mechanical stress of the left ventricular 
wall by aortocaval shunt formation or intraventricular balloon expansion (Kim et al. 2002). 
Similar increases in the amount of HIF-1α protein have been reported in fibroblasts that were 
cyclically stretched for 24 hour (Petersen et al. 2004). Although HIF-1α and HIF-2α have been 
identified in vascular tissues (Ke and Costa 2006; Lee et al. 2006; Patel and Simon 2008; 
Semenza 2010b), their role in venous tissue has not been thoroughly examined. In this study, 
analysis of rat IVC segments following isometric contraction with Q-PCR demonstrated that HIF-
1α and HIF-2α mRNA were expressed in rat IVC. Importantly, the HIF-1α and HIF-2α mRNA 
were over expressed in rat IVC subjected to prolonged mechanical stretch, supporting an 
association between prolonged mechanical vein wall stretch and HIF-1α and HIF-2α regulated 
pathways. Furthermore, western blot analysis revealed no HIF-1α protein and little HIF-2α 
protein in IVC segments under control basal tension, but significant protein amounts of HIF-1α 
and HIF-2α in IVC subjected to prolonged mechanical stretch. Thus both the Q-PCR and western 
blot data supported the idea that prolonged vein wall stretch is associated with increased 
expression of HIF-1α and HIF-2α. 
It is unlikely that the observed up-regulation of HIF-1α and HIF-2α mRNA and protein in 
rat IVC subjected to prolonged mechanical stretch was a response to external hypoxic stimuli. In 
the present study, the culture medium in which the rat IVC segments were incubated when 
subjected to prolonged tension was exposed to room air. Furthermore, during the measurement of 
the isometric contraction properties of the rat IVC exposed to control basal tension or prolonged 
stretch, the vein segments were incubated in Krebs solution continuously bubbled with oxygen. 
Furthermore, the observed up-regulation of HIF-1α and HIF-2α mRNA could not be due to 
hypoxia-induced regulation of HIF because hypoxia usually causes stabilisation and up-regulation 
of HIF protein rather than de novo mRNA expression (Milkiewicz et al. 2007a; Semenza 2009b). 
The observations that the HIF inhibitor U0126 and to a lesser extent echinomycin inhibited the 
over expression of HIF-1α and HIF-2α mRNA and prevented the reduction in IVC contraction 
associated with prolonged vein wall stretch are consistent with a role of HIF-1α and HIF-2α in the 
reduced venous contractile response during wall stretch (Figure 5-8). In addition, the observation 
that DMOG, a HIF protein stabiliser, did not reduce the expression of HIF mRNA while further 
reducing venous contraction supports the contention that HIF-1α and HIF-2α are involved in the 
reduced venous contraction associated with prolonged vein wall stretch. 
The regulation of venous contraction by mechanical stretch and HIF also involves MMPs. 
Studies have shown that the expression and activity of MMP-2 and MMP-9 are regulated by HIF 
(Fujiwara et al. 2007; Misra et al. 2008b). It has also been previously demonstrated that prolonged 
increases in IVC wall tension were associated with increased protein amount of MMP-2 and 
MMP-9 (Raffetto and Khalil 2008a). Consistent with the previous report, prolonged increases in 
IVC tension were associated with increased expression of MMP-2 and MMP-9 mRNA and up-
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regulation of MMP-2 and MMP-9 protein. Importantly, the increased MMP-2 and MMP-9 mRNA 
expression associated with prolonged vein wall stretch was reversed in veins treated with the HIF 
inhibitors U0126, 17-DMAG and echinomycin. The inhibition of MMP expression by HIF 
inhibitors supports the hypothesis that over expression of MMP-2 and MMP-9 in rat IVC 
subjected to prolonged mechanical stretch is regulated by HIF-1α and HIF-2α. 
It is important to note that during acute stretch of capillary endothelial cells of skeletal 
muscle, an increase in DNA-binding activity of HIF-1α and HIF-2α may occur as an early event 
but without up-regulation of HIF-1α and HIF-2α protein translation (Milkiewicz et al. 2007a). On 
the other hand, increased HIF-1α and HIF-2α mRNA and their protein translation have been 
demonstrated when skeletal muscle fibres are subjected to prolonged mechanical stretch 
(Milkiewicz et al. 2007a). This has led Milkiewicz and colleagues to postulate that early increases 
in DNA-binding activity of HIF-1α and HIF-2α protein in response to mechanical stretch may 
contribute to the subsequent over expression of HIF-1α and HIF-2α mRNA through an autocrine 
transcriptional regulation (Milkiewicz et al. 2007a). Also, the increases in HIF-1α and HIF-2α 
mRNA secondary to mechanical stretch are inhibited by blocking the pathways that increase 
protein translation and activity of HIF-1α and HIF-2α (Milkiewicz et al. 2007a). This is consistent 
with the present observation that the inhibition of protein stabilisation and DNA-activity of HIF-
1α and HIF-2α by 17-DMAG and echinomycin, respectively, decreased the expression of HIF-1α 
and HIF-2α mRNA. 
Although 17-DMAG inhibited the over expression of HIF-1α, HIF-2α, MMP-2 and 
MMP-9, it did not reverse the reduction of contraction in rat IVC segments subjected to prolonged 
stretch. 17-DMAG is a geldanamycin-derived Hsp90 inhibitor which promotes HIF-α protein 
destabilisation and subsequent degradation. Hsp90 stabilises HIF-α by acting as a molecular 
chaperone which associates with HIF-α during nuclear translocation (Gaber et al. 2005; Semenza 
2009b). However, Hsp90 may also affect other pathways and regulate vascular tone through the 
mediation of nitric oxide synthase and superoxide anion (Shah et al. 1999; Zhang et al. 2009). 
Thus it is not unlikely that inhibition of Hsp90 by 17-DMAG would cause venorelaxation effects 
unrelated to inhibition of HIF. 
5.6. CONCLUSION 
Prolonged increases in vein wall tension are associated with over expression of HIF-1α 
and HIF-2α in rat IVC. The up-regulation of HIF-1α and HIF-2α is associated with increased 
MMP-2 and MMP-9 expression and reduced venous contraction. The data suggest that the 
increased vein wall tension secondary to venous hypertension may induce HIF over expression, 
and cause an increase in MMPs expression and reduction of venous contraction, leading to 
progressive venous dilation and varicose vein formation. 
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6. SUMMARY OF RESULTS AND FUTURE WORKS 
6.1. SUMMARY OF RESULTS 
The aims of this study were: 
1. To demonstrate that varicose and non-varicose veins are structurally different using 
special histological stains. 
2. To investigate and measure the expression of HIF-1α and HIF-2α, their target genes, and 
HIF regulatory enzymes in varicose and non-varicose veins 
3. To prepare and use a varicose and non-varicose vein organ culture to assess the regulation 
of HIF-1α and HIF-2α, and their target genes by oxygen tension, and the effects of 
doxycycline and MPFF at a concentration corresponding to their physiological 
therapeutic dose on the HIF pathway 
4. To study the effects of prolonged increases in vein wall tension on the expression of HIF-
1α, HIF-2α and MMPs, and venous tone 
To demonstrate that varicose and non-varicose veins are structurally different, semi-
quantitative histological analysis of ten varicose and ten non-varicose veins stained with H&E, 
EVG and MT was performed by two independent vascular surgical trainees (CSL and JS). The 
intra- and inter-observer agreements between the two trainees were overall acceptable (kappa 
score ≥ 0.7). Increased SMC and reduced elastic tissue content of tunica media was observed in 
varicose compared to non-varicose veins. No difference in the connective tissue content of tunica 
media of varicose and non-varicose veins was found. The SMC, elastic tissue and connective 
tissue content of tunica adventitia also did not differ between the two types of veins. Intimal 
hyperplasia was present in some but not all of the varicose and non-varicose veins, and with 
different severity. Overall, there was no difference observed in terms of the presence and severity 
of intimal hyperplasia between both types of veins.  
To investigate and compare the expression of HIF-1α and HIF-2α, and their target genes 
in varicose and non-varicose veins, surgically retrieved whole varicose and non-varicose veins 
that were immediately snap frozen and stored at -80ºC, or fixed with formalin were analysed for 
mRNA and proteins expression of HIF-1α, HIF-2α and HIF target genes using Q-PCR, western 
blot and immunohistochemistry. HIF-1α and HIF-2α mRNA was up-regulated in varicose 
compared to non-varicose veins (mean of 89.8 ± SEM 18.6, n=11 versus 10.4 ± 7.2, n=5; 
P=0.012) and (384.9 ± 209.4, n=11 versus 8.1 ± 4.2, n=5; P=0.008), respectively. Increased HIF-
1α and HIF-2α protein expression was also observed in varicosities. The mRNA expression of 
HIF target genes was elevated in varicose compared to non-varicose veins; namely GLUT-1 (8.7 
± 2.1, n=20 versus 1.0 ± 0.3, n=10; P<0.001), CA9 (8.5 ± 2.1, n=20 versus 2.8 ± 1.2, n=10; 
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P=0.006), VEGF (7.5 ± 2.1, n=20 versus 0.9 ± 0.2, n=10; P=0.001), BNIP-3 (4.5 ± 0.7, n=20 
versus 1.4 ± 0.3, n=10; P=0.004), ENO-1 (11.2 ± 2.1, n=11 versus 3.1 ± 1.9, n=5 ; P=0.019), 
PHD-2 (5.6 ± 1.1, n=11 versus 1.7 ± 0.7, n=5; P=0.034), and PHD-3 (9.9 ± 2.2, n=11 versus 2.4 ± 
1.2, n=5; P=0.047). The up-regulation of HIF target genes in varicosities was also reflected at the 
protein level. The expression of PHD-1 and FIH-1, both were HIF regulatory enzymes but not 
HIF targets, was similar in varicose and non-varicose veins. Using immunohistochemistry, HIF-
1α was observed to be expressed in all 8 (100%) varicose veins but only 4 of 8 (50%) non-
varicose veins. HIF-1α was found to be expressed in some endothelial cells, whereas HIF-2α was 
expressed by endothelial cells and SMC of all the layers in varicose and non-varicose veins. The 
data suggest that increased HIF pathway activation in varicose compared to non-varicose veins, 
and HIF-2α rather than HIF-1α may be the key regulator of the HIF pathway. 
To assess the regulation of HIF-1α and HIF-2α, and their target genes by hypoxia, an 
organ culture model of varicose and a non-varicose vein was used. The viability of the vein organ 
culture model was initially validated with a cell death assay. Relatively high level of cell death 
was detected in the first two days of the culture which then decreased and plateaued off to a low 
level. The vein organ culture model was also shown to contain living cells by demonstrating 
increased cell death in cultures that were treated with sodium azide compared to those untreated. 
Sodium azide inhibits oxidative phosphorylation and thereby caused cell death. Exposure of 
varicose and non-varicose vein organ cultures to 16 hours of hypoxia or hypoxia mimetic DMOG 
in normoxia was associated with increased expression of HIF-1α and HIF-2α protein, and their 
target genes compared to those subjected to normoxia only. Doxycycline at a concentration 
corresponding to its therapeutic dose (5μg/ml) did not appear to alter the expression of HIF-1α, 
HIF-2α, and their target genes compared to those untreated. Meanwhile, MPFF at a concentration 
corresponding to its therapeutic dose (10
-5
M) significantly reduced the expression of HIF-1α but 
not HIF-2α mRNA expression in varicose vein organ cultures compared to those untreated. MPFF 
also appeared to decrease the up-regulation of HIF target genes in varicose vein organ cultures 
exposed to 16 hours of hypoxia compared to those untreated although the reduction did not 
achieve statistical significance. Such effects of MPFF 10
-5
M were less obvious in non-varicose 
vein organ cultures.  
To study the effects of prolonged increases in vein wall tension on the expression of HIF-
1α, HIF-2α, MMP-2 and MMP-9, and venous tone, an in vitro model that stretched segments of 
rat IVC to pre-determined tensions, and measured their isometric contraction was used. Compared 
to control IVC contraction at 0.5g tension for 1 hour, the fold change of PHE and KCl contraction 
after prolonged 0.5g tension was 2.0 ± 0.35 and 1.1 ± 0.06, respectively. Vein contraction to PHE 
and KCl after prolonged 2g tension was significantly reduced (0.87 ± 0.13 and 0.72 ± 0.05, 
respectively). PHE-induced contraction was restored in IVC exposed to prolonged 2g tension plus 
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the HIF inhibitor U0126 (1.38 ± 0.15) or echinomycin (1.99 ± 0.40). U0126 and echinomycin also 
restored KCl-induced contraction in IVC exposed to prolonged 2g tension (1.14 ± 0.05 and 1.11 ± 
0.15, respectively). Treatment with DMOG further reduced PHE- and KCl-induced contraction in 
veins subjected to prolonged 2g tension (0.47 ± 0.06 and 0.57 ± 0.01, respectively). HIF-1α and 
HIF-2α mRNA were over expressed in IVC exposed to prolonged 2g tension, and the over 
expression was reversed in by U0126. The over expression of HIF-1 and HIF-2 in stretched 
IVC was associated with increased MMP-2 and MMP-9 mRNA. The protein amount of HIF-1α, 
HIF-2α, MMP-2 and MMP-9 was also increased in IVC exposed to prolonged 2g wall tension.  
6.2. FUTURE WORKS 
The discovery of increased activation of the HIF pathway in varicose compared to non-
varicose veins will potentially lead to many important future research studies investigating the 
pathway in the pathophysiology of the disease since HIF represents a major regulator of a 
significant number of genes involved in various cellular functions. Furthermore, the regulation of 
HIF is very complex and at present not fully understood. Future work should focus on the 
upstream and downstream regulation of the HIF pathway, with the ultimate aim of improving our 
understanding of the role of the pathway in varicose veins formation and identification of 
potential therapeutic targets that can improve the prevention and/or treatment of the disorder.  
Upstream regulation of the HIF pathway that may be of interest includes various external 
factors that may affect the HIF-α expression and activity. In this study, the effects of hypoxia and 
mechanical stress on the expression of HIF-1α, HIF-2α, and HIF target genes in varicose and non-
varicose veins were investigated. Other factors including inflammatory cytokines and mediators, 
and low shear stress are also known to affect HIF and target genes expression. Therefore, a 
preliminary study investigating the effects of inflammatory mediators on the HIF pathway has 
been set up for the next clinical research fellow of our department. My preliminary in vitro results 
on 2 varicose and 2 non-varicose veins supported that HIF-1α, HIF-2α, and HIF target genes 
expression could be affected by inflammatory mediators in non-varicose and varicose veins. 
Exposure of non-varicose and varicose vein organ cultures to inflammatory mediators including 
TNF-α, IL-1 and lipopolysaccharides (LPS) was associated with increased mRNA expression of 
HIF-1α, HIF-2α, and HIF target genes (BNIP-3 and PHD-2) (Figure 6-1 and Figure 6-2). The 
findings are consistent with previous reports that inflammatory cytokines and mediators regulate 
HIF-α expression at the mRNA rather than protein level, i.e. through the oxygen-independent 
regulation of the HIF pathway (Gaber et al. 2005; Ke and Costa 2006; Semenza 2009b). 
Interestingly, inflammatory mediators are also likely to play a role in the pathogenesis of varicose 
veins (Lim and Davies 2009). However, the role of inflammatory mediators in the regulation of 
HIF pathway in varicose veins will require further investigation before any conclusion is made. 
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Other examples of upstream regulation of the HIF pathway that are potentially important and 
deserve further investigation include the role of HIF-PHDs, FIH-1, and the negative feedback 
mechanisms of HIF-α, and studying the genetic predisposition to abnormal HIF-α expression such 
as in patients with Chuvash polycythaemia.  
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Figure 6-1  The effects of inflammatory mediators on HIF-1α, HIF-2α and HIF target 
genes expression in non-varicose veins  
HIF-1α, HIF-2α and HIF target genes (BNIP-3 and PHD-2) mRNA expression in non-varicose vein organ 
cultures treated with 16 hours of tumour necrosis factor- α (TNF-α) 10ng/ml, interleukin-1 (IL-1) 10ng/ml, 
and lipopolysaccharides (LPS) 50µg/ml in normoxia. The non-varicose veins were retrieved from a patient 
with no history of varicosities. The mRNA expression was measured with Q-PCR relative to an untreated 
culture and normalised to 18S RNA. Data represents mean±SD. 
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Figure 6-2  The effects of inflammatory mediators on HIF-1α, HIF-2α and HIF target 
genes expression in varicose veins  
HIF-1α, HIF-2α and HIF target genes (BNIP-3 and PHD-2) mRNA expression in varicose vein organ 
cultures treated with 16 hours of tumour necrosis factor- α (TNF-α) 10ng/ml, interleukin-1 (IL-1) 10ng/ml, 
and lipopolysaccharides (LPS) 50µg/ml in normoxia. The varicose veins were retrieved from the same 
patient. The mRNA expression was measured with Q-PCR relative to an untreated culture and normalised 
to 18S RNA. Data represents mean±SD. 
 
Besides the upstream regulation, studying the downstream regulation of HIF is also 
important and interesting because it will help to improve our understanding of the 
pathophysiology of various varicose vein wall changes that may be directly or indirectly related to 
the HIF pathway activation. In this study, HIF target genes were shown to be significantly 
increased in varicose compared to non-varicose veins. Furthermore, the up-regulation of HIF 
target genes in varicose and non-varicose vein organ cultures was also demonstrated to be 
associated with increased HIF-1α and HIF-2α expression secondary to exposure to hypoxia or 
DMOG. In order to demonstrate that the up-regulation of HIF target genes in varicose and non-
varicose vein organ cultures exposed to hypoxia or DMOG was specifically caused by increased 
HIF-1α and HIF-2α, gene knockdown of HIF-1α and HIF-2α with RNAi using siRNA was 
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performed. This was again a preliminary study that was set up for the next clinical research fellow 
of our department. The protocol used was described in Chapter 2. My early results demonstrated 
that successful knockdown of HIF-1α gene prevented the up-regulation of HIF target genes 
observed in varicose vein organ cultures exposed to hypoxia (Figure 6-3) or DMOG (Figure 6-4). 
Gene knockdown using siRNA in organ cultures is known to be more difficult and less 
predictable than cell culture (Lee et al. 2008). Therefore, future work will include optimisation of 
the conditions needed for more effective gene knockdown. 
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Figure 6-3 HIF-1α and HIF target genes expression following an effective HIF-1α 
knockdown in varicose vein organ cultures exposed to hypoxia 
HIF-1α and HIF target genes mRNA expression following knockdown of HIF-1α using RNAi in a single 
representative set of varicose vein organ cultures of a patient. Varicose vein organ cultures were either not 
transfected (H/Nil), transfected using only oligofectamine (H/Mock), transfected using oligofectamine and 
100nM of scrambled siRNA (H/Scr), or transfected using oligofectamine and 100nM of HIF-1α siRNA 
(H/siHIF-1α). Varicose vein organ cultures were then incubated in hypoxia (1% oxygen) for 16 hours. Gene 
expression of HIF-1α, GLUT-1, BNIP-3 and VEGF was measured with Q-PCR relative to varicose vein 
organ culture exposed to normoxia, and normalised to 18S RNA. Data represent mean±SD.  
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Figure 6-4 HIF-1α and HIF target genes expression following an effective HIF-1α 
knockdown in varicose vein organ cultures exposed to DMOG 1mM 
HIF-1α and HIF target genes mRNA expression following knockdown of HIF-1α using RNAi in a single 
representative set of varicose vein organ cultures of a patient. Varicose vein organ cultures were either not 
transfected (D/Nil), transfected using only oligofectamine (D/Mock), transfected using oligofectamine and 
100nM of scrambled siRNA (D/Scr), or transfected using oligofectamine and 100nM of HIF-1α siRNA 
(D/siHIF-1α). Varicose vein organ cultures were then incubated in DMOG 1mM for 16 hours. Gene 
expression of HIF-1α, GLUT-1, BNIP-3 and VEGF was measured with Q-PCR relative to untreated 
varicose vein organ culture, and normalised to 18S RNA. Data represent mean±SD. 
 
Future work should ultimately aim to identify new, effective and safe pharmacological 
treatment that targets the HIF pathway for varicose veins and CVI. Further animal and laboratory 
research including the use of my vein organ culture to examine the effects of various new and 
more specific HIF-α modulating drugs on the HIF pathway in venous tissues will help to 
understand and determine if any of these pharmacological agents are suitable for clinical trials. 
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For example, the in vitro effects of HIF inhibitors on the biochemical and structural changes of 
varicose veins could be tested using the vein organ culture subjected to various stresses including 
hypoxia or inflammatory mediators. Although not ideal, animal models of varicose veins, usually 
created by experimental induction of venous hypertension, could also be used to test the effects of 
HIF modulators on the changes of vein wall caused by increased venous pressure. Interestingly 
several HIF modulators are now being tested in clinical trials in diseases including cancers, 
rheumatoid arthritis and chronic anaemia (Cases 2007; Greenberger et al. 2008; Baldewijns et al. 
2010; Koh et al. 2010). It is hoped that some of these pharmacological agents will also be 
beneficial to patients with varicose veins or CVI in future although they need to be tested robustly 
with laboratory and clinical trials before any claim of their safety and effectiveness can be made. 
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7. FINAL DISCUSSION 
A normal venous system is dependent on the integrity of the valves, vein wall and the 
haemodynamic of venous blood flow. These components are interdependent and the disruption of 
one will alter the integrity of the others. The secondary alterations will cause further disruption to 
the initial event, triggering a vicious cycle. Unfortunately, by the time varicose veins are present, 
these components are already disrupted, making it difficult to pinpoint the primary stimulus and 
map the sequence of events. Besides this so-called “chicken and egg” phenomenon, the multi-
factorial aetiology of the disease further complicates the understanding of varicose vein formation 
(Lim and Davies 2009). 
Although valvular incompetence may precede vein dilatation in many cases, there is a 
significant body of evidence supporting the view that vein dilatation can also precede venous 
reﬂux, and that valvular dysfunction may be an epiphenomenon of vein wall dilatation (Gandhi et 
al. 1993; Labropoulos et al. 1999; Kirsch et al. 2000a; Kirsch et al. 2000b; Raffetto and Khalil 
2008b). Clinical studies using duplex ultrasonography have demonstrated that venous 
insufﬁciency can occur in varicosities without axial reﬂux of the superﬁcial, deep, or perforator 
veins (Labropoulos et al. 1997; Labropoulos et al. 1999; Qureshi et al. 2010a; Qureshi et al. 
2010b). Furthermore, imbalances in ECM proteins may cause connective tissue changes prior to 
valvular insufficiency (Gandhi et al. 1993). Thus, blood stasis leading to venous hypertension and 
vein wall dilatation may contribute to the initiation and progression of varicose veins (Raffetto 
and Khalil 2008b; Lim and Davies 2009). Several stresses related to blood stasis and venous 
hypertension including hypoxia, mechanical stretch and low shear stress have been postulated to 
contribute to vein wall changes (Michiels et al. 2002b; Naoum et al. 2007). Blood stasis may 
cause endoluminal and media hypoxia leading to vein wall remodelling and weakening. Venous 
hypertension may also damage the vein wall and valves directly through mechanical stress 
leading to increases in vein wall tension. Alternatively, venous hypertension may cause dilatation 
of the vein, separating the valves which in turn become incompetence. Either way, this would 
then cause venous reflux leading to further blood stasis and venous hypertension, creating a 
vicious cycle of progressive varicose vein formation. 
During standing, the ankle venous pressure generated by the blood column in human may 
be as high as 100mmHg compared to only 5 to 25mmHg when the vein is empty such as when 
lying flat (Meissner et al. 2007b; Raffetto and Khalil 2008b). Therefore, the human venous 
system of the leg is likely to have evolved with mechanisms to cope with these stresses. Such 
coping ability may vary between individuals, depending on multiple factors, both genetic and 
environmental, as suggested by the multi-factorial aetiology of varicose veins. Leg veins of 
individuals who are less able to cope with these stresses are likely to suffer more frequent injury. 
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Chronically recurring injury will subsequently cause vein wall inflammation, remodelling and 
alteration of venous tone leading to valvular dysfunction, venous reflux and varicosity.  
The potential for venous hypertension to initiate vein wall and valvular damage leading to 
venous insufficiency has been shown in animal models. In one rat model, acute venous 
hypertension was created through an AV fistula between the femoral artery and vein (Takase et al. 
2004; Pascarella et al. 2005; Misra et al. 2008a; Pascarella et al. 2008). The limbs with the AV 
fistula developed venous reflux and oedema which worsened over time (3-6 weeks) compared to 
the legs without AV fistula. Valvular and vein wall injury and fibrosis were also observed in the 
veins from the legs with AV fistula (Takase et al. 2004; Pascarella et al. 2005). Increased 
infiltration of inflammatory cells including granulocytes, monocytes and macrophages, and up-
regulation of P-selectin and intercellular adhesion molecules expression were found in the 
saphenous vein walls in the presence of AV fistula compared to those without (Takase et al. 2004; 
Pascarella et al. 2008). Furthermore, over expression of MMP-2 and MMP-9 were also measured 
in the veins subjected to venous hypertension (Pascarella et al. 2005; Misra et al. 2008a; 
Pascarella et al. 2008). Interestingly, rats that received oral treatment with MPFF demonstrated 
reduced leg oedema and venous reflux caused by the AV fistula (Pascarella et al. 2008). 
Although experimental AV fistula formation with the intention to cause varicosity in 
human subjects is unlikely to gain ethical approval, temporary venous hypertension can be 
indirectly induced through postural blood stasis (Saharay et al. 1998) or venous occlusion using 
inflated blood pressure cuff (Signorelli et al. 2000). Venous hypertension induced by these 
methods has been shown to activate inflammatory processes in the venous system including 
endothelial activation. For example, postural venous stasis was found to augment the expression 
of adhesion molecules including endothelial leukocyte adhesion molecule-1 (ELAM-1 or E-
selectin), ICAM-1 and VCAM-1 in the plasma obtained from leg veins of patients with and 
without varicose veins (Saharay et al. 1998). In another study, venous hypertension induced 
through venous occlusion with an inflated cuff was shown to elevate the expression of IL-1β, IL-6 
and TNF-α in patients with and without varicose veins, although more so in the former (Signorelli 
et al. 2000). Inflammation is an important feature of varicose veins. Increased expression of 
inflammatory markers such as VCAM-1, ICAM-1 and vWf by the endothelium of varicose 
compared to non-varicose veins have been measured (Aunapuu and Arend 2005; Somers and 
Knaapen 2006). Significantly more mast cells, monocytes and macrophages infiltration have been 
observed in varicose compared to non-varicose veins (Yamada et al. 1996; Kakkos et al. 2003; 
Sayer and Smith 2004). Furthermore, cytokines including TNF-α, IL-1 and IL-6 have also been 
found to be elevated in patients with varicose compared to non-varicose vein (Signorelli et al. 
2000; Takase et al. 2000a). Therefore, similarities between inflammatory processes observed in 
varicose veins and those activated by experimental venous hypertension in non-varicose veins 
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indirectly support that venous hypertension may contribute to the initiation and progression of 
varicose vein formation. 
In this study, increased expression and activity of HIF-α was demonstrated in varicose 
compared to non-varicose veins. The mRNA and protein expression of HIF-1α and HIF-2α was 
up-regulated in varicose compared to non-varicose veins. This finding suggests that varicose vein 
wall is under some kind of stress leading to the activation of the HIF pathway as a response. 
Interestingly, elevated expression of several HIF target genes in varicose compared to non-
varicose veins was also measured reflecting increased HIF activity. The HIF target genes that 
were measured had different cellular functions including glucose metabolism (GLUT-1 and ENO-
1), apoptosis and survival (BNIP-3), angiogenesis (VEGF) and pH regulation (CA9). This 
suggests that increased expression of HIF-α is associated with various biochemical and structural 
changes in varicose vein wall. Therefore, the HIF-α pathway may have an important role in 
contributing to vein wall remodelling leading to weakening and dilatation in varicosities.  
Over expression and increased activity of HIF-α in varicose compared to non-varicose 
veins did not come as a surprise since findings from previous studies have pointed towards this 
possibility. Firstly, cellular stresses including hypoxia and increased mechanical strain secondary 
to blood stasis and venous hypertension are potential factors contributing to varicose vein 
formation, as well as known to regulate the expression and activity of HIF-α (Michiels et al. 2000; 
Gaber et al. 2005; Semenza 2009b). Secondly, patients with Chuvash polycythaemia, a congenital 
disorder of inappropriate increased expression of HIF-α due to VHL gene mutation, were more 
likely to have varicose veins compared to those without disorder (Gordeuk et al. 2004). Thirdly, it 
has been shown that internal spermatic veins of patients with varicocoele, i.e. varicosity in the 
testes, expressed significantly more HIF-1 than those of patients without the disease (Lee et al. 
2006). Fourthly, many changes reported in varicose vein wall including imbalances of 
MMP/TIMP, impaired vascular tone, dysregulated apoptosis, altered angiogenesis and abnormal 
glucose metabolism (Lim and Davies 2009) were also related to the adaptive responses regulated 
by HIF (Somers and Knaapen 2006; Raffetto and Khalil 2008b; Lim and Davies 2009). This was 
reflected by the functions of the HIF target genes that were shown to be up-regulated in varicose 
compared to non-varicose veins in the study. Other genes that are known to be regulated by HIF 
and have been reported to be abnormal in varicose veins but not investigated in this study include 
TIMP-1, and iNOS (Semenza 2003; Jacob et al. 2005; Patiar and Harris 2006; Raffetto and Khalil 
2008b; Weidemann and Johnson 2008). MMP and TIMPs regulate extracellular matrix 
metabolism (Raffetto and Khalil 2008a; Lim et al. 2010), and iNOS affect vascular tone (Semenza 
2003; Weidemann and Johnson 2008). 
Only very recently, HIF-1α expression in varicose compared to non-varicose veins was 
reported. Using immunohistochemistry, Hossein-Ghaderian and colleagues identified HIF-1α 
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expression in endothelial cells of the intima and vasa vasorum of 5 out of 20 varicose vein 
specimens but none of the 20 non-varicose saphenous vein tissues. The authors also found that the 
expression of HIF-1α was strongly correlated with the ICAM-1 positive staining of the same 
specimens (Hossein Ghaderian et al. 2010). However, in this study the author did not assess the 
expression of HIF pathway in detailed including the expression of HIF-2α and HIF target genes, 
and their regulation by hypoxia and other stresses.  
It is not clear at what stage of the varicose veins formation that HIF pathway was 
activated. In other words, it is unknown if the over expression of HIF-1 and HIF-2 contributes 
to the formation of varicose veins or if it is an effect caused by varicosity. Like many features of 
varicose veins, the cause and effect relationship of HIF and varicosity may be difficult to answer 
since the disease progresses through a vicious cycle as discussed earlier. However, this does not 
undermine the importance of identifying the increased activation of the HIF pathway in varicose 
veins. HIF regulates over 100 genes, many of them involved in oxygen homoeostasis that include 
various functions that may alter the integrity of the vein wall such as angiogenesis, matrix 
metabolism, glucose metabolism, vascular tone, pH regulation, cell cycle and apoptosis (Semenza 
2003; Gaber et al. 2005; Ke and Costa 2006; Patiar and Harris 2006). Therefore, regardless of the 
stage at which HIF pathway is affected in the pathogenesis of varicose veins, HIF is likely to 
contribute to various biochemical and cellular changes leading to varicosity formation, making it 
a potentially important and attractive therapeutic target.  
The cause of the increased activation of the HIF pathway in varicose compared to non-
varicose veins remains unclear. It is likely that a combination of factors may be involved due to 
the heterogeneity of varicose veins. Hypoxia, mechanical strain and inflammatory cytokines are 
some of the potential factors contributing to the activation of HIF pathway in varicose veins. 
Furthermore, genetic susceptibility is also possible as demonstrated by patients with Chuvash 
polycythaemia although hereditary factor is unlikely to be acting on its own since varicose veins 
are common in the general population.  
Cells have evolved with the HIF pathway to protect them from changes in the 
surrounding oxygen tension and other stresses including mechanical strain and radiation 
(Semenza 2009b). This cellular adaptive pathway is important both physiologically and 
pathologically (Semenza 2009b; Semenza 2010b). In embryology, HIF pathway is important in 
determining various functions including cell cycle, apoptosis and angiogenesis to ensure the 
accurate development of the embryo spatially and temporally (Provot and Schipani 2007; Webster 
and Abela 2007). In pathology, the expression and activity of HIF-α may be protective or 
disruptive depending on the disease. In general, the expression of HIF-α is protective in diseases 
that involve ischaemic insult threatening the survival of normal cells. Examples of pathology in 
which HIF is protective include cerebrovascular accident or stroke (Myllyharju 2009; Shi 2009; 
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Kasivisvanathan et al. 2010), myocardial infarction (Shohet and Garcia 2007; Myllyharju 2009; 
Kasivisvanathan et al. 2010) and ischaemic limb secondary to peripheral arterial disease (Ho et al. 
2006; Myllyharju 2009; Kasivisvanathan et al. 2010). In these diseases, HIF improves the survival 
of the normal cells (for example in cardiomyocytes in myocardial infarction) by increasing 
collateral blood circulation through angiogenesis, facilitating glucose metabolism, and reducing 
apoptosis (Ho et al. 2006; Shohet and Garcia 2007; Myllyharju 2009). In contrast, HIF is 
generally disruptive in pathology that involves excessive proliferation. Typical examples of these 
diseases include cancers (Ke and Costa 2006; Semenza 2010a) and rheumatoid arthritis (Gaber et 
al. 2005; Muz et al. 2009). In cancers, HIF protects malignant cells from hypoxia and other 
stresses caused by the over populated tumour cells and the hostile microenvironment (Ke and 
Costa 2006; Dehne and Brune 2009; Semenza 2010a). HIF also contributes to the invasive and 
metastatic nature of the cancer cells by increasing their motility and facilitating them to evade the 
immune system of the host (Lukashev et al. 2007; Dehne and Brune 2009; Liu et al. 2010). In 
some cancers, patients with tumour that demonstrates increased expression of HIF have been 
shown to have a poorer outcome than those without (Semenza 2010a). Meanwhile, in rheumatoid 
arthritis, increased expression of HIF is thought to protect and facilitate the proliferation of 
synovial vasculature and excessive degradation of ECM leading to the destruction of the joint 
(Gaber et al. 2005; Muz et al. 2009; Paleolog 2009). It is not clear at this stage if the increased 
activation of the HIF pathway in varicose veins is protective or disruptive. The expression and 
activation of HIF-α may protect the cells in the vein wall from the stresses of blood stasis and 
venous hypertension including hypoxia and mechanical stretch. On the other hand, over 
expression of HIF in the vein wall may lead various changes in the cells including increased 
proliferation of SMC, degradation of ECM proteins and alteration of venous tone causing 
varicosity formation. It is likely that in the initial event of varicose vein formation, the HIF 
pathway is activated to protect the vein wall from haemodynamic stresses. Chronically recurring 
stresses leads to repeated activation of the HIF pathway in the vein wall causing excessive 
changes that ultimately contribute to weakening and dilatation of the vein. However, this 
hypothesis remains a speculation at the present time and therefore warrants further investigation.  
Using a vein organ culture, this study found that varicose and non-varicose vein tissues 
responded to hypoxia by up-regulating the expression of HIF-1α and HIF-2α protein. This finding 
is consistent with the oxygen-dependent regulation of HIF-α which has been demonstrated in 
various other cell and tissue types. The up-regulation of HIF-1α and HIF-2α protein secondary to 
hypoxia appeared to be associated with the increased expression of HIF target genes. This finding 
does not prove that hypoxia is a feature of varicosities which causes or contributes to the 
increased expression and activity of HIF in varicose compared to non-varicose veins. However, 
this finding supports that both varicose and non-varicose veins are able to respond to hypoxia by 
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up-regulating the expression of HIF and their target genes. 
The regulation of the HIF pathway by mechanical stretch of venous tissue was 
investigated by a rat IVC model subjected to prolonged increases in vein wall tension. This part of 
the study demonstrated up-regulation of HIF-1α and HIF-2α expression were associated with 
prolonged increases in vein wall tension of rat IVC. The mechanism of HIF regulation by 
mechanical stretch is unclear at the present time, but may involve PI3K and MAPK (Chang et al. 
2003; Gaber et al. 2005; Milkiewicz et al. 2007a). Cell membrane proteins such as ion channels, 
integrins, and receptor tyrosine kinases are mechano-sensitive to stretch (Haga et al. 2007). 
Mechanical stretch may stimulate PI3K by activating Ca
2+
 influx through transient receptor 
potential ion channels such as TRPV4 (Thodeti et al. 2009). Also, integrins have been shown to 
transduce mechanical stretch to initiate signalling cascades and cause MAPK activation (Oktay et 
al. 1999). Receptor tyrosine kinases and G protein-coupled receptors are also stimulated by 
biomechanical stress with subsequent activation of MAPK (Li and Xu 2000). Furthermore, 
mechanical stretch may increase the generation of ROS which are capable of activating MAPK 
(Hishikawa et al. 1997; Ungvari et al. 2003). U0126 may have inhibitory effects on MAPK. The 
observation in this study that the increased HIF-1 and HIF-2 mRNA expression and the 
reduction in venous contraction associated with prolonged vein wall stretch were reversed in 
veins treated with U0126 suggested a role of MAPK in the regulation of HIF-α by mechanical 
stretch. 
Over expression of HIF-1α and HIF-2α secondary to prolonged increases in vein wall 
tension were also found to be associated with the up-regulation of MMP-2 and MMP-9 in rat 
IVC. MMP-2 and MMP-9, as well as several other MMPs and TIMPs are known to be regulated 
by hypoxia and mechanical stretch through the HIF pathway (Fujiwara et al. 2007; Misra et al. 
2008a). Imbalances in MMP and TIMP activity have been widely reported to be contributing to 
the remodelling of varicose vein wall leading to weakness and dilatation (Raffetto and Khalil 
2008b; Lim and Davies 2009). Although this study on the relationship between HIF and MMP 
was based on an in vitro rat IVC model, the overall findings suggest that HIF-α may play a role in 
contributing to the imbalances of MMP and TIMP observed in varicose veins. Besides MMP 
regulation, the data from the in vitro rat IVC model also suggested that the expression of HIF was 
associated with alteration of the venous tone, again supporting the multiple functions regulated by 
this pathway.  
7.1. CLINICAL IMPLICATIONS OF THE STUDY 
This study identified an important regulatory pathway, i.e. the HIF pathway that may be 
contributing to various biochemical and structural changes in varicose veins. This finding may 
have significant clinical implications both in the understanding of the pathogenesis of varicose 
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veins and treatment development. Increasing research on the HIF pathway in various pathology 
including rheumatoid arthritis (Muz et al. 2009), atherosclerosis (Sluimer and Daemen 2009; 
Semenza 2010b), pulmonary hypertension (Nagel et al. 2010), anaemia (Semenza and Wang 
1992) and cancers (Semenza 2003; Semenza 2010a) has led to significant clinical implications 
especially in the development of therapeutic agents, and predicting disease progression and 
prognosis. Targeting the HIF pathway with drugs is an attractive treatment option for varicose 
veins and CVD. The development of a cost-effective drug will benefit many patients since the 
treatment of varicose veins is still at present largely limited to interventional treatment such as 
surgery. Effective drug treatment may also help patients who are not fit for surgery.  
Various drugs modulating the HIF pathway are being developed and some of them are 
being investigated in clinical trials. Drugs that inhibit HIF-α expression or activity are being 
developed and tested for the treatment of diseases associated with increased expression of HIF-α 
including cancers (Baldewijns et al. 2010; Koh et al. 2010). Examples of HIF inhibitors include 
EZN-2968 (Greenberger et al. 2008), sorafenib (Baldewijns et al. 2010) and echinomycin (Kong 
et al. 2005). On the other hand, drugs that increase the activity of HIF-α are also being developed 
for diseases including ischaemic heart diseases, stroke, peripheral arterial diseases, and chronic 
anaemia (Nangaku et al. 2006; Myllyharju 2009; Harten et al. 2010). The most important group of 
drugs that increased the expression and activity of HIF-α are the HIF-PHD inhibitors (Myllyharju 
2009; Harten et al. 2010). This group of drugs inhibits HIF-PHD, thereby “stabilising” HIF by 
preventing their proteosomal degradation (Myllyharju 2009; Harten et al. 2010). Examples of 
HIF-PHD inhibitors include DMOG, desferrioxamine and 3,4-dihydroxybenzoate. FG-2216 
and FG-4592 are two orally active HIF-PHD inhibitors being tested in clinical trials for the 
treatment of chronic anaemia in patients with chronic kidney disease (Cases 2007; Semenza 
2009a).  
Besides the development of pharmacological agents, understanding the role of HIF 
pathway in varicose veins may help to understand the natural history and progression of the 
disease. As demonstrated in this study, HIF is associated with various changes in varicose vein 
wall including glucose metabolism, pH regulation, angiogenesis, apoptosis, and possibly matrix 
metabolism and venous tone. This suggests that the involvement of the HIF pathway is relatively 
high or upstream in the level of regulation of these changes. Therefore, there is a possibility that 
the involvement of the HIF pathway may be early in the natural history and progression of the 
disease although this remains a speculation and requires further investigation. Understanding the 
natural history and progression of varicose veins is important in identifying patients who may 
become symptomatic or develop recurrences following treatment.  
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7.2. OVERALL CONCLUSION 
In conclusion, the study demonstrates that the expression and activity of HIF is increased 
in varicose compared to non-varicose veins. HIF-2α is more widely expressed and is found in 
SMC and endothelium as compared to HIF-1α which is only seen in some endothelial cells. 
Hypoxia and prolonged increases in vein wall tension secondary to mechanical stretch are 
associated with increased expression of HIF-1α, HIF-2α and their target genes in venous tissues. 
MPFF at a concentration corresponding to therapeutic dose appears to reverse the increases of 
HIF-α and target genes expression in in vitro varicose vein tissues exposed to hypoxia, although 
the findings are not statistically significant. Meanwhile, doxycycline at a concentration 
corresponding to therapeutic dose does not have any effect on the HIF pathway. The data suggest 
that the HIF pathway may be an important regulator of various biochemical and structural 
changes in varicose vein wall. Furthermore, HIF-2α instead of HIF-1α may be the key regulator 
of the HIF pathway in varicose and non-varicose veins. Therefore, the HIF pathway is potentially 
an important therapeutic target in the pharmacological treatment development for varicose veins. 
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Appendix 1 Primers and sequences (Imperial College) 
Primer Orientation Sequence Product size (bp) 
HIF-1 forward 5'-CACCTCTGGACTTGCCTTTC-3' 194 
reverse  5'-GGCTGCATCTCGAGACTTTT-3'  
HIF-2 forward 5'-CCTTCAAGACAAGGTCTGCA-3' 190 
reverse  5'-TTCATCCGTTTCCACATCAA-3'  
CA9 forward 5'-GCTGTCACCAGCGTCGCGT(T) -3' 100 
reverse  5'-CCAGTCTCGGCTACCTCTGCT-3'  
BNIP3 forward 5'-GATATGGGATTGGTCAAGTCGG-3' 101 
reverse  5'-CGCTCGTGTTCCTCATGCT-3'  
GLUT-1 forward 5'-TGGCATGGCGGGTTGT-3' 63 
reverse  5'-CCAGGGTAGCTGCTCCAGC-3'  
VEGF forward 5'-CTTGCCTTGCTGCTCTACCT-3' 282 
 reverse  5'-CTGCATGGTGATGTTGGACT-3'  
ENO-1 forward 5'-GCAAGAAACTGAACGTCACAGAAC-3' 137 
 reverse  5'-CAACGGCACCAGCTTTGC-3'  
PHD-1 forward 5'-CAGCTAGCATCAGGACAGAAA-3' 174 
 reverse  5'-CAGAGGCAAAGTCAGAAGCA-3'  
PHD-2 forward 5'-GCACGACACCGGGAAGTT-3' 178 
 reverse  5'-CCAGCTTCCCGTTACAGT-3'  
PHD-3 forward 5'-TTGGGATGCCAAGCTACA-3' 125 
 reverse  5'-CGTGTGGGTTCCTACGATCT-3'  
FIH-1 forward 5'-CAATGTACTGGTGGCATCACATAG-3' 131 
 reverse  5'-GGCCACTTTCTGATGAGCTT-3'  
18S RNA forward 5'-GTAACCCGTTGAACCCCA-3' 152 
 reverse  5'-CCATCCAATCGGTAGTAGCG-3'  
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Appendix 2 Master mix for reverse transcription and reagents for Q-PCR 
 
Master mix preparation for reverse transcription  
Reagent Volume for one sample (μl) 
0.1% DEPC-ddH2O 1.5 
5x RT buffer 4 
dNTPs 10mM 1 
RNAsin 40U/µl 1 
M-MLV (200units/µl) 0.5 
Total master mix volume per sample 8 
 
 
 
Reagents used in Q-PCR reaction 
Reagent Concentration Final concentration Volume (l) 
cDNA   3µl 
SYBR Green I 2x 1x 3.25l 
Forward primer 6.25µM 0.25µM 0.25l 
Reverse primer 6.25µM 0.25µM 0.25l 
ddH2O   6.25l 
Final volume 13l 
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Appendix 3 Representative Q-PCR graphs 
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Representative graphs depicting the increase in fluorescence as a result of intercalation of SYBR Green I 
into the dsDNA of Enolase-1 gene, which were being amplified by the cycles of PCR reactions. The 
samples were extracted from whole varicose and non-varicose veins. 
(a) Four phases of the amplification: (I) linear ground, (II) early exponential, (III) log-linear, and (IV) 
plateau. (b) The kinetics of a Q-PCR reaction analysed in real-time depicted in logarithmic scale. The red 
horizontal line depicted the cycle threshold (Ct=0.05). (c) Melt curve visualising the dissociation kinetics of 
the amplified products showing a single, sharp peak, indicating that only one specific PCR product was 
generated with this set of primers. Coloured lines represent different tested samples (every sample in 
triplicate). 
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Appendix 4 Recipe for reagents used for western blots  
 
Urea lysis buffer 
8M urea 
 1/10 volume glycerol 
 1/1000 volume 1M DTT 
 1/100 volume 1M Tris (pH 6.8) 
 1/200 volume 0.1M stock of phenylmethylsulfonylfluoride (PMSF) 
 1/100 volume complete mini EDTA-free protease inhibitor cocktail 50mM (Roche)  
 
PMSF and protease inhibitor cocktail were only added to the mixture just before the urea lysis 
buffer was used. At the end of the homogenisation, 1/20 volume of 20% SDS was added to the 
homogenate, mixed well, and left for 30 minutes at 4C. SDS was only added at the end of 
homogenisation because it produced a lot of froth if included during homogenisation. 
 
Loading buffer 
 250mM Tris/HCl/SDS pH 6.8 
 20% glycerol 
 20mM DTT 
 4% SDS 
 0.01% bromophenol blue, and ddH2O 
 
MOPS running buffer 
 50mM 3-N-morpholino propane sulfonic acid or MOPS 
 50mM Tris Base 
 0.1% SDS,  
 EDTA and ddH2O 
 
Transfer buffer 
 10% methanol 
 10mM Tris base 
 100mM glycine, and ddH2O 
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Washing buffer 
 1/10 volume dilution of PBS 10X Concentrate; (vWR® BDH Prolab®, Leicestershire, 
UK)  
 0.1% Tween® 20 (Sigma-Aldrich, St. Louis, USA) 
 
Blocking buffer  
 5% skimmed milk (Tesco, UK) in washing buffer 
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Appendix 5 Typical optical density (OD) readings at absorption A550nm 
 
(a) Typical optical density (OD) readings at absorption A550nm, and protein concentration calculated from 
standards and blank. (b) Typical standard curve and linear equation, in this example the standard curve and 
equation (y=0.169x) were generated from the measurements obtained from (a). (c) Typical OD readings at 
absorption A550nm, and protein concentration calculated from protein extracted from whole vein tissues 
based on the standard curve in (b). The OD, standard curve and protein concentration of the standards and 
samples were measured and calculated using the Multiskan Ascent model 354 plate reader and the Ascent 
Software. 
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Appendix 6 Antibodies and dilution used in western blotting 
 
Imperial College London 
Protein Molecular 
weight (kDa) 
Antibody source Antibody 
dilution 
Secondary antibody 
used 
HIF-1α 120 BD Transduction 
(#610959) 
1:250 Rabbit polyclonal anti-
mouse (1:3000) (P0260; 
Dako, Denmark)  
HIF-2α 119 Novus biologicals 
(NB100-312) 
1:250 Rabbit polyclonal anti-
mouse (1:3000) (P0260; 
Dako, Denmark) 
CA9 54 and 58 Novus biologicals 
(NB100-417) 
1:1000 Swine polyclonal anti-
rabbit (1:3000) (P0217; 
Dako, Denmark) 
GLUT-1 40-80 Alpha Diagnostic 
International 
(#GT12-A) 
1:500 Swine polyclonal anti-
rabbit (1:3000) (P0217; 
Dako, Denmark) 
PHD-2 46 Abcam (ab4561) 1:1000 Swine polyclonal anti-
rabbit (1:3000) (P0217; 
Dako, Denmark) 
PHD-3 27 Gift from Professor Chris 
W. Pugh, University of 
Oxford 
1:25 Rabbit polyclonal anti-
mouse (1:3000) (P0260; 
Dako, Denmark) 
FIH-1 40 Novus biologicals 
(NB100-428/A3) 
1:1000 Swine polyclonal anti-
rabbit (1:3000) (P0217; 
Dako, Denmark) 
ERK 2 
(C14) 
42 Santa Cruz 
Biotechnology (sc-154) 
1:500 Swine polyclonal anti-
rabbit (1:3000) (P0217; 
Dako, Denmark) 
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Appendix 7 Ponceau S and Coomasie blue staining 
Ponceau S staining was performed following the transfer step. The PVDF membrane was stained 
in 0.25% Ponceau S solution (Sigma-Aldrich, St. Louis, USA) in 1% acetic acid until the protein 
bands were visible, usually in 1-3 minutes. The PVDF membrane was then destained with ddH2O. 
Coomasie blue stain was only performed after immunodetection of proteins of interest because 
the staining was permanent. The PVDF membrane was treated with Coomasie blue (50%MeOH, 
10% acetic acid, 0.05% Coomasie Brilliant Blue R-250) for 15 minutes, followed by destaining 
(5%MeOH and 10% acetic acid) until the bands were clear on a low background, usually for 
about 30 minutes. 
Varicose veinsNon-varicose veins RCC
(a)
(b)
Varicose veinsNon -varicose veinsRCC
 
(a) A representative Ponceau S staining (b) A representative Coomasie blue staining. Samples were 4 
varicose veins, 4 non-varicose veins and 1 renal cell carcinoma (RCC) as positive control of HIF-1α 
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Appendix 8 Tissue processing prior to histological staining 
Tissue processing and paraffin embedding 
Tissue processing and paraffin embedding were performed by the Department of 
Histopathology, Charing Cross Hospital. Tissue processing involved the process of dehydration, 
clearing and impregnation. Vein tissue blocks were processed according to the standard Charing 
Cross Hospital Histopathology Departmental protocols. Automated Bayer vacuum impregnation 
processors (VIPs) were used to process the vein specimens over a 24-hour period. The blocks 
were immersed in a warm formalin bath (37
o
C) for 3 hours. This was to ensure complete tissue 
fixation and raise the processing temperature to the optimal. The blocks were then taken through a 
series of graded ethanol bath (70%, 90%, and absolute alcohol) for 90-minute intervals to 
dehydrate the tissues, and remove aqueous fixative and any tissue water content before the 
clearing process. Clearing was achieved by sequential transfer of the tissues into xylene baths of 
90-minute durations. Xylene was completely miscible with the dehydrating ethanol and the 
embedding paraffin. Clearing removed any unbound cell components in the tissue and replaced 
the alcohol. The final stage of the process involved paraffin embedding or impregnation of the 
tissues with molten wax at 60
°
C. The paraffin impregnation of the tissues allowed the tissues to be 
cut for microscopic examination, whilst retaining both the tissue antigenicity and morphology. T 
Cutting 
Cutting of tissues was performed by the Department of Histopathology, Charing Cross 
Hospital. Sections of tissue blocks embedded in paraffin wax were cut at a thickness of 3μm using 
a Microm rotary microtome and Accu-edge® microtomy blades. The tissue sections were picked 
up onto Menzel-Glaser Superfrost® Plus glass microscope slides (Thermo Scientific and Gerhard, 
Menzel GmbH, Braunschweig, Germany) in order to aid adherence of the tissue sections to the 
slides. The sections were left to drain on a rack to ensure adherence of the tissue sections to the 
slides. 
Removal of paraffin wax (deparaffin) and hydration 
The slides have to be dewaxed and re-hydrated prior to staining with special stains or 
immunohistochemistry. The slides were warmed in an oven at 60
°
C to soften the paraffin wax. 
The slides were then immersed in xylene to remove the paraffin wax. They were then transferred 
to series of alcohol or industrial methylated spirit (IMS) of decreasing gradient to rehydrate the 
tissue sections followed by distilled water to wash off the alcohol. 
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Appendix 9 Antibodies for immunohistochemistry 
 
Imperial College London 
Antibody Antibody source Antibody dilution Isotype control 
HIF-1α BD Transduction (#610959) 1:100 Mouse monoclonal IgG1 
HIF-2α Gift from Professor Patrick H. 
Maxwell, University College 
London 
1:2000 Rabbit polyclonal IgG1 
CA9 Novus biologicals (NB100-417) 1:1000 Rabbit polyclonal IgG1 
PHD-2 Abcam (ab4561) 1:1000 Rabbit polyclonal IgG1 
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Appendix 10 Sequences of siRNA 
 
siRNA Sense sequence 
siHIF-1α #1 5' [agcaguaggaauuggaacauu]RNA [tt]DNA 3' 
siHIF-1α #2 5' [cugaugaccagcaacuuga]RNA [tt]DNA 3' 
siHIF-2α #1 5' [gcgacagcuggaguaugaauu]RNA [tt]DNA 3' 
siHIF-2α #2 5' [cagcaucuuugauagcagu]RNA [tt]DNA 3' 
scrHIF-1 5' [gaugaguaugacgaacaugau]RNA [tt]DNA 3' 
scrHIF-2 5' [ggguuauggcucggaaucaaa]RNA [tt]DNA 3' 
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Appendix 11 Solution and drugs used in Harvard University 
Physiological Krebs solution contained (in mM): NaCl 120, KCl 5.9, NaHCO3 25, 
NaH2PO4 1.2, dextrose 11.5, CaCl2 2.5, MgCl2 1.2, bubbled with 95% O2 and 5% CO2 and 
maintained at pH 7.4. Membrane depolarization by high KCl is known to induce vascular smooth 
muscle contraction by mainly stimulating Ca
2+
 entry from the extracellular space.(Khalil and van 
Breemen 1988) High KCl (96 mM) depolarizing solution was prepared as Krebs solution with 
equimolar substitution of NaCl with KCl. The -adrenergic agonist phenylephrine (PHE) 10-5 M 
(Sigma Chemical Co, St Louis, MO, USA) was also used to stimulate IVC contraction. Tissue 
culture medium was used to incubate the veins overnight and was composed of Minimum 
Essential Medium (MEM) 1X with Hanks salts and L-glutamine (Gibco/Invitrogen, Grand Island, 
NY, USA) supplemented with 100 units/ml penicillin G sodium, 100 g/ml streptomycin sulphate 
and 0.25 g/ml amphotericin B (Gibco/Invitrogen). Drugs used to inhibit the expression or 
activity of HIF were U-0126 10
-5
 M (Cayman Chemical, Ann Arbor, MI, USA), 17-DMAG 10
-5
 
M (NSC707545; 17-[2-(dimethylamino)ethyl]amino-17-desmethoxygeldanamycin) and 
echinomycin 10
-6
 M (Alexis Biochemicals, San Diego, CA, USA). Dimethyloxallyl glycine 
(DMOG) 10
-4
 M (Cayman Chemical) was used to inhibit hydroxylation of HIF by PHD and FIH-
1 and hence preventing protein degradation and increasing the amount and activity of HIF. 
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Appendix 12 RNA study and western blot protocol used in Harvard University 
RNA Study 
The RNA study involved RNA isolation, reverse transcription and Q-PCR. Frozen vein 
tissues in RNAlater® were first homogenised at 4°C. RNA was isolated from vein samples using 
an RNeasy Fibrous Tissue Mini Kit (QIAGEN, Valencia, CA, USA) according to the 
manufacturer‟s protocol. Total RNA (1 g) was used for reverse transcription to synthesise 
single-strand cDNA in a 20l reaction mixture according to the protocol of the First-Strand 
cDNA Synthesis Kit (Amersham Biosciences, Pittsburgh, PA, USA). Then, 2l of the cDNA in 
the dilution of the reverse transcription product was applied to 20l Q-PCR mixture. 
Quantification of the gene expression was performed using a Q-PCR machine (Mx4000, 
Multiplex Quantitative PCR System, Stratagene, La Jolla, CA, USA) and using previously 
published oligonucleotide primers specific to the gene of interest (Integrated DNA Technologies, 
Coralville, IA, USA) and the Bio-Rad iQ SYBR® Green Supermix, which employs the 
fluorescence compound SYBR® Green for amplicon detection (Bio-Rad, Hercules, CA, USA). 
The smooth muscle -actin primer which was previously designed and used by the laboratory 
with an expected product length of 285 bp was included in the Q-PCR as an internal standard to 
normalise the results. 
PCR was carried out with 1 cycle for 10 min at 95°C and then 40-45 cycles of 30s of 
denaturation at 95°C, 45s of annealing at 56°C, and 30s of elongation at 72°C followed by 1 min 
of final elongation at 95°C. The number of PCR cycles varied according to the expression level of 
the target gene. The appropriate primer concentration and number of cycles were determined to 
ensure that the PCR took place in the linear range and thereby guaranteed a proportional 
relationship between the input RNA and the cycle readout. The relative amount of gene 
expression was calculated by a comparison of cycle thresholds with the housekeeping gene -
actin (Stennett et al. 2009). 
 
Western blot 
Vein segments were homogenized in a 2ml homogenisation or lysis buffer at 4°C. The 
homogenate was centrifuged at 10,000 g for 2 min, the supernatant was collected, and the protein 
concentration was determined. Tissue homogenate was subjected to electrophoresis on 8% SDS 
polyacrylamide gel then transferred electrophoretically to nitrocellulose membranes (Bio-Rad, 
Hercules, CA). The membranes were incubated in 5% dried non-fat milk in phosphate buffer 
solution (PBS)-Tween buffer for 1 hour, then incubated in the primary antibody solution of 
protein of interest in appropriate dilution at 4°C for 24 hour. Actin was used as internal control to 
standardise loading and its protein amount was detected using monoclonal anti-smooth muscle -
actin antibody (1:500,000, Sigma). The membranes were washed in PBS-Tween then incubated in 
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HRP-conjugated secondary antibody (1:1000) for 1.5 hour. The membrane blots were washed 
with PBS-Tween, and visualised with ECL Western Blotting Detection Reagent (GE Healthcare 
Bio-Sciences Corp., Piscataway, NJ) and the reactive bands corresponding to the specific protein 
of interest were analyzed quantitatively by optical densitometry and analysed using ImageJ 
software (NIH). The densitometry values represented the pixel intensity, and were normalised to 
-actin to correct for loading (Raffetto et al. 2008). 
 
Primers and sequences 
Primer Orientation Sequence 
HIF-1 Forward 5´- AAGAAACCGCCTATGACGTG - 3´ 
reverse  5´- CCACCTCTTTTTGCAAGCAT - 3´ 
HIF-2 Forward 5´- CCCCAGGGGATGCTATTATT - 3´ 
reverse  5´- GGCGAAGAGCTTCTCGATTA - 3´ 
MMP-2 Forward 5´- CATCGCTGCACCATCGCCCATCATC - 3´ 
reverse  5´- CCCAGGGTCCACAGCTCATCATCATCAAAG - 3´ 
MMP-9 Forward 5´- GAAGACTTGCCGCGAGACCTGATCGATG - 3´ 
reverse  5´- GCACCAGCGATAACCATCCGAGCGAC - 3´ 
-actin Forward 5‟-GCAGCCCAGCCAAGCACTGTCAGGAAT-3‟ 
reverse  5‟-AGCCCAGAGCCATTGTCACACACCAAGG-3‟ 
 
 
 
Antibodies used for Western blot analysis  
Antibody Type of antibody Manufacturer Dilution used 
HIF-1 rabbit polyclonal IgG Novus Biologicals Inc, Littleton 1:1000 
HIF-2 rabbit polyclonal IgG Novus Biologicals Inc, Littleton 1:500 
MMP-2 rabbit polyclonal IgG Santa Cruz Biotechnology, 
Santa Cruz, CA 
1:500 
MMP-9 rabbit polyclonal IgG Santa Cruz Biotechnology, 
Santa Cruz, CA 
1:500 
-actin monoclonal Sigma 1:500 000 
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Appendix 13 Demographic data of patients  
(A) Demographic data of patients whose veins were used to study the structural differences 
between varicose and non-varicose veins with special stains 
Non-varicose veins 
Number of patients 10 
Mean age (range) / year 64.1 (40 – 89) 
Sex 8 Males 
2 Females 
Smoking 4 Non smokers 
3 Ex-smokers 
3 Smoker 
Laterality 4 Right 
6 Left 
Past Medical History 
Deep vein thrombosis 
Cardiac disease 
Diabetes Mellitus 
Peripheral arterial disease 
Hypertension 
Varicose veins 
 
0 
2 
4 
8 
4 
0 
Drugs 
Aspirin 
Statin 
 
5 
7 
Type of vein 
Neck (facial or external jugular) 
Saphenous 
Groin  
 
3 
6 
1 
Type of surgery 
Carotid endarterectomy 
Below knee amputation 
Lower limb revascularisation with vein graft/patch 
Open inguinal hernia repair 
 
3 
2 
4 
1 
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Varicose veins 
Number of patients 10 
Mean age (range) / year 45.9 (28 – 59) 
Sex 6 Males 
4 Females 
Smoking 8 Non smokers 
2 Ex-smokers 
0 Smoker 
Laterality 5 Right 
5 Left 
Past Medical History 
Deep vein thrombosis 
Cardiac disease 
Diabetes Mellitus 
Peripheral arterial disease 
Hypertension 
 
0 
0 
0 
0 
1 
Drugs 
Aspirin 
Statin 
 
0 
0 
Clinical CEAP  
C2 
C3 
C4a 
C5 
 
4 
1 
4 
1 
Sites of reflux 
GSV 
SSV 
Perforator 
 
9 
2 
1 
Recurrence 1 
Treatment  
Endovenous ablation and multiple avulsions 
Open surgery 
Multiple avulsions only 
 
6 
3 
1 
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(B) Demographic data of patients whose veins were used for analysis of HIF-1α, HIF-2α, 
HIF target genes and HIF regulatory enzyme mRNA and protein expression with Q-PCR 
and Western blot 
Non-varicose veins  
Number of patients 11 
Mean age (range) / year 67.4 (46 – 85) 
Sex 8 Males 
3 Females 
Smoking 6 Non smokers 
3 Ex-smokers 
2 Smoker 
Laterality 5 Right 
6 Left 
Past Medical History 
Deep vein thrombosis 
Cardiac disease 
Diabetes Mellitus 
Peripheral arterial disease 
Hypertension 
Varicose veins 
 
0 
3 
4 
9 
8 
0 
Drugs 
Aspirin 
Statin 
 
8 
6 
Type of vein 
Neck (facial or external jugular) 
Saphenous 
Groin  
Arm 
 
5 
4 
1 
1 
Type of surgery 
Carotid endarterectomy 
Below knee amputation 
Lower limb revascularisation with vein graft/patch 
Open inguinal hernia repair 
AV fistula formation 
 
5 
1 
3 
1 
1 
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Varicose veins  
Number of patients 20 
Mean age (range) / year 48.9 (30 – 74) 
Sex 9 Males 
11 Females 
Smoking 11 Non smokers 
2 Ex-smokers 
7 Smoker 
Laterality 5 Right 
5 Left 
Past Medical History 
Deep vein thrombosis 
Cardiac disease 
Diabetes Mellitus 
Peripheral arterial disease 
Hypertension 
 
0 
0 
1 
0 
3 
Drugs 
Aspirin 
Statin 
 
2 
2 
Clinical CEAP  
C2 
C3 
C4a 
C5 
 
9 
6 
3 
2 
Sites of reflux 
GSV 
SSV 
Perforator 
Posterior thigh vein 
 
17 
8 
1 
1 
Recurrence 2 
Treatment  
Endovenous ablation and multiple avulsions 
Open surgery 
Multiple avulsions only 
 
16 
2 
2 
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(C) Demographic data of patients whose veins were used for immunohistochemistry analysis 
of HIF-1α, HIF-2α and HIF target genes expression 
Non-varicose veins  
Number of patients 8 
Mean age (range) / year 71.6 (54 – 89) 
Sex 6 Males 
2 Females 
Smoking 2 Non smokers 
2 Ex-smokers 
4 Smoker 
Laterality 3 Right 
5 Left 
Past Medical History 
Deep vein thrombosis 
Cardiac disease 
Diabetes Mellitus 
Peripheral arterial disease 
Hypertension 
Varicose veins 
 
0 
2 
3 
8 
3 
0 
Drugs 
Aspirin 
Statin 
 
7 
5 
Type of vein 
Neck (facial or external jugular) 
Saphenous 
Groin  
Arm 
 
1 
4 
2 
1 
Type of surgery 
Carotid endarterectomy 
Open inguinal hernia repair 
Lower limb revascularisation with vein graft/patch 
AV fistula formation 
 
1 
2 
4 
1 
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Varicose veins  
Number of patients 8 
Mean age (range) / year 51.5 (28 – 74) 
Sex 5Males 
3 Females 
Smoking 11 Non smokers 
2 Ex-smokers 
7 Smoker 
Laterality 3 Right 
3 Left 
2 Bilateral 
Past Medical History 
Deep vein thrombosis 
Cardiac disease 
Diabetes Mellitus 
Peripheral arterial disease 
Hypertension 
 
0 
0 
0 
0 
0 
Drugs 
Aspirin 
Statin 
 
1 
1 
Clinical CEAP  
C2 
C3 
C4a 
C5 
 
3 
1 
3 
1 
Sites of reflux 
GSV 
SSV 
Perforator 
 
8 
4 
1 
Recurrence 3 
Treatment  
Endovenous ablation and multiple avulsions 
Open surgery 
Multiple avulsions only 
 
6 
1 
1 
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(D) Demographic data of patients whose varicose veins were used for cell death assay 
Assessment of cell death of varicose veins cultured for 27 days 
Number of patients 14 
Mean age (range) / year 46.0 (21 - 70) 
Sex 5 Males 
9 Females 
Smoking 11 Non smokers 
1 Ex-smokers 
2 Smoker 
Laterality 7 Right 
3 Left 
4 Bilateral 
Past Medical History 
Deep vein thrombosis 
Cardiac disease 
Diabetes Mellitus 
Peripheral arterial disease 
Hypertension 
 
0 
0 
1 
0 
1 
Drugs 
Aspirin 
Statin 
 
0 
1 
Clinical CEAP  
C2 
C3 
C4a 
C4b 
 
6 
5 
2 
1 
Sites of reflux 
GSV 
SSV 
Perforator 
Popliteal 
Tributaries only 
 
11 
4 
2 
1 
1 
Recurrence 5 
Treatment  
Endovenous ablation and multiple avulsions 
Open surgery 
Multiple avulsions only 
 
9 
1 
4 
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Assessment of the effects of sodium azide on cell death on varicose vein organ culture 
Number of patients 4 
Age / year 35, 38, 38, and 63 
Sex 1 Males 
3 Females 
Smoking 3 Non smokers 
1 Smoker 
Laterality 1 Right 
1 Left 
2 Bilateral 
Past Medical History 
Deep vein thrombosis 
Cardiac disease 
Diabetes Mellitus 
Peripheral arterial disease 
Infections 
 
0 
0 
0 
0 
0 
Drugs 
Aspirin 
Statin 
 
0 
0 
Clinical CEAP  
C2 
C4b 
 
3 
1 
Sites of reflux 
GSV 
SSV 
 
4 
1 
Recurrence 1 
Treatment  
Endovenous ablation and multiple avulsions 
 
4 
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Assessment of the effects of hypoxia on cell death of varicose vein organ culture 
 
Number of patients 3 
Age / year 32, 58, and 63 
Sex 2 Males 
1 Females 
Smoking 2 Non smokers 
1 Smoker 
Laterality 1 Right 
1 Left 
1 Bilateral 
Past Medical History 
Deep vein thrombosis 
Cardiac disease 
Diabetes Mellitus 
Peripheral arterial disease 
Hypertension 
 
0 
0 
0 
0 
0 
Drugs 
Aspirin 
Statin 
 
0 
0 
Clinical CEAP  
C2 
C3 
 
2 
1 
Sites of reflux 
GSV 
SSV 
Perforator 
 
3 
1 
1 
Recurrence 1 
Treatment  
Endovenous ablation and multiple avulsions 
 
3 
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(E) Demographic data of patients whose veins were used for the study of the in vitro 
regulation of HIF by hypoxia, DMOG, doxycycline and MPFF 
 Non-varicose vein  
Number of patients 6 
Mean age (range) / year 64.2 (45 – 72) 
Sex 5 Males 
1 Females 
Smoking 2 Non smokers 
2 Ex-smokers 
2 Smoker 
Laterality 3 Right 
3 Left 
Past Medical History 
Deep vein thrombosis 
Cardiac disease 
Diabetes Mellitus 
Peripheral arterial disease 
Hypertension 
Varicose veins 
 
0 
3 
2 
5 
5 
0 
Drugs 
Aspirin 
Statin 
 
3 
5 
Type of vein 
Saphenous 
Arm 
 
5 
1 
Type of surgery 
Lower limb revascularisation with vein graft/patch 
AV fistula formation 
 
5 
1 
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Varicose veins  
Number of patients 6 
Mean age (range) / year 47.5 (33 - 63) 
Sex 3Males 
3 Females 
Smoking 3 Non smokers 
1 Ex-smokers 
2 Smoker 
Laterality 1 Right 
3 Left 
2 Bilateral 
Past Medical History 
Deep vein thrombosis 
Cardiac disease 
Diabetes Mellitus 
Peripheral arterial disease 
Hypertension 
 
0 
1 
0 
0 
0 
Drugs 
Aspirin 
Statin 
 
1 
1 
Clinical CEAP  
C2 
C3 
C4a 
C5 
 
0 
3 
2 
1 
Sites of reflux 
GSV 
SSV 
Perforator 
 
6 
2 
0 
Recurrence 3 
Treatment  
Endovenous ablation and multiple avulsions 
Open surgery 
Multiple avulsions only 
 
4 
1 
1 
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